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Abstract 
Maintenance of anaesthesia using the intravenous agent propofol has markedly increased 
following the development of pharmacokinetic models for drug delivery.  These models 
estimate drug concentrations based on a small cohort of patients used to develop the 
model.  It is proposed that an analyser capable of determining propofol concentrations at 
the point of care may lead to an improved accuracy of drug delivery.  Validation work on an 
analyser with the novel capability of measuring blood propofol concentrations in near real 
time, developed in collaboration with our department, has been analysed.  Results 
demonstrate a high level of precision for samples in the clinical range between 0.25 and 
10µg.ml-1 (bias 0.13 µg.ml-1, precision -0.1 to 0.4 µg.ml-1). 
A review of the literature and supplementary experimentation were performed in order to 
determine whether variation in methods of blood sample preparation for analysis were 
significant.  Wide variations in reported methods of blood preparation were found, which 
have implications for the validity of published data.     
Further work in the clinical setting was carried out using the novel propofol analyser to 
further research its potential use in patients with organ dysfunction, as well as to further 
explore propofol pharmacokinetics in a diverse patient cohort.  Studies were performed in 
intensive care correlating blood propofol concentrations with depth of sedation, and 
demonstrating a correlation with level of organ failure.  The Marsh model of Target 
Controlled Anaesthesia was poorer at predicting propofol concentration in patients with 
significant organ dysfunction than in those without organ failure (correlation coefficient 
0.36 vs. 0.73 respectively).  Studies in the operating room were performed in which 
measured propofol concentrations were compared with those predicted using the Marsh 
model.  Results demonstrated significant inaccuracies of the model (bias 32%, precision -
8.7 to 72.6%).  Anaesthetists relied on estimated concentrations of anaesthetic, with 46% 
iv 
 
making no changes to the set concentration.  A method of Marsh model bias correction 
using a single blood propofol measurement was tested.  Results demonstrated insufficient 
predictability to allow a single point calibration.  Use of a model with better performance 
during early anaesthesia, or multiple sampling may yield more promising results.  
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1 CHAPTER 1 - INTRODUCTION  
1.1 General Anaesthesia 
Anaesthesia is the term used to describe the depression of activity of nervous tissue 
locally, regionally, or within the central nervous system.  General anaesthesia 
describes drug-induced loss of consciousness with loss of sensation and 
amnesia.(Brown, Lydic et al. 2010)  Effective general anaesthesia combines loss of 
consciousness, in addition to analgesia and skeletal muscle relaxation to prevent 
movement.  General anaesthesia is also accompanied by the loss of protective 
reflexes, and so necessitates continuous monitoring of vital signs, and advanced 
physiological and airway management by trained staff to ensure safe recovery.  The 
primary aim is to deliver an adequate dose of drug to provide effective therapy, but 
at concentrations lower than those producing toxicity.   The first anaesthetics were 
primarily given to suppress the pain and stress associated with minor procedures 
such as dental extractions.  These early anaesthetics achieved unreliable pain relief, 
without a clear goal of lack of awareness, and were fraught with dangers related to 
the undefined nature of the drugs administered and lack of adequate monitoring.  
Anaesthetic practice has become more effective and safe for a number of reasons.  
Modern drugs with increased potency and well established safety profiles are 
available, advanced monitoring allows early detection and remediation of drug or 
surgery related complications , and professional training and regulation maintain 
extremely high standards of practice.  The modern expectation of general 
anaesthesia from patients, a reflection of how far the art has progressed over the 
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last one hundred years, is for a risk free anaesthetic without intra-operative 
awareness and effective control of post operative pain.   
The ever increasing complexity and duration of surgical procedures has only been 
allowed by the complementary development of safe, controlled general anaesthesia.  
Modern general anaesthesia combines expertise in not just control of consciousness 
and airway control, but pre-operative patient optimisation, complex fluid 
management, control of major organ systems, perioperative analgesia and surgical 
stress control.  Furthermore, the practice of anaesthesia is no longer confined to 
the operating theatre.  Adaptations to the specialty and to the methods of delivery 
and monitoring have had to be made to facilitate work in remote settings both 
within hospital and in the field for military anaesthesia. 
 
1.2 Inhalational Anaesthesia 
Anaesthetic agents may be delivered through inhalational route or intravenously.  
Most general anaesthetics throughout the world are currently delivered using a 
short acting intravenous induction agent to achieve rapid unconsciousness, and a 
volatile inhalational agent to maintain anaesthesia.  Volatile agents are liquids with 
a low boiling point and a high saturated vapour pressure so that they evaporate 
easily.  These agents are delivered via a vaporiser to the lungs by inhalation at a 
set concentration and thus enter the circulation via the pulmonary capillaries.  
Induction of anaesthesia is possible using some inhalational agents which are not 
pungent such as sevoflurane, and this method may be employed when intravenous 
access is difficult in the awake patient, commonly during paediatric anaesthesia, or 
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may be felt to be of benefit in situations where a difficult airway is anticipated.  
Disadvantages of this method of induction are the prolonged duration of induction, 
during which time the patient may become difficult to control, or develop airway 
complications such as laryngospasm.  In view of these problems, inhalational 
induction is generally reserved for the special circumstances highlighted.   
Inhalational agents remain the most popular method for maintaining anaesthesia 
for a number of reasons: 
• An excellent safety track record over many years, with the first agents used 
in the mid 19th century.(Bovill 2008) 
• The ability to continuously monitor anaesthetic concentrations in expired 
breath and rapidly titrate these against concentrations previously known to 
achieve consistent and effective general anaesthesia. 
• The ability to monitor anaesthetic concentrations continuously to ensure that 
the drug is being effectively delivered without interruption. 
• A historical infrastructure including piped anaesthetic agents, effective 
scavenging apparatus, and inhalational anaesthetic delivery machines in 
operating theatres making the ongoing delivery of inhalational agents 
feasible and cost effective. 
Inhalational anaesthesia does however have drawbacks, which have led to the 
exploration and recent expansion in the use of alternative methods of achieving 
general anaesthesia.  Drawbacks include: 
• Requirement for intravenous induction agent to overcome relatively slow and 
unsafe period of induction of anaesthesia when using inhalational agents 
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alone.  Many inhalational agents cannot be used for induction of anaesthesia 
because of pungent, irritant aroma. 
• Environmental costs of delivering exhaust gases into the atmosphere. 
• Health and safety costs of healthcare staff exposure to inhalational agents, 
and resultant requirement to invest in effective air filtration and scavenging 
systems wherever inhalational agents are used.(Sessler 1997) 
• Lack of portability – anaesthesia in remote settings is difficult to achieve 
effectively and safely without the infrastructure present in an advanced 
operating theatre environment. 
• Small incidence of severe life-threatening reactions to inhalational 
anaesthetic agents (malignant hyperthermia).(Rosenberg, Davis et al. 2007) 
 
1.3 Determining Amount of Anaesthetic Delivered During Maintenance 
Anaesthesia 
Whether using inhalational or intravenous anaesthetic agents to maintain 
unconsciousness, some estimation of amount of anaesthetic likely to ensure 
unconsciousness is important.  Inhalational anaesthetics vary greatly in their 
potency; for instance, nitrous oxide is a relatively weak anaesthetic, and even when 
80% is delivered to the patient, this concentration is usually insufficient to maintain 
anaesthesia alone.  Contrasting with this, inhaled concentrations of 2% of 
sevoflurane, a relatively modern volatile anaesthetic, are likely to maintain 
unconsciousness in most patients. (Katoh and Ikeda 1987) In view of this variability 
in potency, inhalational anaesthetic agents have undergone investigation to 
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determine concentrations required to prevent any reaction to a standard surgical 
stimulus (skin incision) in the absence of co-administered drugs in 50% of subjects.  
This potency value is termed the ‘minimum alveolar concentration’ or MAC value, 
expressed as a percentage.(Eger, Saidman et al. 1965)  MAC values are affected by 
both patient characteristics and co-administered drugs.  They are highest in 
childhood, and decline with advancing age.  When more than one volatile 
anaesthetic agent are used together, MAC values are found to be additive and this 
allows the calculation of an additive MAC value during the administration of multiple 
inhalational anaesthetic agents. (DiFazio, Brown et al. 1972; Katoh and Ikeda 1987; 
Rampil, Lockhart et al. 1991; Swan, Crawford et al. 1999; Nakata, Goto et al. 2001; 
Eger, Xing et al. 2003)  This phenomenon suggests a common mechanism of 
action.  The correlation between minimum alveolar concentration and lipid solubility 
(oil:gas partition coefficient) of volatile anaesthetic agents is excellent, and the 
additive nature of these their action may be explained by a proportional 
contribution of anaesthetic molecules at the site of action at lipid rich sites within 
the brain and spinal cord, where they are likely to interact with proteins ion 
channels such as GABAA .(DiFazio, Brown et al. 1972; Campagna, Miller et al. 2003)    
Importantly, the co-administration of other drugs commonly used during 
anaesthesia, including analgesic agents, serve to reduce the inhalational 
anaesthetic MAC value.(Quasha, Eger et al. 1980)  As is clear in the definition and 
description of influencing factors, it is not possible to dial up a predetermined 
concentration of inhaled anaesthetic agent and guarantee absence of movement 
and unconsciousness.  However, a knowledge of the expected influence of co-
administered drugs, age, and other patient variables can allow the fairly accurate 
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estimate of likely requirements, and these can be further titrated to 
pharmacodynamic parameters of depth of anaesthesia.  Continuous gas 
concentration monitors, which show the increase and decrease of anaesthetic 
concentrations during the respiratory cycle, measure how much drug is being 
delivered to the lungs and how much is being returned to the circulation.  The end 
tidal anaesthetic gas concentration may be used as a surrogate for blood 
anaesthetic concentration, bearing in mind that this may be less accurate in certain 
patient groups including those with severe lung pathology.(Eger and Bahlman 
1971)  Such monitors are used routinely during most general anaesthetics, and 
serve to determine patient specific anaesthetic concentrations, and act as an early 
warning of problems with anaesthetic supply such as vaporiser failure.  This 
monitoring has served to make volatile anaesthesia hugely popular and safe.   
Intravenous anaesthetic agents are not expired from the lungs in concentrations 
high enough to enable quantitative evaluation to determine equivalent MAC 
concentrations and so concentrations in the blood have been evaluated during 
bolus and infusion studies, and these results used to allow estimation of circulating 
anaesthetic concentrations through manual manipulation or more advanced model 
driven infusion.  Concentrations of intravenous anaesthetic agents required to 
maintain unconsciousness or sedation are similarly influenced by patient 
characteristics and co-administered drugs.  Subsequent chapters expand upon the 
background and current practice of intravenous anaesthetic drug estimation. 
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1.4 Intravenous Anaesthesia 
Although inhalational anaesthesia continues to account for the largest proportion of 
general anaesthetics, anaesthesia using intravenous agents alone has a long 
history, and a number of advantages which have led to a large increase in its use in 
preference to inhalational agents.  Before the introduction of rapidly acting 
intravenous agents, induction of anaesthesia required the inhalation of gases, which 
were often unpleasant, and necessitated a prolonged more risky period of 
induction.  The popularity of intravenous anaesthetic agents could only begin 
following the development of acceptable and sterile methods of administration.  
The use of needle and syringe as a method for administering drugs was invented in 
the mid 19th century by Alexander Wood (1817-1884).(Wood 1858)  The hollow 
hypodermic syringe for drug administration was first developed by Rynd.(Corssen, 
Reves et al. 1988)  Shortly following these technical developments, intravenous 
anaesthesia was attempted using compounds such as chloral hydrate, chloroform 
and ether, as well as potent opiate mixtures, all without consistent success or with 
unacceptable toxicity.  Oré (1828-1891) performed the first successful intravenous 
anaesthetic in 1872 using chloral hydrate on a human.(Oré 1874) The first 
intravenous anaesthetic agents to be used effectively and consistently, and with an 
acceptable frequency of adverse reactions, were the barbiturates.  The first 
sedative barbiturate was synthesised by Fischer (1852-1919).(Miller 2005)  The first 
agents produced were not sufficiently short acting to be useful as anaesthetic 
agents, but by the 1930s, the use of rapidly acting barbiturates such as 
hexobarbital, and sodium thiopental shortly afterwards, was being described in 
large numbers of patients.(Lundy 1935)  These agents were not well suited to the 
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maintenance of anaesthesia because of rapid accumulation, and were best used as 
single boluses for short procedures or to induce anaesthesia, followed by the use of 
the newly developed halogenated hydrocarbons such as halothane, discovered in 
the 1950s by Charles Suckling and first introduced by Michael Johnstone,(Johnstone 
1956) which benefitted from relatively easy titratability.   
The development of intravenous anaesthetic agents for both induction and 
maintenance of anaesthesia is linked with the improved pharmacokinetic profiles of 
modern intravenous anaesthetic agents.  A newer generation of intravenous agents 
with rapid onset and short duration including midazolam, ketamine, propofol and 
etomidate have led to increasing interest in general anaesthesia without using the 
inhalational route.   
Midazolam a benzodiazepine agent, commonly used within anaesthesia and critical 
care, because it has the fastest clearance, as well as being water soluble when 
formulated in an acidic carrier.(Reves, Fragen et al. 1985)  The hypnotic action of 
midazolam is caused by reversible binding to the benzodiazepine receptor, located 
on GABAA, primarily within the central nervous system.  Binding to this receptor  
enhances the GABAA receptor function, leading to an increase in GABAA chloride 
channel opening, leading to membrane hyperpolarisation.(Mohler, Fritschy et al. 
2002)  Dose titration allows use for anxiolysis, amnesia, sedation, anticonvulsant 
activity, or general anaesthesia.  Emergence is primarily through redistribution of 
drug, and after prolonged intravenous infusion (primarily in critical care), blood 
concentrations will fall more rapidly than the other benzodiazepines such as 
lorazepam and diazepam because of rapid hepatic clearance.  Midazolam may be 
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used for general anaesthesia, although recovery from anaesthesia is more 
prolonged than with propofol.  Maintenance of anaesthesia is possible with bolus 
followed by intravenous infusion or repeat boluses, although prolonged 
administration will still lead to accumulation and a consequent increase in time to 
arousal.  The benzodiazepine antagonist flumazenil can be used to reverse the 
residual effects of benzodiazepines, although a short half live of approximately one 
hour leads to the potential for its clearance prior to adequate clearance of the 
agonist. 
Ketamine, a phencyclidine derivative, offers the advantage of being simple to use 
via repeated bolus or infusion, as well as possessing analgesic properties, although 
it exhibits a number of undesirable effects, including hallucinations and unpleasant 
dreams, termed ‘emergence phenomena’ which have limited its widespread 
use.(Craven 2007)  Ketamine acts on the central nervous system, as well as 
possessing local anaesthetic properties.  Its effects are mediated primarily at the N-
methyl-D-aspartate (NMDA) receptor, where it competitively antagonises at the 
Ca2+ channel pore.(Hirota and Lambert 1996)  Additional actions include reduction 
in the presynaptic release of glutamate, and interactions with the mu and kappa 
opioid receptors (although with much lower affinity than at the NMDA 
receptor).(Finck and Ngai 1982)  Ketamine also exhibits anticholinergic effects 
through antagonism at muscarinic and nicotinic receptors.  High doses can lead to 
direct sodium channel inhibition, leading to local anaesthetic activity.(Wagner, 
Gingrich et al. 2001)  General anaesthesia using this drug has been termed 
‘dissociative anaesthesia’, because patients appear to be in a cataleptic state during 
its use, often keeping their eyes open with the relative preservation of reflexes.  
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Titration of anaesthesia may be difficult because of the lack of a clear clinical 
distinction between the awake state and anaesthesia.(Craven 2007)  It remains 
popular as a drug for emergency anaesthesia and sedation, because of its limited 
depression of the respiratory and cardiovascular systems, and its potent analgesic 
action.  The drug consists of two stereoisomers.  The S (+) isomer is more potent 
and is associated with fewer adverse effects,(White, Schuttler et al. 1985) although 
it is not yet commercially available for use in humans in the UK.  There has been a 
renewed interest in ketamine because of its unique analgesic qualities, including in 
the prevention and treatment of chronic pain conditions and as a potent opiate 
sparing agent.  (Hocking and Cousins 2003) 
The imidazole derivative etomidate became popular because of its haemodynamic 
stability coupled with favourable pharmacokinetic characteristics including rapid 
clearance and short elimination half time, particularly amongst higher risk patients.  
This agent’s predominant action is on the GABA receptor.  It became popular as 
both an induction agent and for maintenance by continuous infusion or sedation 
particularly in critical care.  Its use has been markedly reduced because of its action 
on the adrenocortical axis, with a prolonged reversible inhibition of the 11-β 
hydroxylase enzyme important for adrenal steroid production and hence the stress 
response, particularly following infusion.(Wagner, White et al. 1984)  This has 
almost eliminated its utility as a maintenance agent, particularly in the critically ill, 
where it is now rarely used even for induction of anaesthesia, particularly in 
patients with septic shock, where mortality has shown to be 
increased.(Cuthbertson, Sprung et al. 2009) 
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Alpha-adrenergic agonists such as dexmedetomidine have enjoyed a significant 
increase in use over the last few years with an emphasis on use by infusion for 
relatively short durations to achieve sedation, particularly in critical care (Triltsch, 
Welte et al. 2002), for which they have been well characterised.(Iirola, Ihmsen et 
al. 2012)  These drugs have a number of properties making them ideal in this 
setting, although they are not useful for induction or maintenance of anaesthesia.  
Sedation can be achieved with relatively stable cardiovascular parameters, 
particularly during weaning from a mechanical ventilator, with a greater recall of 
events during critical care, but described as pleasant by patients.(Venn and 
Grounds 2001)  These drugs have also been used as an adjuvant during 
anaesthesia, to reduce hypnotic agent requirements and because of their analgesic 
properties.(Aantaa, Kanto et al. 1990) 
Since its introduction and following a few minor modifications to its formulation, 
propofol has overtaken all other intravenous agents both for induction and 
maintenance of general anaesthesia.  It possesses a number of properties of the 
ideal general intravenous anaesthetic agent, which will be discussed in the following 
section.  
Concurrent with the development of improved anaesthetic agents, the development 
of analgesic agents such as fentanyl, alfentanil, and remifentanil with short 
durations of action have enabled a reduction in the total dose of anaesthetic agent 
required, and led to improved, more clear headed wake up following general 
anaesthesia.  Neuromuscular blocking agents designed to improve ease of tracheal 
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intubation and operating conditions by preventing skeletal muscle contraction have 
also improved with fewer side effects and shorter durations of action. 
The improved pharmacokinetic and safety profile of all of these intravenous agents 
have led to an increasing interest in the provision of balanced general anaesthesia 
using the intravenous route alone. 
 
1.5 Propofol 
 
Propofol is the most frequently used intravenous anaesthetic agent.  The drug, 
2,6-di-isopropyl phenol was developed in the 1970s during work on substituted 
derivatives of phenol, with the first evidence of its clinical efficacy as an induction 
agent from a clinical trial in 1977.(Kay and Rolly 1977)  In common with all 
anaesthetic agents, propofol causes profound short term physiological disturbance, 
detailed in section 1.5.5, although other adverse effects are very rare if it is used at 
appropriate doses by trained anaesthetic staff.  Potential for toxicity is increased 
when the drug is delivered at high concentrations for prolonged periods.  Drug 
manufacturers advise regular blood triglyceride measurement in patients receiving 
prolonged infusions of propofol because of the associated lipid load of the carrier 
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solution.  Propofol infusion syndrome is a rare complication associated with 
prolonged infusions at high dose, in particular in the paediatric population.  This is 
detailed further in section 1.5.6 
The insolubility of propofol in water has necessitated its preparation with additional 
agents to overcome this problem.  It was initially solubilised with Cremophor EL, a 
derivative of castor oil, (BASF Corp.).  The association with anaphylactoid reactions 
related to the Cremophor has led to its reformulation as a lipid emulsion of soya oil 
in water, with purified egg phospholipid used as an emulsifier.(Briggs, Clarke et al. 
1982)  The drug is now widely used for both induction and maintenance of 
anaesthesia, as well as for sedation. 
 
1.5.1 Chemistry 
Propofol is an alkylphenol.  It is stable at room temperature and not light sensitive, 
and may be diluted in crystalloid solution if necessary. (Kay, Sear et al. 1986) 
Propofol is an oil at room temperature, and highly lipid soluble.  In order to deliver 
this water-insoluble chemical intravenously, it must be formulated into a lipid 
carrier.  The most frequently available formulation consists of 1% propofol, long 
chain triglycerides as 10% soybean oil, 2.25% glycerol, 1.2% purified egg 
phosphatide, and 0.005% disodium edetate (to retard bacterial growth).  
Alternative formulations are also available including a 2% propofol formulation 
which is primarily used in continuous infusions.  A formulation with long and 
medium chain triglycerides has been launched in an attempt to reduce the rise in 
blood triglyceride concentrations as well as to limit pain on injection (Morey, Modell 
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et al. 2006) (Lipuro, B.Braun, Melsungen, Germany).  Further propofol preparations 
are also under investigation, including a number of alternative lipid based 
preparations as well as non-lipid excipients. (Knibbe, Aarts et al. 2000; Song, 
Hamza et al. 2004; Morey, Modell et al. 2006; Ravenelle, Vachon et al. 2008)  An 
attempt to use a water soluble prodrug of propofol has been hampered by drug 
assay inaccuracies, leading to retraction of some of the initial research. (Struys, 
Vanluchene et al. 2005; Struys, Vanluchene et al. 2010)  A non lipid based product 
is under investigation using a modified cyclodextrin based formulation, designed to 
mitigate some of the problems associated with propofol in lipid emulsion, including 
pain on injection, hypertriglyceridaemia, and allergic reactions. (Egan, Kern et al. 
2003)  Care must be taken when evaluating any new formulations, as reformulation 
has been shown to alter propofol’s pharmacokinetic and pharmacodynamic 
characteristics. (Bielen, Lysko et al. 1996; Dutta and Ebling 1997; Dutta and Ebling 
1998) 
 
1.5.2 Mechanism of Action 
General anaesthesia results from the inhibition of neurotransmission by neuronal 
hyperpolarisation, via the facilitation of increased chloride transmission through the 
pore of the GABAA receptor at a site adjacent to the chloride channel.  Its main 
sites of action are at the beta subunits of the receptor. (Solt and Forman 2007)  
Research on mice with transgenetically modified GABAA receptors demonstrate a 
primary role of the β3 subunit of the receptor for propofol-induced immobility and a 
significant role of the β2 subunit receptor for sedation.(Jurd, Arras et al. 2003; 
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Reynolds, Rosahl et al. 2003; Drexler, Jurd et al. 2009)  The β1 subunit appears to 
play little role.  It is likely that the primary site where immobility is induced is in the 
spinal cord, with effects most marked in the ventral horn.(Kungys, Kim et al. 2009)  
These sites of action are distinct from those responsible for the effect of 
benzodiazepines and barbiturates.  Propofol also results in inhibition of the N-
methyl D-aspartate (NMDA) glutamate receptor via a modulating effect on sodium 
channel gating. (Lingamaneni, Birch et al. 2001)  Other receptors undergoing 
research for possible actions during propofol induced anaesthesia include the 
glycine receptor.  Propofol can cause direct  activation of the inhibitory glycine 
receptor in rats, although high concentrations are required.(Chau 2010) 
 
1.5.3 Metabolism 
Propofol is rapidly metabolised within the liver by direct conjugation to the inactive 
glucuronide and sulphate to enable excretion in the urine as a water soluble 
compound. (Simons P 1985)  In humans, the major pathway is a direct 
glucuronidation, accounting for half to three quarters of the total 
metabolites.(Simons, Cockshott et al. 1988; Vree, Lagerwerf et al. 1999)  Less than 
1% of propofol is excreted unchanged in the urine.  (Gepts, Camu et al. 1987)  
Propofol not undergoing immediate conjugation in the liver is metabolised primarily 
by cytochrome p450 enzyme CYP 2B6, although CYP1A2, CYP2C9 and CYP2C19 
may also play a minor role. (Oda, Hamaoka et al. 2001) The metabolite is 
subsequently conjugated and excreted in urine.  Propofol clearance exceeds hepatic 
blood flow, suggesting a degree of extrahepatic metabolism and excretion.  This 
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hypothesis was corroborated when propofol metabolites were detected during the 
anhepatic phase of orthotopic liver transplantation.(Veroli, O'Kelly et al. 1992)  
Metabolism and excretion from the lungs have been demonstrated, and are 
responsible for almost a third of uptake and first pass metabolism after a single 
bolus.(Kuipers, Boer et al. 1999)  Propofol is an example of a drug with very high 
extraction (intrinsic liver clearance is large compared to liver blood flow) making 
hepatic clearance blood flow dependent, rather than hepatic enzyme activity or 
level of plasma protein binding dependent (hepatic clearance 1967 mL.min-1 (1631-
2303) for a 70kg adult).(Jones, Chan et al. 1990; Calvey and Williams 2008)  
According to the well-stirred model of hepatic elimination, the blood clearance and 
steady state concentration of total drug are independent of the proportion of 
unbound drug when the extraction ratio is high.(Wilkinson and Shand 1975) 
 
1.5.4 Pharmacokinetics 
Pharmacokinetics is the relationship between dose administered and the resulting 
concentration in the plasma or effect site.  The processes of absorption (for 
non-intravenously delivered drugs), distribution, and clearance govern this 
relationship.  The success of propofol in clinical practice is partly attributable to its 
unique pharmacokinetic profile, particularly its redistribution and rapid metabolic 
clearance.  After a bolus of propofol, the blood concentration decreases rapidly 
primarily as a result of rapid redistribution from the blood to highly vascular tissues 
such as muscle, followed by poorly vascular tissues such as fat.  Initial decline in 
concentration has only a small contribution from elimination.  The initial distribution 
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half life of propofol has been calculated using three compartment modelling as 1 to 
8 minutes, whereas the elimination half-life is 4 to 24 hours. (Gepts, Camu et al. 
1987; Kirkpatrick, Cockshott et al. 1988; Shafer, Doze et al. 1988)   
The context sensitive half-time is the time for the plasma concentration of a drug to 
fall 50% after termination of a variable-length continuous infusion at a steady-state 
drug level.(Hughes, Glass et al. 1992)  The pharmacokinetics of propofol make it a 
good drug for prolonged infusions when compared with other agents, with a slow 
increase in context-sensitive half-time for prolonged infusion as shown in Figure 1 
(for example propofol plasma concentration will half in less than 40 minutes 
following an 8 hour infusion).(Hughes, Glass et al. 1992) 
 
Figure 1:  from Hughes, Glass et al, 1992. Context sensitive half-times (bars) for each 
pharmacokinetic model after terminating a 1min, 1hr, 3hr, 8hr, or steady state BET type 
infusion shown relative to the elimination half life (dot) for each model. (Hughes, Glass et 
al. 1992)   
18 
 
 
The pharmacokinetics of propofol are influenced by numerous patient variables in 
common with most drugs including weight, comorbid conditions, and 
age.(Kirkpatrick, Cockshott et al. 1988; Dyck and Shafer 1992; Coetzee 2009)  The 
significant cardiovascular effects of propofol, causing hypotension and 
vasodilatation can impact on its own clearance by reduction in hepatic blood 
flow.(Upton, Ludbrook et al. 1999; Kurita, Morita et al. 2002)  During haemorrhagic 
shock, propofol concentrations rise significantly, and this is more marked during 
decompensated shock.(Kurita, Morita et al. 2002)  The type of surgery, including 
level of stimulation and potential for blood loss, can therefore also affect propofol 
pharmacokinetics. 
Drug therapies influencing the cardiovascular system administered in the peri-
operative period can significantly impact intra-operative cardiovascular stability, and 
hence propofol pharmacokinetics.  Furthermore, opiates appear to have an 
important effect on propofol pharmacokinetics, leading to increases in propofol 
concentrations by up to a fifth,(Pavlin, Coda et al. 1996) with various modes of 
action including direct effects on cardiovascular system and liver blood 
flow,(Ludbrook and Upton 2003) reductions in clearance rates, and reductions in 
volumes of distribution.(Benoni, Cuzzolin et al. 1990)  The co-administration of 
remifentanil, a very common combination in modern anaesthetic practice, has 
significant impact in some work,(Koitabashi, Johansen et al. 2002) although work 
by Bouillon has shown no influence of remifentanil on propofol 
pharmacokinetics.(Bouillon, Bruhn et al. 2002) 
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Another pharmacokinetic consideration important during cardiac surgery is the 
influence of cardiopulmonary bypass on propofol concentrations.  The initiation of 
cardiopulmonary bypass leads to an increase in central compartment volume and a 
more rapid clearance requiring an increased rate of infusion to maintain a constant 
drug concentration.(Bailey, Mora et al. 1996)  More recent work has demonstrated 
that plasma dilution can lead to an increased effect of propofol through reduced 
protein binding of the drug.(Takizawa 2006)  Generally, a drug’s pharmacological 
effect is a reflection of its unbound concentration in the circulation, as only drug 
which is not bound to plasma protein is able to pass to the target sites.  Engdahl 
has shown that equilibration of propofol across the blood-brain barrier is likely to be   
limited by plasma protein binding.(Engdahl, Abrahams et al. 1998) 
 
1.5.5 Pharmacodynamics 
Pharmacodynamics describes the relationship between plasma drug concentration 
and pharmacological effect.  The desired effect on the central nervous system is 
combined with effect on all other organ systems which need to be managed to 
maintain safe anaesthesia. 
 
1.5.5.1 Central nervous system 
The main desired action of propofol is its hypnotic property.  Time to peak effect 
following bolus administration is approximately 90 seconds, with a median effective 
dose (ED50) for unconsciousness of 1 to 1.5 mg.kg-1.  Dosing is greatly influenced 
by age, with paediatric patients often requiring double the induction dose of adults, 
20 
 
and elderly patients requiring proportionately lower dosing.  Propofol may also be 
used for its amnesic and sedative properties at subhypnotic doses.  Other effects on 
the central nervous system, which contribute to its widespread popularity are its 
anti-emetic properties, probably via its action on GABA receptors, causing localised 
anti-seritonergic activity in the area postrema.(Cechetto, Diab et al. 2001)  Others 
have proposed a direct anti-emetic effect on cannabinoid receptors.(Patel, Wohlfeil 
et al. 2003)  Propofol may also be used for its antiepileptic properties, causing burst 
suppression on EEG with high infusion rates.  Propofol reduces intracranial pressure 
(ICP) when this is pathologically elevated, making this a useful drug during 
neuroanaesthesia, although the impact on systemic vascular resistance will also 
lead to a reduction in cerebral perfusion pressure.  Reductions in cerebral perfusion 
pressure are offset by the neuroprotective effects of reduced cerebral oxygen 
consumption.(Stephan, Sonntag et al. 1987) 
 
1.5.5.2 Respiratory System 
Administration of propofol has a powerful respiratory depressant activity, with 
around a third of patients becoming apnoeic following an induction dose, which is 
generally short lived (< 30sec) although may be more prolonged, particularly if 
propofol is coadministered with an opiate.  The respiratory depressant action is 
ongoing when propofol is used by infusion, with a resultant reduction in tidal 
volume and respiratory rate.(Goodman, Black et al. 1987)  Propofol also possesses 
some bronchodilatory properties, although less potent than inhalational anaesthetic 
agents.(Mehr and Lindeman 1993)  Additional beneficial effects on the upper airway 
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include a strong blunting of the upper airway reflex, facilitating the insertion of 
upper airway adjuncts. 
 
1.5.5.3 Cardiovascular System 
Propofol causes a significant reduction in arterial blood pressure following induction 
dosing, which is caused by a reduction in both afterload and preload by a 
multimodal mechanism.  Cardiac index is reduced by around 15%.  Negative 
inotropic effects on the heart are probably limited to its inhibition of sympathetic 
activity, with most studies demonstrating no direct negative inotropic 
actions.(Graham, Thiessen et al. 1998)  Reduction in sympathetic activity and 
inhibition of parasympathetic tone may result in a reduction in heart rate, and a 
blunting of the reflex tachycardia in response to hypotension.(Ebert, Muzi et al. 
1992)  Constant infusions of propofol lead to an ongoing depression of blood 
pressure in the order of 30%, with preserved cardiac contractility.  Although 
myocardial blood flow is consequently reduced, this is offset by a reduction in 
myocardial oxygen demand, with some evidence for myocardial protection.(Ko, Yu 
et al. 1997; Kokita, Hara et al. 1998) 
1.5.6 Side Effects 
Propofol infusion syndrome is a rare response to the infusion of propofol for 
prolonged periods.  Clinically, patients develop a severe metabolic acidosis, 
lipaemia, cardiac and skeletal muscle myopathy, hepatomegaly and hyperkalaemia.  
Early theories on the likely causation included an impairment of hepatic lactate 
metabolism caused by the intralipid carrier agent.  However, more recent work has 
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proposed that the syndrome may be caused by either direct inhibition of the 
mitochondrial respiratory chain or impaired mitochondrial fatty acid metabolism 
caused by propofol or one of its metabolites. (Wolf, Weir et al. 2001)  The 
consequence of impaired fatty acid oxidation is a build up of toxic fatty-acid 
intermediates, and when coupled with cellular hypoxia, acidosis is 
exacerbated.(Kam and Cardone 2007)  It is still not clear whether the propofol 
infusion syndrome is attributable to an unidentified propofol metabolite, or to an 
underlying neuromuscular defect predisposing the patient.  A fatality was first 
described in a child in Denmark in 1990, and subsequently a case series of five 
fatalities describing the syndrome was published in 1992. (Parke, Stevens et al. 
1992)  Although also reported in adults, (Ernest and French 2003) the syndrome is 
seen to be prominent particularly in the paediatric population, with over half of all 
deaths reported in the literature occurring in children. (Kam and Cardone 2007)  
The syndrome has resulted in a reduced use of propofol by infusion in the 
paediatric population, particularly in paediatric critical care.  Only a third of reported 
deaths occurred during anaesthesia, the remainder occurring during more 
prolonged infusions in critical care.  These data suggest that duration of infusion is 
a very important factor in the development of propofol infusion syndrome, given 
the proportionately much larger number of individuals receiving the drug for short 
durations during anaesthesia.  The major risk factors for the development of this 
syndrome include reduced oxygen delivery, serious neurological injury or sepsis, the 
use of high doses of the drug (usually in excess of 4 mg.kg-1hr-1 for extended 
periods).  Clinicians should urgently withdraw the drug and choose an alternative 
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sedative agent should the described symptoms occur, particularly in a patient at 
high risk. (Kam and Cardone 2007) 
Even in the absence of propofol infusion syndrome, the risk of increased blood lipid 
concentrations from prolonged infusions of propofol is real, and the manufacturers 
recommend monitoring blood lipid concentrations in patients at high risk of fat 
overload.  A higher concentration of propofol, at 2%, is available for use in 
continuous infusions to reduce the lipid load. 
Other less severe side effects of propofol include pain on injection, which may occur 
in around a third of patients via an unknown mechanism and may be severe. 
(McLeskey, Walawander et al. 1993)  Injection of lidocaine or use of large more 
central vein for infusion can reduce its incidence. (Jalota, Kalira et al. 2011) 
Propofol preparations promote the growth of micro-organisms, (Sosis and 
Braverman 1993; Bennett, McNeil et al. 1995) and so aseptic precautions should be 
adhered to when preparing and administering the drug, ensuring that continuous 
infusion sets are changed if not used within 12 hours to minimise the risk of 
bacterial contamination. 
 
1.5.7 Contraindications 
Propofol is contraindicated in patients with a known hypersensitivity to the drug or 
any of its excipients.  Hypersensitivity to propofol itself is very uncommon, although 
reported, (de Leon-Casasola, Weiss et al. 1992; Laxenaire, Mata-Bermejo et al. 
1992) with an incidence of less than 1 in 10,000.  The soya oil within propofol 
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preparations is more likely to lead to hypersensitivity reactions, and so such 
preparations should be avoided in patients with allergy to soya oil or to peanuts. 
 
1.6 The Administration of Propofol Intravenous Anaesthesia 
The delivery of a general anaesthetic or sedation using intravenous propofol can be 
achieved using a number of techniques, which all rely on the principal of balanced 
anaesthesia, where suitable analgesic drugs and neuromuscular blocking drugs are 
used in addition to an anaesthetic agent when necessary, to achieve a stable, safe, 
and effective anaesthetic.  The simplest method of inducing and maintaining 
general anaesthesia is by the use of intermittent boluses of the drugs.  This method 
leads to fluctuating drug concentrations.  Steady maintenance of anaesthesia 
without risk of anaesthetic awareness is achieved by close vigilance of physiological 
parameters, and the experience of the anaesthetist.  This form of intravenous 
anaesthesia continues to be popular for very short surgical procedures, although 
becomes very difficult to achieve effectively and safely without the risk of over or 
under-sedation over prolonged periods.  For such situations, propofol delivered by 
continuous, variable infusion has been advocated.  One such method of 
administration is the rate controlled infusion.  This method of administration is 
rarely useful during anaesthesia, although is commonly used for much more 
prolonged periods of sedation in a critical care environment, where the very long 
periods of infusion allow full equilibration with body compartments to take place, 
and less emphasis is placed on rapid and clear headed emergence from sedation. 
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1.6.1 Manually Controlled Infusion Systems 
In order to achieve a constant concentration of propofol within the brain at its site 
of action, then a constant concentration within the blood is required.   The method 
of achieving a constant concentration of drug is based on the use of a loading dose, 
followed by the administration of a maintenance infusion rate, which is given by the 
equations: 
 
Loading dose  =  volume of distribution at steady state  X  Desired blood concentration  
Maintenence infusion rate  =  Systemic Clearance  X  Desired blood concentration 
(Calvey and Williams 2008) 
Although these equations appear to allow a simple method to achieve a desired 
anaesthetic level, things are not as straight forward as they first appear.  The 
problem arises from the difficulty in quantifying the apparent volume of distribution 
for propofol drug loading.  For many drugs, the volume of distribution will 
approximate the blood volume, termed the initial volume of distribution, which can 
be easily calculated from basic patient demographic data.  However, propofol very 
rapidly disperses into other body compartments during the time required for 
equilibration between the blood and the effect site to take place.  This leads to a 
much larger apparent volume of distribution, which requires advanced 
mathematical techniques in order to estimate.  The movement of drug outside of 
the central compartment (blood) into other tissues at differing rates also leads to a 
more complicated rate of clearance as the drug continues to slowly diffuse from 
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various body compartments at different rates as the infusion rate is slowed or 
stopped.  The concept of ‘context sensitive halftime’ has been coined in order to 
explain the influence of duration of infusion of drugs on the rate at which they are 
cleared from the body.    
A further problem encountered by those delivering maintenance anaesthesia 
intravenously is the lag between those concentrations achieved in the blood, and 
concentrations of drug at the effect site (the brain).  It is possible to quantify the 
relationship between blood and effect site concentration of propofol, although the 
mathematical transformations required are too complicated to allow their 
application during user determined manual infusion techniques. 
 
Bearing these principles in mind, the maintenance of a constant blood concentration 
of propofol has been approximated by the use of a stepped infusion scheme, which 
involves an initial bolus to fill the central compartment, followed by a series of 
decreasing rates of infusion.  A popular example of this technique to achieve a 
predicted blood propofol concentration of approximately 3-4µg.ml-1  is the 
administration of a fixed bolus at induction of anaesthesia of 1mg.kg-1 followed by a 
reducing rate of infusion of 10 mg.kg-1.hr-1  for 10 minutes, 8 mg.kg-1.hr-1  for 
10 minutes, and 6 mg.kg-1.hr-1  for ongoing maintenance.(Roberts, Dixon et al. 
1988)  This technique requires the use of balanced anaesthesia using both 
benzodiazepine premedication and potent opioids such as alfentanil or inhaled 
nitrous oxide to achieve effective anaesthesia.  This work was able to demonstrate 
fairly stable mean blood propofol concentrations between 3.4 and 4.1µg.ml-1 over 
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the course of 80 minutes of anaesthesia, with good anaesthetic conditions 
throughout. Clearly, the target blood concentration will in reality be variable, and 
can only be determined by studies which define the ‘ EC50 (the effective 
concentration in 50% of the population) or the EC95 for a specific level of surgical 
stimulation, and a significant range exists – with an EC50 and EC95 of 1.66 and 
3.39 µg.ml-1 respectively in one study with morphine premedication and inhaled 
nitrous oxide,(Spelina, Coates et al. 1986) and 2.5 and 5.92 µg.ml-1  in another 
using a benzodiazepine premedication and nitrous oxide (Turtle, Cullen et al. 1987).   
Therefore, a significant disadvantage of this technique is that the concentration of 
blood propofol is not accurately modifiable beyond the original research which 
allowed a fixed concentration of between 3.4 and 4.1 µg.ml-1 to be approximated 
during different levels of stimulation.   
 
1.6.2 Target-Controlled Infusion (TCI) 
One of the major advantages of inhalational anaesthesia over intravenous 
anaesthesia has been the ability to rapidly and simply modify the dose of 
anaesthetic delivered to the patient and be confident that the brain will within a 
short period of time be receiving a similar concentration.  The most advanced 
methods of administration of intravenous anaesthetic agent available by manually 
adjusted infusion have at best been able to approximate a desired concentration of 
drug, with limited ability to manipulate the drug concentration intelligently.  A 
significant advance has been the work performed on pharmacokinetic modelling of 
intravenous agents, which when combined with sophisticated software packages 
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have been able to deliver accurate algorithm determined quantities of drug via a 
linked syringe driver in order to achieve a constant and modifiable predicted blood 
concentration.   These systems have their roots in the BET infusion scheme 
(representing Bolus for drug loading, Elimination for the steady rate of infusion to 
offset the drugs elimination, and Transfer representing an exponentially decreasing 
rate of drug delivery to match the rate of redistribution of drug between central and 
peripheral compartments).(Kruger-Thiemer 1968)  In order to calculate the rate of 
transfer into peripheral compartments, the pharmacokinetics of the drug must be 
described mathematically.(Calvey and Williams 2008)  A number of drugs may be 
described using simple unicompartmental modelling, in which the body is 
considered as a single compartment into which the drug is administered, and from 
which it is eliminated at a rate proportional to the amount within the compartment.  
This can be expressed in the following formula: 
Cp = Be-βt  
Cp is concentration of drug in plasma, β is the rate of drug elimination, B is a drug specific constant, t 
is time, e = 2.718. 
For more complex drugs such as propofol, the intravenous concentration following 
injection declines initially very rapidly due to redistribution, but slower rates of 
redistribution are also described, whose rate vary according to the nature of the 
tissue.  In order to mathematically account for this varying rate of distribution and 
transfer from one body compartment to another, a mathematical model is required 
with multiple compartments, each of which is represented by its own apparent 
volume of distribution and rate constant, for movement in and out of each 
compartment.  Propofol can be described adequately in terms of three theoretical 
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compartments: a central compartment into which drug is delivered and eliminated 
(the blood), and two peripheral compartments, one with rapid movement of drug 
between the central compartment representing highly vascular tissue, and one with 
slower movement of drug representing tissues with poor vascularity.  The 
performance of these models is not improved by increased complexity because of 
error introduced by inter-patient differences in pharmacokinetics, as well as errors 
within the methods of sampling and drug assays.  Following the determination of 
the values representing the volume of each compartment, and the concentration 
dependent rate of movement of drug between compartments, a calculation can be 
made to estimate the amount of drug required to maintain a constant concentration 
of drug within the blood.  This has been explained by Glass in terms of a three 
bucket hydraulic model illustrated in Figure 2 below.  The tap delivers drug to the 
central compartment (bucket) which has a concentration dependent rate of 
elimination (hole) as well as connections to peripheral compartments (buckets).  
The size of the peripheral compartments, the volume of drug within them, and the 
size of the connection with the central compartment determines the rate of 
movement between compartments.  Using this theory, the concentration of drug at 
any time point can be determined with incorporation of the duration of infusion and 
hence the consequent influence on peripheral compartment drug concentrations.  
The time taken for the central drug compartment concentration to halve following 
discontinuation of drug has been termed the context-sensitive half time.(Hughes, 
Glass et al. 1992)  
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Figure 2:  Hydraulic model analogy to three compartment pharmacokinetic modelling. V1 
represents the central compartment, V2 the well perfused peripheral compartment, V3 a 
poorly perfused peripheral compartment. The kij represent distribution rate constants for 
transfer from one compartment to another, or elimination rate constant (k10) Adapted from 
(Hughes, Glass et al. 1992). 
 
One of first systems developed to administer anaesthetic drugs using the BET 
infusion theory interfaced with a microcomputer to link it to an infusion pump was 
tested clinically using etomidate.(Schuttler, Schwilden et al. 1983)  Such a system 
was able to incorporate an algorithm to calculate an infusion rate required to 
maintain a steady state concentration of drug.  It is important to consider with 
these systems however, that there are physical limitations that must be adhered to, 
such as that infusion rates can never be reduced to below zero.  Based on this 
theory, Schuttler later described a system representing the target controlled 
infusion of propofol.(Schuttler, Kloos et al. 1988)  Although pharmacokinetic models 
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have been devised for a number of anaesthetic agents, the properties of propofol 
have made it the most suitable drug for delivery using TCI, and it has become the 
only commercially available system for the delivery of intravenous anaesthetic 
agent, although other systems are available for the delivery of other agents such as 
the opioids sufentanil and remifentanil.(Gepts, Shafer et al. 1995; Minto, Schnider 
et al. 1997)  The first system of an anaesthetic agent delivered by TCI made 
commercially available was the Diprifusor™, which used a system of prefilled 
syringes of propofol tagged with a microchip to ensure that the appropriate drug 
was being used in the system.  This system was developed by Zeneca in 
collaboration with Kenny.(Gray and Kenny 1998)   The Diprifusor system utilises the 
Marsh pharmacokinetic model, first published in 1991(Marsh, White et al. 1991).   
This model used adapted data from work by Gepts to develop a three compartment 
model using 18 patients receiving constant rate propofol infusions at different 
rates.(Gepts, Camu et al. 1987)  A number of other manufacturers now offer TCI 
systems based on a number of published algorithms for propofol pharmacokinetics 
which do not require the use of specific prefilled syringes, making the delivery of 
TCI more cost effective.  These systems can offer a choice of pharmacokinetic 
model for propofol administration, commonly allowing the original Marsh model 
present in the Diprifusor system, and the Schnider model in which kinetics are 
adjusted by patient age, gender and height in addition to weight.(Schnider, Minto 
et al. 1998; Schnider, Minto et al. 1999) 
1.6.3 Differences between pharmacokinetic models for propofol 
All pharmacokinetic models suffer from error.  Errors may be caused by the 
pharmacokinetic modelling, by the computer and mechanical infuser device, or by 
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the variation of the patient characteristics from the original model.  However well 
the model performs during its development, the parameters to develop the model 
are always calculated from a cohort of patients differing from the patient being 
anaesthetised.  Incorporation of additional patient specific parameters to the model 
will help to minimise this difference, and the better the model is able to represent 
specific groups of patients and perform in the clinical setting.  The first 
commercially available, and one of the most widely used models for propofol target 
controlled infusion is the Marsh model. (Marsh, White et al. 1991)  Compartmental 
volumes are proportional to weight, and rate constants for slow and fast 
redistribution are fixed (Table 1).  The model validated by Marsh was derived from 
earlier work by Gepts, who developed the three compartment model from a study 
of three sets of six patients receiving fixed rate propofol infusions at 3, 6 or 
9 mg.kg-1.hr-1.(Gepts, Camu et al. 1987)  The patient cohort was not documented 
fully, but did not include the elderly or obese.  The Marsh model is identical to that 
of Gepts, except for an increase in central compartment volume to 0.228 litres.kg-1 
(no rationale for this adjustment has been published).  The work by Marsh used 
paediatric patients in order to validate the model parameters.  The relatively 
homogeneous nature of children when compared to adults (smaller gender 
differences in body composition, more predictable body compartment estimations, 
lower likelihood of comorbidities) made these patients ideal for the production of a 
model, which performs well in a predefined group of patients.  Error caused by 
pharmacokinetic modelling can be minimised here.   
In order to improve the applicability of the model to groups which fall out of the 
mean, more complex models have subsequently been developed in which age, 
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gender, and lean body mass have been incorporated.  The Schnider model is the 
most widely used alternative to the Marsh model, and attempts to reduce inter-
individual variability through the addition of covariates.  This model was derived 
during a combined pharmacokinetic and pharmacodynamic volunteer study.  
Analysis was performed on bolus, and fixed rate infusions of propofol.  A 
generalised additive model (GAM) analysis was performed to identify potentially 
significant covariates in a stepwise fashion, and multi-compartment models 
incorporating these covariates were estimated using a non-linear mixed effects 
modelling tool (NONMEM1).  Patient characteristics were well documented and 
included an even distribution of gender, a wide adult age range from 25 to 
81 years, and a weight range from 44 to 123 kg. (Schnider, Minto et al. 1998; 
Schnider, Minto et al. 1999)  However, the patient numbers were small with 24 in 
total.  Clearly, the broader the population included in a model, the larger the 
number of patients required to develop a model using multiple covariates in its 
development.  There is a real risk that each patient group (for instance elderly 
female obese patients) will not be well represented at the point of modelling.  Even 
so, the inclusion of multiple covariates in the model is an improvement on earlier 
attempts.  Complex best fit modelling led to a final model with a fixed V1 and V3, 
and an age dependent V2.  The elimination rate constant (K10), is influenced by 
body mass only, and is thus the only parameter influencing estimated rates of drug 
metabolism, with no age related adjustment, as might be expected.  This may be a 
result of the good health of the volunteers.  No gender covariate was included in 
                                        
1 Beal SL, Sheiner LB: NONMEM User’s Guide, San Francisco, University of California San Francisco, 
1979 
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the model, following analysis demonstrating no significant improvement with its 
inclusion.   
The development of multiple models, each improving performance, or each 
performing better in a certain population of patients has obvious advantages.  
There are drawbacks to the proliferation of multiple models for propofol TCI with 
different optimal patient characteristics for each.  An increase in choice could 
potentially lead to an increased likelihood of unfamiliarity with every model, and 
increased user error at the expense of improved model performance. 
Table 1 shows the pharmacokinetic parameters used in the two most commonly 
used propofol TCI models by Marsh and Schnider.  Some observations can be made 
about the differences between these models.  For instance, the central 
compartment (or V1) has been developed with a variable volume based on body 
weight in the Marsh model, but has been given a fixed volume (4.27 litres) in the 
Schnider model.  For this reason, the Marsh model is heavily influenced by patient 
weight at the initial bolus induction phase, whereas the Schnider model will not 
administer a much larger dose in larger patients – a component of the model which 
is counter-intuitive given the experience of the need for weight dependent dose 
adjustment at induction by most clinicians.  For this reason, the rate of induction of 
anaesthesia between the models is markedly different when used in plasma 
targeting mode, so much so, that some authors do not recommend the use of the 
Schnider model in plasma targeting mode, but only in effect site targeting mode in 
which this problem of slow induction is overcome. (Absalom, Mani et al. 2009)   
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 Marsh Schnider 
 Model 70kg  Model (LBM weight, height, gender) 70kg male 
170cm 
V1 0.228 L.kg-1 15.9 4.27 litre 4.27 
V2 0.463 L.kg-1 32.4 18.9-0.391x(age–53) litre 24.0 
V3 2.893 L.kg-1 202 238 litre 238 
K10 (min-1) 0.119 0.119 0.443+0.0107x(weight-77)-0.0159 x (LBM-59)+0.062x(height-177) 0.384 
K12 (min-1) 0.112 0.112 0.302-0.0056x(age-53) 0.375 
K13 (min-1) 0.042 0.042 0.196 0.196 
K21 (min-1) 0.055 0.055 [1.29-0.024x(age-53)]/[18.9-0.391x(age-53)] 0.067 
K31 (min-1) 0.0033 0.0033 0.0035 0.0035 
Ke0 (min-1) 0.26 
(1.2 modified) 
0.26 0.456 0.456 
TTPE (min) 4.5 
(1.6 modified) 
4.5 1.69 1.69 
Table 1:  Adult propofol models, adapted from (Absalom, Mani et al. 2009).  TTPE – time to 
peak effect. V – compartment volume, kij – rate constant between compartments (the 
subscript represents direction of drug movement e.g. k12 denotes movement from 
compartment 1 to 2. k10 denotes the elimination rate constant, and ke0 denotes the effect 
site rate constant (later modified in Marsh), Keo, explained further in chapter 1.6.5). 
 
It is only when viewing the differences in structure of the propofol TCI models 
(shown in Table 1 for two commonly used models) that the large differences in 
dose administration between models for a given patient can be appreciated, 
particularly at the extremes of patient characteristics. 
1.6.3.1 Propofol TCI in paediatrics 
In addition to the two most commonly used TCI models by Marsh and Schnider, 
alternative models have been developed specifically for use in the paediatric 
population.(Kataria, Ved et al. 1994; Absalom and Kenny 2005)  Commercially 
available TCI infusion devices will not as standard allow the infusion of propofol TCI 
using the Marsh or Schnider model to children because of concern about 
pharmacokinetic differences, particularly in young children and infants.  The 
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alternative models have been developed using data from a cohort of young 
children, and are designed to take account of these differences, including larger 
central volumes of distribution and much increased drug clearances in children 
(although very low in neonates).  Such models are of course difficult to apply to all 
ages of children and also maintain reasonable accuracy, given the enormous 
changes in volumes of distribution, metabolic activity and excretory efficiency as an 
infant grows.  Restrictions on the advisable minimum age and weight in order for 
acceptable performance are placed on these models (Kataria age of one year, 
weight 5 kg, and Paedfusor age 3 years, weight 15 kg). (Mani and Morton 2010)  
They are used effectively within these limits in many institutions.  Another 
important and well recognised consideration in children is that the median plasma 
propofol concentration required to produce anaesthesia is higher than in adults, 
requiring a propofol concentration of 4.8 µg.ml-1 to produce a 50% fall in Bispectral 
index in one study.(Jeleazcov, Ihmsen et al. 2008) 
1.6.3.2 Propofol TCI in the obese population 
The differences highlighted between the main TCI propofol models by Marsh and by 
Schnider are magnified in the obese population.  In fact, many clinicians do not use 
the actual body weight when inputting values into the Marsh model, but use a 
correction, for instance that proposed by Servin to reduce the risk of overdosing. 
(Servin, Farinotti et al. 1993)  Servin’s correction does not however consistently 
improve the model performance, and no model currently performs reliably in the 
morbidly obese.  The Schnider model makes an attempt to account for the influence 
of variable body fat by including calculated lean body mass in the modelling (see 
Table 1).  The James equation for the calculation of lean body mass (shown below), 
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(James 1976) which the Schnider model incorporates, is flawed however in the 
morbidly obese population, such that these patients are at risk of relative 
overdosing of drug.  The lean body mass calculated by the James equation 
increases with total body mass as expected, until it reaches a maximum value, after 
which calculated lean body mass values paradoxically decrease.  The body mass 
index (BMI) value above which this paradoxical calculation occurs is 37 kg.m-2 for 
females, and 42 kg.m-2 for males.  In order to protect against   this error, some 
manufacturers of TCI infusers have placed an upper limit on body mass index, 
above which the machine will not function, and others have modified the James’ 
LBM formula when this situation arises to fix the calculated weight at the maximal 
LBM figure for the given height.(Absalom, Mani et al. 2009)  Currently, work is 
ongoing into the development of alternative ways of accounting for the influence of 
body size on pharmacokinetic modelling, as it is recognised that weight alone is not 
sufficient, and calculated values such as ideal body weight or lean body mass are 
not sufficiently robust.  Allometric scaling is a mathematical examination of the 
relationship between body function and body size. Numerous physical and 
physiological parameters vary according to some mathematical function of body 
size. This theory has been used to enable pharmacokinetic comparisons between 
animal models and humans, as well as for some extrapolation of paediatric 
modelling from adult data. (Knibbe, Zuideveld et al. 2005; Peeters, Allegaert et al. 
2010)  It is possible that the use of allometric modelling may further improve the 
validity of propofol TCI models in a broader cohort, to include the extremes of 
weight and height.  No model using allometric modelling is yet available for 
clinicians to use. 
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The James equation: 
Males:   LBM = 1.1 x weight – 128 x (weight/height)2 
Females:  LBM = 1.07 x weight – 148 x (weight/height)2 
 
1.6.4 The Evaluation of Target Controlled Infusion Systems 
Following the development of a pharmacokinetic model based on the BET system 
described, the system requires validation on a clinical population in order to confirm 
its efficacy.  The system for validation involved the recruitment of small numbers of 
patients into clinical trials in which the anaesthetic agent is infused using software 
running the pharmacokinetic model, and serial samples of blood are taken during 
anaesthesia.  Drug concentrations predicted from the model are compared with 
those measured from blood, and the bias and precision of the model are 
determined from these data.  When pharmacokinetic modelling was first developed, 
Schuttler proposed early on in the development of TCI systems that the 
performance of the systems that he had developed were clinically acceptable when 
the mean variation of measured concentrations around predicted values were up to 
30%, with a maximal variation of up to 60%.(Schuttler, Kloos et al. 1988)  He also 
proposed that a bias of up to 20% was acceptable.  He commented that the patient 
variability causing these significant deviations could be overcome by adjustment of 
the device to clinically determined parameters.  These figures are still quoted as 
targets within which new pharmacokinetic models should fit, although are seen as 
excessive by some.  Significant bias and large errors in precision have been 
identified in groups falling outside of limits used in the development of these 
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algorithms such as the morbidly obese, or when used in special situations such as 
on-bypass cardiac surgery. (Bailey, Mora et al. 1996; Barvais, Rausin et al. 1996; La 
Colla, Albertin et al. 2009) 
 
1.6.5 Effect-Site Estimation 
TCI technology when first introduced focused solely on the estimation of blood 
propofol concentrations as a marker of the drug concentration at the site of action 
in the brain.  More recently, an attempt has been made to estimate a constant to 
determine the rate of equilibration between blood and brain (the ke0).  If an 
accurate estimate of the rate of equilibration between measured site (blood) and 
effect site (brain) can be made, then pharmacokinetic models can incorporate this 
into their algorithms in order to achieve more accurate titration of anaesthetic 
concentrations in the brain.  Work using measures of depth of anaesthesia have 
attempted to validate the rates of equilibration between blood and brain. (Jacobs 
and Williams 1993; White, Schenkels et al. 1999; Struys, De Smet et al. 2000) 
These values have been incorporated into the commonly used pharmacokinetic 
models, and these are currently available for use on most commercial TCI systems.  
The disadvantages of the incorporation of the ke0 into these models relate in part to 
the problems in determining an accurate value.  Certainly, very different values are 
used for different models, and some models use constant values, whereas others 
modify the value used based on patient demographic data.  To add to the 
confusion, the Marsh model has two values of Ke0, as the originally proposed value 
of 0.26 min-1 has been replaced in some devices by a value of 1.2 min-1 following 
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work to demonstrate improvements using this figure.(Struys, De Smet et al. 2000)  
The original Ke0 value was derived by Billard using propofol pharmacokinetic data, 
but not using the Marsh model for derivation.(Billard, Gambus et al. 1997)  The 
value of 1.2 min-1 was determined using pharmacodynamic analysis during infusion 
using the Marsh model.  There are data to suggest that ke0 values actually have a 
significant variability based on age or method of determination, making their 
estimation less predictable.(Kazama, Ikeda et al. 1999)  Another disadvantage of 
targeting the effect site is that blood propofol concentrations are allowed to swing 
more significantly, leading to the accentuation of haemodynamic side effects of the 
drug. 
 
1.6.6 Advantages and Disadvantages of Target Controlled Infusion 
TCI systems are able to rapidly achieve and maintain predicted drug concentrations 
through the administration of boluses followed by variable rate infusions based on 
the predicted rates of drug clearance previously determined through 
pharmacokinetic modelling.  A drop in desired drug concentration is achieved 
rapidly by a calculated period of infusion suspension, followed by a modified rate of 
infusion to maintain the drug at the new desired concentration.  These devices have 
a number of advantages: 
• User friendly, and method of drug dose manipulation more similar to 
inhalational anaesthesia 
• Ability to modify predicted blood concentration according to level of noxious 
stimulation 
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• Computer software performs calculations of dose and volumes required 
reducing the likelihood of error. 
• Usability in remote environments away from the infrastructure required for 
inhalational anaesthesia. 
 
These systems do however continue to have disadvantages when compared to 
more traditional methods of anaesthesia: 
• Predicted values are theoretical and are validated on a relatively small 
number of physiologically normal individuals.  There may be a tendency to 
rely too heavily on estimated concentrations, particularly amongst those used 
to the more reliable measured drug concentrations available using 
inhalational anaesthesia. 
• Risk of drug maladministration.  The ability of the computer algorithms to 
deliver accurate concentrations of drug also depends on the reliability of 
continuity of drug infuser with the patient, which cannot be guaranteed 
without continuous vigilance. 
• Drug delivery depends on investment in new dedicated TCI infusers, which 
incurs additional expense.  These infusers may be less reliable than 
anaesthetic machines which do not necessarily rely on mains power to 
function safely.  Loss of power to these infusers with loss of stored data can 
lead to difficulty knowing how to continue accurate TCI of anaesthetic agent. 
The major problem holding back more widespread use of intravenous anaesthesia is 
the inability to directly monitor the amount of propofol circulating at the site of 
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action in the brain, or, as a proxy measure, in the blood.  The end tidal drug 
concentration, used as an approximation of blood anaesthetic concentration is 
currently routinely measured when using inhalational anaesthetic agents.  The 
major benefits in being able to measure drug concentrations are twofold.  Firstly, 
continuous anaesthetic concentration monitoring can demonstrate the effective and 
continuous delivery of drug to its site of action.  Secondly, drug concentration 
monitoring is patient specific, and does not rely on the assumptions made in 
pharmacokinetic modelling which are based on small numbers and do not include 
data on physiological outliers. 
 
1.7 Methods of Measuring Blood Propofol Currently Available 
Blood propofol concentrations can currently be measured, although only in the 
research setting using laboratory equipment requiring skilled technicians, and 
generating results in a timeframe which is not clinically useful.  The research tools 
are described below: 
 
1.7.1 High Performance Liquid Chromatography (HPLC) 
The technique most commonly used to measure blood propofol concentrations for 
research purposes is based on high performance liquid chromatography (HPLC).  
HPLC is a form of column chromatography used to separate, identify, and quantify 
compounds. 
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HPLC uses a column filled with a chromatographic packing material (the stationary 
phase), a high pressure pump to move the chosen solvent through the column (the 
mobile phase), and one of various detectors to detect the substances in the solvent 
after it emerges from the column.  The analyte is slowed down within the column 
by interaction with the packing material, and the rate of passage through the 
column for a given solvent and packing material can be determined.  This can be 
used to identify the analyte. The identification (peak) and quantification (area under 
the curve) of the analyte requires the use of a detector, which is determined by the 
properties of the analyte, but usually uses optical or electrochemical techniques. 
The majority of centres measuring propofol using HPLC use the technique originally 
described by Plummer, or a modification of this technique.(Plummer 1987)  This 
process uses a solvent (mobile phase) consisting of a mixture of acetonitrile and 
water.  In order to improve the accuracy of quantification, an additional predefined 
amount of a chemical, thymol, is added to the sample to act as an internal standard 
and compensate for any variability in the extraction efficiency.  The sample is 
measured using a fluorescence detector set at 276 nm (excitation) and 310 nm 
(emission).  The propofol concentration is then estimated from the ratio of the peak 
areas for propofol and thymol on the chromatograph.  Using this technique a 
coefficient of variation of between 1.3 and 5.5% can be achieved over a 
concentration range between 0.01 and 0.1μg.ml-1, and is thus useful for quantifying 
very low concentrations of propofol often required in pharmacokinetic analysis.  It is 
also highly accurate when measuring propofol in the clinical range, with coefficients 
of variation between 2.9 and 4.4% in work by Plummer.(Plummer 1987) 
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1.7.2 Gas Chromatography (GC) 
Propofol is an example of a chemical which can be relatively easily vaporised with a 
low boiling point, enabling it to undergo analysis using gas chromatography.(Yu and 
Liau 1993)  This process involves a sample being vaporised prior to injection onto 
the head of a chromatographic column.  The mobile phase is provided by a flow of 
inert gas, and the stationary phase is in this case a liquid adsorbed onto the surface 
of an inert solid with a high surface area, often narrow capillary tubes.  In a similar 
fashion to HPLC, the analytes will be slowed down in their passage through the 
column, and elute at a known time (the retention time).  Again, detectors are 
required to quantify the analyte, an example for propofol analysis is the flame 
ionisation detector.  Detection accuracy for this system is good, with linearity over a 
wide range of concentrations (10-10,000 ng.ml-1).(Yu and Liau 1993)   These 
systems are expensive, require precise temperature control for accurate extraction 
of analyte, and are time consuming to perform.  An attempt to simplify the process 
using gas chromatography and solid phase micro-extraction of propofol has been 
published, although the equipment required is bulky and labour intensive.(Fujita, 
Higuchi et al. 2000) 
 
1.7.3 Mass Spectrometry 
Both liquid and gas chromatography techniques described can be linked to a mass 
spectrometer for detection and quantification of propofol concentrations.(Stetson, 
Domino et al. 1993; Guitton, Desage et al. 1995; Bajpai, Varshney et al. 2004)  The 
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mass spectrometer allows precise quantification, and preserves specificity in the 
presence of a complex physiological mixture (coadministered drugs which may be 
falsely detected as propofol).  In order to improve quantification, an internal 
standard may also be used when using mass spectrometry for detection, in order to 
control for the variability in the extraction process occurring prior to detection. 
 
1.8 Surrogate Methods of Estimating Blood Propofol Concentration 
One of most promising technologies with potential for clinical utility by allowing 
continuous measurement of propofol concentration, is the measurement of propofol 
metabolites in exhaled breath.  This idea is appealing, as it mirrors the current 
standard practice of measuring volatile anaesthetic agents in the operating room to 
enable the minute to minute quantification of administered anaesthetic agent and 
to allow the early alert of the failure to administer anaesthetic via alarm systems 
(for example machine failure or operator error).  The properties of inhalational 
anaesthetic agents make them ideal for this system of analysis.  Although the 
intravenous agent propofol is partially excreted via its metabolites in the breath, the 
concentrations are extremely small (measured in the parts per billion), making the 
likelihood of accurate correlation between the blood (or effect site) unlikely.  This 
technology has undergone some early research however (Harrison, Critchley et al. 
2003; Grossherr, Hengstenberg et al. 2009; Laurila, Sorvajarvi et al. 2011)  
Intermittent gas sampling by Grossherr during anaesthesia has demonstrated no 
equilibrium at clinically meaningful time points between exhaled gas and plasma, 
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making this technology unlikely to be of clinical benefit in the way that it is for 
volatile anaesthetics. 
 
1.9 Methods to determine depth of anaesthesia during Total Intravenous 
Anaesthesia with Propofol 
1.9.1 Introduction  
There is currently no method of measuring blood propofol concentrations in 
anything like a clinically meaningful timeframe.  Commercially available propofol TCI 
machines using pharmacokinetic modelling to estimate blood propofol concentration 
suffer from a number of drawbacks; estimated propofol concentrations rely on the 
patient being anaesthetised having similar characteristics to the patient cohort used 
during development of the drug administration algorithm.   
The simplest method employed by anaesthetists to assess depth of anaesthesia is 
the interpretation of clinical signs.  These include blood pressure, heart rate, 
sweating, tearing, pupillary response, and muscle reflexes.  Whilst routinely used to 
aid depth of anaesthesia assessment, many of these signs when taken individually, 
are subject to change based on events unrelated to depth of anaesthesia.  For 
instance,  use of vasoactive drugs either pre or intraoperatively, or the patient 
volume status, will influence the measured haemodynamic parameters 
independently of depth of anaesthesia.  Furthermore presence of concurrently 
administered drugs, particularly those such as neuromuscular blocking agents will 
lead to a suppression of voluntary and involuntary muscular contraction.  Pupillary 
responses can be masked through the use of opiates.  Noxious stimulation will 
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affect autonomic responses independently of the concentration of anaesthetic 
agents.(Cullen, Eger et al. 1972)  Consequently, inaccurate assessments can be 
made, leading to potential under or overdosing of anaesthetic agents.   
The assessment of beat to beat heart rate variability has been proposed as a more 
advanced method of assessment of depth of anaesthesia.(Pomfrett, Barrie et al. 
1993; Pomfrett, Sneyd et al. 1994)  Loss of respiratory sinus arrhythmia is related 
to depth of anaesthesia through direct medullary inhibition.  This potentially useful 
aid to depth of anaesthesia assessment has not been adopted however.  There is 
difficulty determining the influence of vasoactive drugs on the phenomenon, and 
the method requires the integrity of the autonomic control mechanisms, which may 
be disrupted by comorbidities such as diabetic autonomic neuropathy. 
The isolation of the arm from the effects of neuromuscular blocking agents using a 
tourniquet has been described, allowing the patient, if inadequately anaesthetised, 
to control movement in this limb in response to verbal command.  To prevent 
ischaemia, the tourniquet needs to be relaxed, and reapplied should more 
neuromuscular blocking agent be required.  Although accepted as a useful measure, 
and having been used in research as a benchmark against other techniques, it is 
not without limitations, and has not been found to be universally protective against 
risk of awareness.(Bogod, Orton et al. 1990)  This technique is only designed to 
distinguish between overt awareness and anaesthesia, and cannot aid in the 
determination of anaesthetic depth. 
A number of commercial devices are available, designed to continuously assess the 
depth of anaesthesia directly.   The advantage of these monitoring devices is that 
48 
 
they attempt to assess directly the desired outcome i.e. unconsciousness rather 
than the drug concentration, which is subject to pharmacodynamic variation.  These 
devices are increasing in popularity in both anaesthesia using inhalational and 
intravenous agents, although their benefits are still not well defined.  They are 
currently not recommended as part of routine anaesthetic 
monitoring.(ASA_Taskforce_on_Intraoperative_awareness 2006)   Evidence for 
their use has focused on the reduction in anaesthetic agent use and improved time 
to emergence, rather than impact on anaesthetic awareness. 
 
1.9.2 Depth of Anaesthesia Monitors 
Devices are divided into those that monitor spontaneous EEG activity, and those 
that monitor externally evoked brain activity.  All systems include transformation of 
complex electroencephalograph data into an index of depth of anaesthesia, and all 
include systems to detect and exclude artefacts from analysis. 
 
1.9.2.1 Bispectral Index Monitor (BIS) 
The most commonly used monitor is the Bispectral Index (BIS), (Aspect Medical 
Systems, Natick, MA), which converts a single channel of frontal 
electroencephalograph into an index between 0 and 100, with specific ranges (40-
60) reflecting low probability of consciousness.  Several variables from the 
electroencephalogram are combined to form the index, including time domain 
variables (burst-suppression), and frequency domain variables (power spectrum, 
bispectrum: interfrequency phase relationships).  The contribution of these 
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variables on depth of anaesthesia has been established from prospectively collected 
data from a large number of anaesthetics.  Evidence for reduced anaesthetic 
awareness when using BIS includes a randomised controlled trial comparing BIS 
guided anaesthesia versus standard practice in 2500 patients at high risk of 
awareness.(Myles, Leslie et al. 2004)  Explicit recall reduced from 0.91% to 0.17% 
(p<0.02) in the BIS group.   One Chinese randomised controlled trial of over 5000 
patients demonstrated a reduction in awareness when using titration of propofol 
intravenous anaesthesia to predefined BIS levels (p=0.002), however, the rates of 
awareness in the control arm (no BIS titration) were much higher than found in 
other publications at 0.65% of anaesthetics.(Zhang, Xu et al. 2011)  Other trials 
have demonstrated benefits including reduced time to wakening, and reduced 
anaesthetic drug usage with BIS monitoring, although further evidence of reduced 
awareness has been lacking.  A recent publication of anaesthesia in patients at high 
risk of awareness was unable to find an improvement when titrating volatile 
anaesthesia to BIS compared to titrating anaesthesia to within predefined volatile 
MAC.(Avidan, Jacobsohn et al. 2011)  Titration to MAC would of course not be 
possible during intravenous anaesthesia. 
 
1.9.2.2 Entropy 
Entropy (GE Healthcare Technologies, Waukesha, WI), uses the principles that 
electroencephalograph characteristics change from disorder to predictability as 
depth of anaesthesia increases.  Two figures are presented, termed the ‘state 
entropy’ based on analysis of cortical frequencies, and ‘response entropy’ reflecting 
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higher frequencies which also contain electromyographic activity representing scalp 
muscle contraction associated with inadequate depth of anaesthesia.  The ‘response 
entropy’ mode is added to allow a more responsive system with rapid feedback, 
although it is less robust and more susceptible to interference and drugs such as 
neuromuscular blockers than ‘state entropy’ which uses electroencephalographic 
data alone.  ‘State entropy’ uses a scale from 0 to 91, and ‘response entropy’ from 
0 to 100. 
 
1.9.2.3 Narcotrend 
The Narcotrend, (MonitorTechnik, Bad Branstedt, Germany) has been developed 
using a system of classification of electroencephalograph patterns associated with 
stages of sleep.  This system originally reported various states of anaesthesia based 
on this, but has since changed to an index between 0 and 100 to conform with 
other monitors available. 
 
1.9.2.4 Patient State Analyser (PSI) 
The Patient State Analyser, (Physiometrix, North Billerica, MA) derives an index of 
depth of anaesthesia from a four channel electroencephalograph, rather than a 
single channel used in other systems.  The system is based on a finding that there 
are special changes in power distribution of electroencephalograph signals on 
induction of anaesthesia 
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1.9.2.5 Auditory Evoked Potential Monitor (AEP) 
The AEP Monitor 2 (Danmeter, Odense, Denmark), emits sound stimuli (clicks) and 
measures the electroencephalograph response to these.  Responses known as 
middle latency auditory evoked potentials change with depth of anaesthesia, 
although signals are very small and require complex averaging techniques to 
extract.  An index scale is presented from 0 to 100, although a level of less than 25 
representing low probability of consciousness is lower than the other systems. 
 
1.9.3 Weaknesses of Depth of Anaesthesia Monitoring 
• Currently available monitors using the electroencephalogram (EEG) to derive 
depth of anaesthesia estimates utilise complex transformations based on the 
EEG characteristics.  A delay between recording and change in estimated depth 
of anaesthesia of between 20 seconds to over 100 seconds is necessary to allow 
post processing to limit the influence of interference, and to identify trends.  
These delays may be clinically significant, and can lead to a delayed recognition 
of change in anaesthetic depth. 
• Monitors relying on EEG processing are not validated, and frequently practically 
difficult to place during neurosurgery on the brain.  This area of anaesthesia 
currently uses a high proportion of intravenous anaesthetics because of 
evidence of improved outcome and rapid unclouded emergence from 
anaesthesia. 
• The evidence for reduced levels of awareness whilst using these monitors has 
not been clearly defined, and therefore has not been adopted by anaesthetic 
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authorities as routine practise.  The UK National Institute for Heath and Clinical 
Excellence  (NICE) have recently produced a document suggesting that depth of 
anaesthesia monitoring should be considered ‘as an option’ in specific 
circumstances including anaesthetics considered as constituting a high risk of 
awareness, and during intravenous anaesthesia because of potential cost 
effectiveness.(NICE 2012)  There is however considerable dispute amongst 
experts and specialist societies on the as yet unproven benefits of these 
monitors, and this is perhaps why the NICE guidance offers no hard guidelines.  
• These devices are susceptible to artefacts from surrounding electrical devices 
and muscle activity.  Modern algorithms are able to detect these artefacts to 
some extent, although complex processing will delay time from signal 
measurement to value output. 
• EEG based depth of anaesthesia monitors measure cortical activity, rather than 
anaesthesia itself.  Values deemed to indicate anaesthesia have been recorded 
in awake volunteers, in particular in the presence of neuromuscular blockade 
which serves to reduce cortical signals.(Messner, Beese et al. 2003; Vuyk, 
Lichtenbelt et al. 2004) 
• Not all anaesthetic agents lead to cortical signals measured as anaesthesia.  
Anaesthesia using ketamine, nitrous oxide, and xenon gas can be 
misinterpreted, in particular when using BIS or entropy systems. 
• Much of the validation data for depth of anaesthesia monitoring has come from 
normal patients, or routine anaesthesia.  Structural brain lesions, altered 
sensorium, and multiple medications used in critical care are likely to make the 
values less meaningful in this environment. 
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• One publication has demonstrated poor correlation between plasma propofol 
concentration and depth of anaesthesia recorded using the BIS 
monitor.(Hoymork, Raeder et al. 2003)  Figure 3 shows the propofol 
concentrations recorded at BIS index levels between 40 and 60, usually 
representing unconsciousness.  Although most propofol concentrations lie 
between 2 and 4 µg.ml-1, no clear correlation between depth of anaesthesia and 
propofol concentration could be established.   Based on this work, the authors 
were unable to support the theory that BIS represents a continuous 
measurement of depth of anaesthetic-induced hypnosis, assuming that 
increased plasma concentrations of propofol correspond to deeper hypnotic 
levels.  They did also point out, however, that they had insufficient data points 
to allow characterisation of correlations between BIS and propofol 
concentrations in individual patients, and therefore could not rule out inter-
individual differences in the sensitivity to propofol; and a correlation existing but 
not disguised because of pooling of data points. 
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Figure 3:  Graph demonstrating poor correlation between measured propofol 
concentrations and Bispectral index (BIS) scores between 45 and 60 (usual range expected 
to prevent awareness), r2=0.01, p=0.66 (Hoymork, Raeder et al. 2003). 
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2 CHAPTER 2 – CLINICAL VALIDATION OF A MACHINE FOR MEASURING 
BLOOD PROPOFOL CONCENTRATIONS 
2.1 A novel machine to measure propofol concentrations 
As described in chapter one, conventional methods of measuring propofol 
concentrations in blood include high performance liquid chromatography (HPLC), 
gas chromatography and liquid chromatography mass spectroscopy.  Whilst these 
methods have been demonstrated to be accurate, they are both labour intensive 
and time consuming and can therefore not be used to deliver clinically useful 
information in real time.  Other methods of estimating blood propofol from expired 
gases have yet to demonstrate consistent and reliable results in view of the very 
small proportion of propofol excreted in expired breath. (Harrison, Critchley et al. 
2003)  It is possible that advancing research in sensor technology may in the future 
allow expired gas propofol measurement in near real time, although the extremely 
small concentrations of gas are likely to make meaningful use of the values 
recorded to titrate anaesthesia unlikely.(Laurila, Sorvajarvi et al. 2011)  The 
complexity of propofol distribution and elimination and variable propofol 
pharmacokinetics, particularly in patient groups that differ from the norm, make the 
ability to measure propofol concentrations in a clinically meaningful timeframe 
desirable.  Well developed technologies to measure the depth of anaesthesia using 
encephalographic analysis have been reviewed in chapter 1, and their weaknesses 
have been examined.  Their main benefits are that they attempt to assess the 
desired endpoint, i.e. unconsciousness, and that they produce a continuous 
readout.  They are however generally used in combination with other tools 
designed to assess depth of anaesthesia, such as haemodynamic variables, and 
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continuous inhalation anaesthetic concentration recording in expired breath.  The 
inability to measure the concentration of intravenous anaesthetic in this way 
removes a level of safety enjoyed during inhalational anaesthesia.  It is envisaged 
that depth of anaesthesia monitoring could be combined with intermittent 
monitoring of intravenous anaesthetic concentration to monitor the accuracy of 
predicted drug concentrations available from commercially available target 
controlled infusers. 
 
Our group, in collaboration with a medical device company (Sphere Medical Ltd., 
Cambridge, UK), have undertaken development and testing of a device capable of 
extracting propofol from whole blood using solid phase extraction, coupled with 
colorimetric detection techniques.(McGaughran, Voss et al. 2006)  The machine 
requires half a millilitre of blood to perform the analysis with an analysis time of 
approximately five minutes.  Initial work to ensure reliability was followed by work 
on clinical samples to further define the efficacy of the device.  I have performed 
the analysis of data collected previously by others within the group for the 
experiments in this chapter. 
 
2.2 Authors Involvement in Validation Experiments in this Chapter 
The series of validation experiments in vitro and on clinical specimens in this 
chapter were performed by other members of the research group, and I have 
undertaken the collation of data and statistical analysis of results.  All subsequent 
experiments in this report have been designed, performed, and analysed by myself. 
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2.3 Measurement of propofol using the novel propofol analyser 
The conventional method for laboratory measurement of propofol concentrations 
requires the labour intensive process of high performance liquid chromatography 
(HPLC), and using an internal standard chemical to improve quantification.  The 
alternative method of solid phase extraction (SPE) utilised in the novel analyser 
uses exactly the same principles of propofol separation as in HPLC, although it is 
more specifically designed for extraction of a single analyte for quantification.  The 
process involves initially washing the sample using a weak mobile phase solvent to 
remove any impurities, but to allow the analyte to be retained in the stationary 
phase.  A second stronger mobile phase is then introduced to rapidly extract (elute) 
the analyte for quantification.   
The analyser is capable of providing a propofol measurement in heparinised whole 
blood, using automated sample preparation including sample lysis, solid phase 
extraction and detection.   A colour change is induced through the addition of Gibbs 
reagent to the extract, and this is quantified using visible absorption spectroscopy, 
as previously described for propofol.(Adam, Douglas et al. 1981)   
 
2.3.1 Principle of operation 
The fluidics of the system consists of a series of pumps and valves coupled together 
with Teflon tubing.  A schematic diagram of the fluidics is shown in Figure 4.  There 
are two hardware items involved in the instrument control and data acquisition on 
this system, a photodiode array spectrometer and a programmable logic controller.  
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For absorbance spectrometry, a tungsten-halogen light source and 16 bit fibre-optic 
photodiode array spectrometer is incorporated in the system. Automation of the 
fluidics control is achieved using the programmable logic controller and customised 
software developed with LabVIEW 2009 (National Instruments, Austin, Texas).   
 
Figure 4:  Schematic diagram of the fluidics of the new propofol analyser. V: valve, P: 
pump, Rinse 1: deionised water, Rinse 2: 50% methanol in water. 
 
On initialisation of the system, a dark spectrum is initially collected.  In order to 
collect this dark spectrum, the software turns off the tungsten-halogen light source 
and measures the background spectrum of the photodiode array spectrometer. 
Following the dark spectrum collection, the light source is turned on again and the 
instrument is allowed to warm up for a minimum period of 30 minutes for the lamp 
to reach a constant operating temperature.  Following this start-up, the pumps and 
valves are primed by a software-controlled sequence to purge air from the system 
prior to running the samples. Following sample injection into the analyser, a known 
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volume of the blood sample undergoes automated lysis with deionised water at a 
ratio of 1:2 (blood: water).  The sorbent cartridge is conditioned with methanol, 
and the cuvette is filled with methanol for the collection of a reference spectrum.  
Following the acquisition of the reference spectrum, the cuvette is rinsed and 
flushed.  Elution of the sorbent cartridge into the cell is carried out with acetonitrile.  
Gibbs reagent (2,6 dichloro-p-benzoquinone-4-chloroimine) and bicarbonate buffer 
solution are added to the cell.  The eluent is flushed into the cell using compressed 
air in order to achieve an accurate volume and to promote mixing.  Colour 
development is allowed to take place over 40 seconds before a spectrum is taken.  
The cell is then emptied to waste and rinsed with methanol to prepare for the 
subsequent sample. 
 
Propofol concentration is derived from the absorbance of the sample at 595 nm 
(peak absorbance) and normalised by subtraction of the absorbance at 800 nm (a 
wavelength known to have low indophenols absorbance, and used to provide a 
correction for background optical scatter and incident light intensity variation in the 
sample) as summarised in the following equation: 
nmnm DR
DS
DR
DSA
800
10
595
10 loglog 











−
−
−−











−
−
−=
 
 
S, R and D are the counts recorded on a 16 bit photodiode array from the sample, 
reference and dark spectra at the wavelength indicated, respectively. This equation 
represents the standard method to calculate absorbance spectra using dark, 
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reference, and sample spectra, modified for the calculation of propofol 
concentrations by McGaughran et al. (McGaughran, Voss et al. 2006) 
 
 
Figure 5:  Screenshot from novel propofol analyser showing a raw spectrum from 
spectrometer and an absorbance spectrum for a sample containing propofol. 
 
System calibration 
The monitor was calibrated using the working standards WS1, WS2 and WS3. 
These working standards of propofol with concentrations of 0, 2.5 and 7.5 µg.ml-1 
were prepared by diluting 2,6 diisopropylphenol (1%, AstraZeneca) in methanol.  
Measurements with these standards were run at the beginning of each day using 
the automated sequence described above. From the measurement results a 
calibration curve was constructed by the LabView software by plotting the 
measured absorbance values against the concentrations of the three standard 
solutions. The data were fitted using a least squares regression analysis with the 
equation y=mx + c  where m is the gradient and c is the intercept of the ordinate.  
Figure 6 shows an example of a calibration curve.  The propofol concentrations of 
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the unknown blood specimens were derived using the regression equation obtained 
during the calibration. 
 
 
Figure 6: Example screenshot from novel propofol analyser of a calibration curve 
constructed using the LabView software to derive propofol concentration from absorbance 
spectra. 
 
 
2.4 Measurement of propofol using HPLC Reference Method 
An HPLC reference method was used to compare results with the novel propofol 
analyser.  The HPLC reference method for propofol extraction and measurement 
using an internal standard was based on that reported by Cussonneau because of 
efficiency and simplicity of propofol extraction and the effectiveness of the 
fluorescence detection method. (Cussonneau, De Smet et al. 2007)  Several 
methodological differences were required because of differences in HPLC system 
and analysis software, and such changes are highlighted in Table 2.  Propofol 
y = 0.0541x + 0.0138 
R² = 0.9986 
0
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0.2
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concentrations were measured using a Shimadzu HPLC system (Shimadzu UK Ltd, 
Milton Keynes, UK) including a LC-10ATvp solvent delivery pump, a SIL-10A 
automatic sample injector driven via a SCL-10A system controller with a 
fluorescence detector set at 276 nm (excitation) and 310 nm (emission).  A 
Phenomenex (Phenomenex, Macclesfield, UK) reverse phase column was used.  The 
isocratic mobile phase consisted of acetonitrile-water mixture (75:25, v/v) at a flow 
rate of 0.6ml.min-1.  The system was calibrated using seven standard solutions of 
propofol in acetonitrile covering the range 0.1-10 µg.ml-1.  200 µl of the sample was 
mixed with 800µl of acetonitrile containing 1µl.ml-1 thymol as an internal standard in 
order to compensate for variability of the extraction efficacy.  Following mixing, 
these samples were centrifuged for 5 minutes at 13,200 rpm.  The supernatant was 
filtered and injected into the HPLC for analysis, and the propofol concentration 
calculated from the ratio of the propofol and thymol peaks in the HPLC 
chromatograph. (Plummer 1987)  Data collection was facilitated using Clarity Lite 
(DataApex, Prague, The Czech Republic).  The HPLC system underwent evaluation 
with respect to its linearity, range and repeatability, with submitted validation data 
enabling its use for regulatory validation.  The assay was highly linear over the 
clinical range of 0.5 – 10 µl.ml-1, with an R2 of 0.999.  The limit of quantification 
was found to be 2.0 ng.ml-1, and the limit of detection 0.05 ng.ml-1.  Interassay 
precision was 2.10-2.24 % (coefficient of variation) between 0.1 and 10 µg.ml-1.  
Interference testing with drugs commonly co-administered with propofol showed no 
interference with the propofol/thymol peaks. 
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 Cussonneau HPLC system 
   
Modified HPLC System 
HPLC system Kontron Shimadzu 
mobile phase acetonitrile-water (65:35, v/v) acetonitrile-water (75:25, v/v) 
Stationary phase Purospher®  Luna® 
calibration media drug-free serum Acetonitrile 
sample treatment 500µl blood + 500µl acetonitrile 200µl blood+ 800µl acetonitrile 
Sample storage Frozen Lysed blood Fresh blood  
Injection volume 100ul 20ul 
Table 2:  Differences between HPLC system used for sample analysis and that published by 
Cussonneau (Cussonneau, De Smet et al. 2007). 
 
2.5 Validation work on new propofol analyser 
Prior to use on clinical samples, the analyser underwent laboratory evaluation to 
demonstrate that the method of analysis was robust.  Testing using propofol spiked 
volunteer blood was performed to assess linearity and between run repeatability 
over a clinically relevant propofol concentration range.  The machine also 
underwent cross-interference studies using a range of drugs commonly used in the 
operating room and intensive care at twice the normal therapeutic concentration.  
As propofol is strongly bound to cells and protein in blood, the effect of 
haemoglobin concentration was also assessed.   
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2.5.1 Linearity and Repeatability 
The new device underwent linearity testing using propofol spiked with healthy 
volunteer blood over a clinically relevant range.  Samples with propofol 
concentrations ranging from 0.5 – 6 µg.ml-1 were tested using the new monitor on 
four occasions over a two week period, demonstrating excellent linearity with an R2 
value of 0.996, shown in Figure 7.  Table 3 shows values using the novel analyser 
measured for each propofol spiked whole blood specimen.  The coefficient of 
variation was used to assess the between run repeatability, calculated as the 
standard deviation divided by the mean, and expressed as a percentage.  The 
maximum coefficient of variation for propofol concentrations within the range 
tested was 4.45%. 
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Figure 7:  Propofol concentrations measured by the new monitor in propofol spiked whole 
blood samples with concentrations between 0.25 and 6 µg.ml-1; measurements were 
repeated on five propofol concentrations on four occasions over a two week period to 
demonstrate repeatability.  Linear regression line, and 95% confidence interval lines 
shown. 
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 Propofol spiked whole blood (µg.ml-1) 
 
Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 
 
0.66 1.04 1.80 3.81 5.43 
 
0.69 1.06 1.72 3.50 5.26 
 
0.63 1.11 1.84 3.59 5.61 
 
0.66 1.05 1.86 * * 
Mean 0.66 1.06 1.81 3.63 5.43 
SD 0.03 0.03 0.07 0.16 0.18 
CV (%) 4.01 2.68 3.65 4.45 3.24 
Table 3: Propofol concentrations measured using novel analyser prepared in five 
concentrations between 0.5 and 6 µg.ml-1.  Measurements were made on four separate 
occasions over two weeks. *missing data points (spoilt sample)  SD – standard deviation, 
CV – coefficient of variation. 
 
2.5.2 Limits of detection 
The limit of detection (at the 1% confidence level) was calculated as the mean plus 
three times standard deviation of ten samples analysed on the novel propofol 
analyser of whole blood known to contain no propofol.(Westgard 1999)  Results 
from these samples ranged from 0.05 to 0.15 µg.ml-1, with a standard deviation of 
0.04 µg.ml-1.  Mean concentration was calculated to be 0.08 µg.ml-1.  Thus, a limit 
of detection of 0.20 µg.ml-1 was calculated.  The limit of detection lies below the 
lower limit of propofol concentrations required for clinical utility, for which the new 
analyser has been designed.   
 
2.5.3 Limits of Quantitation 
The limit of quantitation, or lower limit of determination is the lowest amount of 
analyte in a sample that can be quantitatively determined with stated acceptable 
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precision.  As the novel propofol analyser has been designed to measure propofol 
concentrations within a clinically useful range, testing was performed to assess the 
analyser at the lower limit of clinical utility, which was set at 0.25 µg.ml-1 for the 
purposes of this analyser, a concentration which could feasibly be desired for very 
light sedation, although much lower than the expected concentrations during 
general anaesthesia.   
2.5.3.1 Study Design 
In order to verify this limit of quantitation, human donor blood was spiked with 
propofol to achieve a concentration of 0.25 µg.ml-1, and samples measured using 
the HPLC as a reference method, as well as the novel propofol analyser.  Both 
analysers were set up and calibrated as detailed in chapters 2.3 and 2.4.  A total of 
twenty duplicate samples were analysed on each analyser, Samples were collected 
on two separate days and results pooled for the purposes of analysis.   
2.5.3.2 Analysis 
Total error at the desired concentration of 0.25 µg.ml-1 was calculated using the 
pooled  bias (difference between the HPLC reference and the new analyser for all 
specimens) and the imprecision (defined as the standard deviation of the pooled 
sample results).  Total error for the limit of quantification is calculated as bias + 
2SD, as determined in the US National Committee for Clinical Laboratory Standards 
(NCCLS) approved guideline EP17-A. (NCCLS 2004) The ability of the analyser to 
measure propofol concentrations at 0.25 µg.ml-1 is verified if there is 95% 
confidence that the new analyser result performs to a predetermined goal for total 
error.  The predetermined goal is typically set as bias of no more than +/-10%, and 
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imprecision of no more than +/-10%.  This gives a total allowable error at 
0.25 µg.ml-1 = max allowable bias + 2 * max allowable 
SD = 0.025 + (2*0.025) = 0.075 µg.ml-1.  Hence, the aim of this study was to 
verify a claimed limit of quantitation of 0.25 ug.ml-1, with a 95% probability that a 
given sample measurement is accurate to within ±0.075 µg.ml-1. 
2.5.3.3 Results 
 Day 1 Day 2 
Sample number Novel Analyser 
(µg/ml) 
HPLC  
(µg/ml) 
Novel Analyser 
(µg/ml) 
HPLC  
(µg/ml) 
1 0.22 0.28 0.28 0.26 
2 0.21 0.27 0.27 0.28 
3 0.21 0.27 0.27 0.24 
4 0.21 0.27 0.29 0.25 
5 0.24 0.26 0.20 0.26 
6 0.23 0.25 0.28 0.25 
7 0.23 0.26 0.24 0.26 
8 0.24 0.26 0.25 0.24 
9 0.22 0.26 0.24 0.24 
10 0.23 0.24 0.24 0.24 
n 10 10 10 10 
mean 0.224 0.262 0.256 0.252 
SD 0.012 0.011 0.027 0.013 
Mean Bias -0.038  0.004  
Pooled Bias -0.017 
Pooled SD 0.026 
Pooled SD*2 0.052 
Total Error 0.069 
Table 4:  Spiked volunteer blood to achieve a propofol concentration of 0.25 µg.ml-1 were 
analysed on HPLC reference machine and new analyser.  20 samples were analysed over 
two days.  Mean difference between analysers was 0.017 µg.ml-1.  Total error was 
calculated as bias + 2*SD, at 0.069 µg.ml-1. 
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The calculated total error for these samples with a propofol concentration measured 
by the HPLC standard as 0.26 µg.ml-1, was 0.07 µg.ml-1, which lies within the 
predetermined goal of 0.075µg.ml-1.  As the mean measured concentration of 
propofol by the HPLC reference was 0.26 µg.ml-1, this can be claimed to be the limit 
of quantitation for the new analyser. 
 
2.5.4 Interference testing with commonly co-administered drugs 
Testing of blood spiked with various drugs commonly co-administered with propofol 
in operating theatres or critical care was performed by spiking volunteer blood 
prepared to an approximate concentration of 8 µg.ml-1 with test drug at twice its 
normal therapeutic concentration, based on Clinical Laboratory Standards Institute 
(CLSI) guidelines.  Duplicate samples for each test specimen were analysed on the 
novel propofol analyser.  Results showed no clinically significant variation of values 
when compared to control samples, with a variance from control of -0.47 to 
+0.14 µg.ml-1, see Figure 8. 
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Interferent Concentration (µM.L-1) 
Glyceryl Trinitrate 3.52 
Amiodarone 352 
Furosemide 181 
Cefuroxime 1415 
Noradrenaline 4.37 
Adrenaline 4.37 
Table 5: Concentration of potential interferents used.  Concentrations based on Clinical 
Laboratory Standards Institute (CLSI) guidelines for interferent testing. 
 Measured propofol concentration (g.ml-1)
0 2 4 6 8 10
Control (no drugs)
Adrenaline
Noradrenaline
Cefuroxime
Furosemide
Amiodarone
Glyceryl Trinitrate
 
Figure 8:  Assessment of the cross interference of the new monitor showing propofol 
concentration measurements in samples spiked with commonly used drugs at twice their 
usual therapeutic concentration.  Variance from control -0.47 to +0.14 µg.ml-1.  Error bars 
show standard deviation. 
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2.5.5 Influence of Haemoglobin Concentration (Haematocrit) 
One litre of heparinised porcine blood was filtered to remove fat and impurities and 
calculated to have a haematocrit of 40% following testing with a blood gas 
analyser.  Haematocrit was calculated using the formula: 3 x haemoglobin 
concentration in g.dl-1. (Bain and Bates 2001)  200 ml plasma was prepared by 
centrifugation at 5500 rpm for ten minutes.  Stock solutions with a known 
theoretical concentration of propofol were prepared by spiking identical amounts of 
propofol into aliquots of the plasma and whole blood solutions and mixed on a roller 
mixer for 15 minutes.  These stock solutions were mixed to achieve blood of 
varying haematocrit, and serial dilution was performed with unspiked blood to 
achieve approximate propofol concentrations of 8, 4, and 2 µg.ml-1 for analysis.  
Analysis of specimens was repeated on three separate occasions to ensure 
repeatability.   
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2.5.5.1 Results 
 
Figure 9:  Assessment of the effect of haemoglobin concentration using the new monitor 
showing samples of varying haematocrit spiked with propofol to achieve  clinically low 
(approx 2 µg.ml-1), medium (approx 4 µg.ml-1), and high propofol concentrations (approx 
8µg.ml-1). Specimens were analysed on three occasions. Error bars show standard 
deviation.   
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Haematocrit 40% 20% 10% 0% (plasma)  
 Measured propofol concentration (one SD) % change from 
Hct 40% to 0% 
2µg.ml-1 2.14 (0.05) 2.00 (0.08) 1.96 (0.07) 1.94 (0.06) -9.50 
4µg.ml-1 3.66 (0.03) 3.58 (0.04) 3.73 (0.05) 3.70 (0.05) 1.09 
8µg.ml-1 6.88 (0.04) 6.92 (0.04) 7.16 (0.02) 7.30 (0.04) 6.10 
Table 6:  Propofol concentrations for blood samples prepared to achieve varying 
haematocrit, spiked to achieve propofol concentrations of approximately 2, 4, and 8 µg.ml-1.  
All specimens were analysed on three occasions. % change in Haematocrit 40% to 0% 
represents % change from normal (40%) to plasma (0%). 
 
Results shown in Figure 9 and Table 6 show no consistent effect of Haemoglobin 
concentration on measured propofol concentration.  A slight decrease in measured 
propofol concentration of 6% with increasing haemoglobin concentration was 
observed at the highest prepared concentration, but a 9.5% higher propofol 
concentration was measured with increasing haemoglobin concentration at the 
lowest prepared propofol concentration.  Repeatability of the measurements was 
good, with standard deviations of 0.02 to 0.08 µg.ml-1. 
 
2.6 Clinical Sample testing 
2.6.1 Methods 
The work on clinical samples was approved by the West Midlands Research and 
Ethics Committee, United Kingdom.  As discard samples only were being used, 
written informed consent was waived by the review board.  80 discard arterial blood 
samples were collected from 72 patients undergoing major cardiac surgery and 
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receiving propofol by infusion as a routine part of their anaesthesia either as a sole 
anaesthetic agent or in combination with isoflurane.  As discard samples were used, 
the point of sampling was not determined by the researcher, although data about 
dose and duration of propofol infused were recorded.  Samples were stored on a 
roller mixer at room temperature until analysis later that day.  Aliquots of each 
sample were tested using the new device, and using the conventional laboratory 
based method of high performance liquid chromatography (HPLC).  Device 
calibration and quality control were performed as described previously. 
2.6.2 Statistical Analysis 
Linearity was assessed by calculating the least squares linear fit line, and calculating 
the coefficient of determination.  The use of correlation and correlation coefficients 
to determine agreement between devices has however been shown to be of limited 
utility.  An excellent correlation can be demonstrated without good agreement 
between actual values.  Furthermore, this method of analysis is influenced by the 
range of the sample – if wide, the correlation will be greater than if narrow. Bland 
and Altman devised a method superior to the use of correlation coefficients for 
comparing the performance of devices in clinical measurement, by comparing the 
mean of the measurements of the devices against the difference in measurements 
between devices.(Bland and Altman 1986)   Results are presented as bias (mean 
difference), precision (+/- 1 SD of the mean difference), and limits of agreement 
(+/- 1.96 SD of the mean difference). Data were analysed using SPSS for Windows, 
Rel. 19.0.0. 2010. Chicago: SPSS Inc. 
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2.6.3 Results 
The correlation between blood propofol concentration measurements using the new 
monitor with the HPLC gold standard is illustrated in Figure 10. The least squares 
linear regression line has a gradient of 0.9992, and an offset of 0.0006 
demonstrating a strong linear relationship, with a coefficient of determination (r2 
value) of 0.9889.  A Bland Altman plot, see Figure 11, shows the deviation of the 
propofol concentration measured using the new monitor from HPLC derived 
measurements for all values.  These data show a small positive bias of 0.13 µg.ml-1, 
a precision of –0.2 to +0.4 µg.ml-1, and limits of agreement of -0.4 to 0.7 µg.ml-1.  
As measured propofol concentrations above 10 µg.ml-1 suffered from a lower 
agreement between devices, a Bland-Altman plot showing performance of the novel 
propofol analyser between the clinically useful propofol concentrations 0-10 µg.ml-1 
is shown in Figure 12.  These data show an identical, small positive bias of 
0.13 µg.ml-1 a precision of -0.1 to 0.4 µg.ml-1, and limits of agreement of -0.3 to 
0.6 µg.ml-1.  Visually, the scatter on the residuals plot shows concentration 
dependence, with lower variation amongst samples with lower propofol 
concentrations. 
 
The data from the clinical study, performed on patients undergoing major cardiac 
surgery whilst receiving propofol as part of their anaesthesia show a strikingly wide 
spread in propofol concentrations from 0.5 to 16 µg.ml-1.  Concentrations of 
0.5 µg.ml-1 will not ensure loss of awareness if used as a sole agent, and 
concentrations of 16 µg.ml-1 are likely to be associated with significant side effects 
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including haemodynamic instability.  Clearly, as described in the methods, propofol 
was not always the only anaesthetic agent used by anaesthetists, and the timing of 
sampling was not determined by the research team.  No attempt was made by the 
research team to influence the rate of propofol infusion or method of delivery.   It is 
however interesting to note that only a third of samples measured achieved 
propofol concentrations in the range of 3-5 µg.ml-1, where patients are unlikely to 
be aware if used as a sole agent, and unlikely to suffer unduly from propofol related 
side effects. 
 
Figure 10:  Correlation of the results obtained for novel analyser with HPLC measurements 
using samples obtained during cardiac surgery.  Black line shows linear regression line, 
grey lines show 95% confidence intervals. n=80.  HPLC – High performance liquid 
chromatography. 
r2 0.9889 
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Figure 11:  Bland–Altman plot comparing propofol concentrations measured using novel 
analyser with HPLC standard.  Mean bias illustrated with dotted line, limits of agreement 
(mean +/- 1.96 SD) shown with dashed lines. n=80.  HPLC – High performance liquid 
chromatography. 
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Figure 12-  Bland–Altman plot comparing propofol concentrations measured using novel 
analyser with HPLC, including only data points within the normal clinical range 0-10 µg.ml-1.  
Mean bias illustrated with dotted line, limits of agreement (mean +/- 1.96 SD) shown with 
dashed lines. n=75.  HPLC – High performance liquid chromatography. 
 
2.6.4 Discussion  
We have been able to process samples using injection of heparinised whole blood 
into the new monitoring device, with output of results in around five minutes.  Our 
data demonstrate a high level of correlation and agreement between whole blood 
propofol concentrations measured using the new analyser and when using the HPLC 
standard; a labour intensive laboratory based method of propofol extraction and 
measurement.  Initial laboratory based work has demonstrated excellent linearity 
and repeatability of results.  We have not detected a significant impact during cross 
interference studies with high concentrations of commonly used drugs.  Further 
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cross-interference studies carried out by others subsequent to this work, examining 
a larger number of drugs detected a statistically significant, but clinically small 
(0.1 µg.ml-1 at a propofol concentration of 2.9 µg.ml-1) interaction with paracetamol 
at three times the peak clinical concentration.(Liu, Pettigrew et al. 2012)  The 
clinical data from patients undergoing major surgery whilst receiving propofol by 
infusion have also shown good agreement with the HPLC standard method, in 
addition to showing a large spread of blood propofol concentrations in the 
population sampled. 
2.6.4.1 Influence of Haemoglobin concentration on point of care propofol analyser 
and implications for the measurement of plasma propofol concentration 
Validation experiments were performed on propofol added to whole blood from 
laboratory-prepared as well as clinical samples in order to identify any significant 
impact on the performance of the analyser.  These validation experiments are 
presented in this chapter.  Although the validation experiments were not repeated 
using plasma, it can be assumed that the analyser will be at least as reliable when 
red cells are removed, and performance is in fact likely to be improved, as plasma 
specimens will be more similar in composition to the stock solutions of propofol 
suspended in solvent used for machine calibration.  An experiment was performed 
comparing blood of varying haematocrit from 40% to plasma, and spiked with 
propofol.  This work, reported in section 2.5.5 demonstrated a modest effect of red 
cells on analyser performance, with variance of up to 9.5% in the low concentration 
group between a haematocrit of 40% and plasma.  Differences in propofol 
concentration measured at variable haemoglobin concentrations are likely to be 
explained by two phenomena: as propofol may be bound to red cell debris, it is 
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possible that a small quantity of drug remains bound to cell components and is 
therefore incompletely extracted from the sample – this potential issue has been 
minimised by the thorough lysis of red cells within the analyser prior to extraction.  
Secondly, the colourimetric analyser used to quantify propofol concentrations may 
be influenced slightly by the coloured haemoglobin within the sample, although the 
majority of haemoglobin should have been removed in the extraction process.   
2.6.4.2 Utilities for Point of Care Propofol Testing 
A number of possible uses are proposed for an analyser capable of measuring 
propofol concentration within a clinically meaningful timeframe.  It is possible that 
certain groups of patients in critical care undergoing deep propofol sedation for 
clinical reasons for prolonged periods may benefit from intermittent assessment of 
propofol concentration in order to minimize risks and costs of over or under 
sedation.   
The analyser may also have utility in total intravenous anaesthesia.  Patients 
undergoing bolus - infusion based anaesthesia could undergo measurement of 
propofol concentration intermittently in order to demonstrate attainment of 
predicted concentrations.  Those anaesthetised using propofol target controlled 
infusion could have intermittent measurement of blood propofol concentration in 
order to validate the TCI algorithm.  There are however, a number of potential 
problems with the use of the novel propofol analyser at the point of care for use in 
general anaesthesia:   
1. In order to ensure accurate blood concentrations, and to prevent the need 
for repeated skin puncture, this device is limited to those patients with an 
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arterial cannula in situ for blood sampling.  This limits the utility of this 
device to major surgery or patients with co-morbidity requiring invasive 
arterial monitoring only.  It is possible to use venous samples during the 
maintenance phase of anaesthesia when equilibration between the arterial 
and venous blood has taken place, and indeed around half of the data used 
to develop TCI models have been venous blood, including the commonly 
used Marsh model. (Marsh, White et al. 1991)  More recently developed 
models have been developed using arterial blood samples, including the 
main competitor to the Marsh model in adults, developed by Schnider. 
(Schnider, Minto et al. 1998) 
2. The inability to detect infuser device failure when relying on single point 
blood sampling.  Avoidance of this risk during general anaesthesia would 
require a near real time continuous monitor akin to the end tidal volatile 
anaesthetic agent monitors available during inhalational anaesthesia. 
3. The risk of unpredictable patient pharmacokinetics particularly early on 
during general anaesthesia when sampling is likely to take place prior to skin 
incision.   
4. If this analyser were used during TCI set in effect site targeting mode, the 
clinician should be aware that the blood anaesthetic concentration is not 
likely to match the effect site concentration until a period of several minutes 
for equilibration have passed. 
Further analysis of these risks and any potential benefit of point of care propofol 
blood measurement should be made before an attempt to introduce this device in 
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to the clinical environment.  It is possible that advanced pharmacodynamic 
monitors such as those already discussed in chapter 1.9 may offer a superior 
answer to some of the problems identified when striving to achieve safe and 
effective intravenous anaesthesia.  It is anticipated that this device in its current 
form is likely to be of use in special environments such as critical care, but primarily 
as a research tool, used to further improve propofol pharmacokinetic modelling. 
 
The company developing the propofol monitor, Sphere Medical Ltd, Cambridge, has 
undertaken further validation studies following the work described in this chapter, 
and following this have licensed the monitor for use as a research tool.  Further 
validation work is being undertaken in order to licence the monitor as a point of 
care in-vitro diagnostic device. 
 
The further work in this thesis relating to blood propofol measurement uses the 
licensed propofol analyser described in this chapter for the measurement of 
propofol concentrations.  The methods of calibration and quality control described 
earlier in this chapter were also used for all later experiments. 
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3 CHAPTER 3 - PREPARATION AND STORAGE OF BLOOD WHEN 
MEASURING PROPOFOL CONCENTRATIONS 
 
3.1 Literature review to determine prior work validating methods of 
propofol preparation and storage 
3.1.1 Introduction 
Patients receiving the intravenous anaesthetic agent propofol for anaesthesia or 
sedation are anaesthetised when the drug reaches the effect site – the brain.  In 
order to reach the brain, the drug must be circulating in the blood.  Once in the 
cerebral bloodstream, propofol can diffuse to its site of action.  During its course to 
the brain, and on subsequent recirculation, a large proportion of propofol is 
redistributed to other perfused body tissues, and a portion of it is metabolised and 
excreted.  Multicompartment pharmacokinetic modelling has therefore been 
developed in order to calculate the estimated concentration of propofol circulating 
in the blood at any given time during an infusion of the drug.  This modelling is 
then used to drive propofol infusers using these algorithms to maintain estimated 
constant blood concentrations of propofol.  Blood propofol concentration is used as 
a surrogate for brain propofol concentration, which is clearly not easily measured.  
It follows that in order for a multicompartment model to accurately estimate brain 
propofol concentration, the blood sample being tested should as closely as possible 
replicate the concentration of propofol in the cerebral circulation available to diffuse 
from blood to brain tissue.  There are a range of points at which inaccuracies can 
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be introduced, and the following literature review highlights where these can occur 
and how a series of errors can lead to inaccurate results. 
 
3.1.2 Whole blood, plasma or serum? 
There is varying practice in the literature in the methods of blood sample 
preparation prior to storage and analysis for propofol concentration.  The potential 
for differences in propofol concentration when choosing to analyse blood, plasma or 
serum have not been clearly recognised in the clinical literature, and so practice is 
variable.  A small amount of work has been published in biochemistry journals 
looking at such differences.  It is clear from previous work that formed blood 
elements (predominantly red blood cells) bind propofol in a complex and time 
dependent manner.(Dawidowicz, Fijalkowska et al. 2001).  Such binding will cause 
time dependent changes in propofol concentrations depending on when red cells 
are separated from plasma.  For this reason, whole blood analysis should lead to 
more predictable concentrations of propofol unless samples are processed to 
remove blood cells (i.e. plasma or serum separation) immediately before binding 
can take place.  However, plasma concentrations (prior to the onset of storage 
related equilibration) are of more pharmacokinetic interest when developing 
pharmacokinetic models of propofol distribution because they are more 
representative of the drug concentrations available to transfer from blood to brain.  
The problem presenting itself when the clinician has to make the decision on what 
to sample is to what degree do the inaccuracies introduced during sampling and 
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storage impact on the drug concentration measured when choosing between whole 
blood and plasma sampling.   
Coetzee performed an experiment to compare blood propofol concentrations when 
processed as plasma and as serum and demonstrated no significant difference in 
drug concentrations measured.  This is not unexpected, as it is likely to be the 
influence of drug binding to red blood cells which causes fluctuations in measured 
propofol concentration.  He demonstrated significantly lower concentrations in 
plasma when compared to whole blood see Table 7.  These data are in conflict with 
the majority of the literature, which demonstrates higher drug concentrations in 
plasma.  This may be a reflection of long times to sample centrifugation allowing 
adherence of drug to red cell membranes, although this is speculation. 
 
Table 7:  Propofol blood, plasma, and serum concentrations of 65 samples from 10 patients 
published in (Coetzee, Glen et al. 1995). 
 
Fan et al performed an important set of work on patients administered propofol by 
bolus or by infusion.(Fan, Yu et al. 1995)  This demonstrated significantly higher 
propofol concentrations in plasma than whole blood, and the effect was most 
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marked (up to 30% higher) if plasma was immediately centrifuged, rather than 
allowed to equilibrate for an hour.  The greatest differences were seen immediately 
following bolus injection, when red cells have had limited time to bind propofol 
(Figure 13). 
   
Figure 13:  Propofol concentrations in whole blood or plasma during infusion of propofol at 
10mg/kg/hr following a 2 mg.kg-1 bolus (blood centrifuged immediately or stored for one 
hour prior to centrifugation) Published in (Fan, Yu et al. 1995). 
 
Interestingly, this effect is reversed for bolus studies when measuring low 
concentrations of propofol during the clearance phase where it would appear that 
the rate of propofol elimination from plasma is faster than the rate that red blood 
cells release propofol (Figure 14).  This phenomenon may explain the lower 
concentrations of plasma propofol demonstrated in Coetzee’s experiments.(Coetzee, 
Glen et al. 1995) 
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Figure 14:  Propofol concentrations following bolus injection of 2 mg.kg-1 published in (Fan, 
Yu et al. 1995). 
 
To further investigate this, they performed another experiment to quantify 
difference in plasma propofol concentration as the time from sampling propofol 
spiked samples to centrifugation was changed.  This table demonstrates a 
significant drop in plasma propofol concentrations over the course of one hour; with 
samples centrifuged three minutes following spiking blood up to 25% higher than 
whole blood, falling to 13% higher than whole blood at one hour (see Table 8).  
The reason for this change over time relates to the uptake of propofol into red 
blood cells, a phenomenon that has been identified.(Dawidowicz, Fijalkowska et al. 
2001) 
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Table 8:  Percentage of difference in propofol concentrations between plasma and whole 
blood samples after adding propofol to the blood samples in different mixing durations and 
temperatures. All values are mean +/- SD.  Percentage difference calculated as [(Plasma – 
Whole blood concn)/whole blood concn]x100 Published in (Fan, Yu et al. 1995). 
 
From a pharmacokinetic point of view, the equilibrium of drug concentrations 
between tissue and plasma must be more direct than that between tissue and 
whole blood when the equilibrium between plasma and whole blood is not instant 
(as demonstrated in the experiments by Fan et al).  Plasma concentrations should 
be more informative than blood concentrations for propofol when developing 
pharmacokinetic models for propofol, although it must be borne in mind that unless 
samples are spun within five minutes, according to Fan et al’s data, then the benefit 
of centrifugation and plasma sampling deteriorates.  It could equally be argued that 
the use of whole blood is not affected by significant swings in propofol 
concentration in this way, and thus enables a more consistent, and replicable 
method of measurement. 
 
89 
 
3.1.3 Arterial or venous blood? 
It has been demonstrated that significant differences in blood propofol 
concentration can be measured when dual samples are taken from arterial and 
venous access sites.  Venous samples are falsely low; in particular during the fast 
redistribution phase in the first few minutes following propofol administration. 
(Coetzee, Glen et al. 1995) No significant differences are demonstrated however 
during the maintenance phase of anaesthesia. 
 
3.1.4 Duration, preservative and temperature of storage? 
A body of work validating the collection, preservation, storage and analysis of blood 
propofol specimens was performed by Plummer.  This work recommended storage 
of whole blood samples at 4 oC in oxalate where propofol is supposedly stable for 
up to 12 weeks.(Plummer 1987)  In a study comparing EDTA, Heparin, and 
oxalated tubes stored at 4 oC, Cuadrado demonstrated no significant difference in 
propofol concentrations measured when stored for at least two weeks (Cuadrado, 
Solares et al. 1998).  All of this work was performed using whole blood, and the 
work of Plummer became the standard method of storage and analysis for the early 
work on propofol pharmacokinetics, and was used when devising the first 
multicompartment pharmacokinetic model for propofol by Marsh, which is still used 
in the majority of  propofol target controlled infusers today.(Marsh, White et al. 
1991)  Since the work of Plummer, further work has been done looking at sample 
storage when refrigerated at 4 oC or frozen at -20 oC.  There is clear evidence of 
sample degradation when whole blood is frozen.  A study by Bienert demonstrated 
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a one third reduction in whole blood propofol concentrations when whole blood 
samples were frozen.(Bienert, Zaba et al. 2005)  This group also analysed stored 
plasma samples when frozen, and in these samples propofol concentrations 
declined by only seven percent over the two month storage period.  They also 
analysed refrigerated samples from both whole blood and plasma samples.  
Samples in both groups deteriorated minimally over the first five days of storage, 
with plasma propofol concentrations deteriorating by 1-4% at two months.  Whole 
blood samples deteriorated by a slightly higher 6-18% over two months.  As 
propofol is a volatile compound, it is likely that over time drug is lost to the head 
space of the storage container.  This phenomenon could be minimised by 
minimising any dead space, and ensuring adequate seal of storage containers. 
 
3.1.5  Storage vial composition 
Propofol is a relatively volatile drug, and also adheres to some plastics leading to 
errors in drug concentration measurement in stored samples.  Glass vials do not 
suffer from this problem, although dead space should be minimised to prevent 
significant evaporation.  There is evidence that polyvinylchloride (PVC) adsorbs 
significant quantities of propofol and therefore should not be used as a storage 
vessel, although other plastics such as polypropylene are less susceptible to 
this.(Sautou-Miranda, Levadoux  et al. 1996)     
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3.1.6 Conclusions and scope for clarification 
Pharmacokinetic computer driven algorithms are widely used for anaesthesia and 
sedation.  Validation of these models suggests a deviation from estimated drug 
concentrations of around thirty percent in ideal situations, and more significant 
deviation in unvalidated groups such as children and the morbidly obese.  There is 
significant scope to improve on the accuracy of pharmacokinetic model 
development if a more accurate and standardised method of blood drug 
concentration measurement can be determined.  Furthermore, studies to validate 
existing models by comparing blood concentrations to estimated concentrations 
should also use the same standardised methods to maximise the likelihood of 
approximating cerebral blood concentrations available for diffusion to the site of 
action. 
 
Based on this review of the current evidence, there is conflicting information about 
how best to approach the sampling of blood for analysis of propofol concentrations.  
Arterial samples are to be preferred, particularly when focusing on the rapid bolus 
phase of administration.  Samples should be collected into inert vessels and not 
kept in PVC syringes for prolonged periods.  Anticoagulant choice and preservative 
for storage do not seem to impact on measured concentrations.  No clear 
consensus has been reached regarding the correct preparation of samples for 
analysis.  The gold-standard sample for propofol pharmacokinetics would as closely 
as possible replicate the concentration of propofol available to diffuse across the 
cerebral vessels to the brain.  Much data, including the majority of early work have 
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used stored whole blood for analysis; it has been demonstrated that there is some 
degradation in propofol concentration over long periods of storage at 4 oC, and 
frozen storage of whole blood is likely to cause unacceptable degradation in 
propofol concentrations.  Furthermore, it would appear that time dependent 
adherence of propofol to red blood cells leads to measured drug concentrations that 
are lower than those available in circulating blood.   No data exist looking at 
immediate processing of whole blood samples as the techniques for analysis have 
up until now not permitted near patient immediate processing of samples.  
Separation of plasma from blood has become more popular in clinical 
pharmacokinetic studies because of the problems of red cell drug adherence, and 
the stability of plasma samples when frozen for long periods, however no 
standardisation of time of centrifugation has been set.  As highlighted above, delays 
in centrifuging samples can cause significantly variable plasma concentrations.  It is 
important to clarify whether existing clinical studies using plasma are centrifuging 
their samples in a timely manner, in order to achieve the benefit of separating the 
plasma from red cells.  It would appear that centrifugation needs to be performed 
within five minutes of collection to avoid this problem.   It is unlikely that this is 
current research practice. The areas of scope for further analysis based on these 
findings are: 
• A literature search of currently published clinical pharmacokinetic trials of 
propofol to identify current and historical practice in sample collection, storage 
and analysis.  It is possible that poor methods of sample collection, storage and 
analysis has led to inaccurate drug concentrations in these studies with 
significant implications for the validity of the data. 
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• Confirmatory data are required to establish whether correctly sampled plasma 
samples are indeed higher than whole blood concentrations, and the degree of 
difference.  There are currently some conflicting data in the literature. 
• Confirmatory data are required to demonstrate stability of whole blood and 
plasma samples when stored at 4 0C.  It is also important to confirm the impact 
of time to centrifugation of samples. 
• Comparison of immediately sampled whole blood samples with immediately 
centrifuged plasma samples is required to identify whether these two methods 
of collection are comparable.  If immediately centrifuged plasma concentrations 
are similar to these whole blood concentrations, it can be stated that either 
method of drug concentration measurement is acceptable. 
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3.2 Review of published studies involving blood propofol measurement 
for pharmacokinetic analysis  
3.2.1 Background and Research Question 
An analysis of the literature above has identified a significant risk of inconsistency in 
blood propofol concentration measurements, depending on chosen method of 
sample preparation.  Since the development of propofol and propofol based 
anaesthesia over the last twenty five years, techniques used to prepare blood 
specimens have changed, although the significance of this is not clear without close 
analysis.  The importance of any inconsistency in method of sample preparation 
and analysis is most significant for studies designed to assess drug 
pharmacokinetics.  In particular, studies collecting specimens for the development 
of propofol TCI models are of particular importance, because the method of sample 
preparation may influence how the model performs, or how model validation can be 
interpreted. 
The published literature was reviewed to determine the methods used to sample, 
prepare, store, and analyse blood propofol concentrations for pharmacokinetic 
analysis.   Publications from this group that were used to develop pharmacokinetic 
models for the delivery of propofol TCI were also analysed separately, to determine 
whether this important subset used differing methods of sample preparation from 
the majority of historical and contemporary publications. 
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3.2.2 Methods 
3.2.2.1 Study Selection Criteria 
Pharmacokinetic studies in which blood samples were taken for the purposes of 
measurement of total blood propofol concentrations in humans.   
3.2.2.2 Participants/Patients 
Humans, undergoing testing of blood propofol concentration for the purposes of 
pharmacokinetic analysis.  No age restrictions were applied. 
3.2.2.3 Inclusion Criteria 
Studies in which blood samples were taken for the study of blood propofol 
pharmacokinetics.  In order to maximise the number of articles identified, the 
chemical name for propofol ‘diisoprophylphenol’, the early industry identifier 
‘ICI35868’, and the first trade name ‘Diprivan’ were all searched for in addition to 
the term ‘propofol’. 
3.2.2.4 Exclusion Criteria 
Studies were excluded if it was not explicitly stated within the manuscript that blood 
propofol concentrations were measured.   
Studies specifically looking at the free fraction of propofol in blood were excluded, 
unless total blood propofol concentrations were also measured for the purposes of 
pharmacokinetic analysis.  The measurement of the free fraction of propofol within 
blood is performed for specific pharmacokinetic analyses, and results are in no way 
comparable to total blood propofol concentrations, as well as requiring completely 
different techniques for extraction, and measurement.   
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Studies published only as abstracts, letters, or conference papers were unlikely to 
provide adequate detail about methodology, may not have undergone peer review, 
and may risk duplication of data if subsequently published as a full manuscript, and 
so were excluded from the analysis.   
Blood propofol measurement when not taken from patients receiving propofol were 
excluded, including studies in which human blood was spiked with propofol for 
analysis. 
Blood propofol measurement specifically for the development of new methods of 
propofol assay, or method comparison between propofol assay types were 
excluded. 
Studies not published in English were excluded from the analysis because of 
inadequate resource to translate the articles for screening of manuscripts and for 
data extraction. 
3.2.2.5 Search Method for Identification of Studies 
MEDLINE (Ovid SP 1950 to May 2013) and EMBASE (Ovid SP 1980 to May 2013) were 
searched using a combination of text words and controlled vocabulary search terms ( 
Appendix 1). 
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3.2.2.6 Selection of Studies 
The abstract, title or both sections of the 1055 records retrieved in search 12 above 
were visually scanned.  All potentially relevant publications in which blood sampling 
had taken place for the measurement of propofol concentration were investigated 
as full text.  Those records in which it was unclear after reading the abstract, title 
or both section of the retrieved record were retrieved as full text for assessment. 
3.2.2.7 Data Extraction and Management 
A standardised data extraction form was used to extract required data.  All data 
were extracted by a single person (Dr Cowley).  A blank data extraction form is 
shown in Appendix 2. 
3.2.2.8 Categorising data 
Raw data were collected for each variable required, and each variable was 
categorised to facilitate analysis.  Variable categories constructed prior to analysis 
are shown in Table 9 below.   
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Year of publication Data were split into early publications (prior to 1990), five year 
intervals up to 2005, and recent publications (after 2005).   
Chemicals used for 
sample prep/storage 
Commonly used agents were included, as well as an ‘other 
category’ and a ‘not stated’ category 
Preparation of samples Categorised to plasma, whole blood, serum, or ‘not stated’ – 
attempts to contact the author if possible were made if data not 
present in full text, as these data were part of the core analysis, 
and would represent important differences in practice. 
Preparation of plasma 
samples 
Text was searched for timing of plasma sample preparation 
following sampling (for publications in which samples were 
prepared as plasma).  Categories were determined based on 
previous publications determining the influence on propofol 
concentration of time to centrifugation.   
Site of sampling Variables were categorised into arterial, venous, other, or ‘not 
stated’.  Attempts to contact the author if possible were made if 
data not present in full text, as these data were part of the core 
analysis, and would represent important differences in practice. 
Storage vial Samples were divided into stable storage mediums (glass or 
polypropylene), other, or ‘not stated’. 
Storage temperature Temperatures were divided into ‘room temperature’, 
‘refrigerated’, ‘frozen’, and ‘low temperature frozen’, as well as a 
‘not stated’ category.  Analysis would be performed separately for 
whole blood, in which refrigerated storage is preferred, and 
plasma samples, in which freezing of samples is preferable.   
Duration of sample 
storage 
Categorised as less than or greater than 12 weeks, (Plummer 
1987) - analysis performed on refrigerated samples only, which 
suffer from time related degradation in drug concentration. 
Method of drug 
extraction 
Categorised into the two most popular methods of high 
performance liquid chromatography (HPLC) and Gas 
Chromatography (GC), other, or ‘not stated’. 
 
Table 9: Categorisation of variables used for literature review. 
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3.2.2.9 Dealing with missing data 
The published manuscript was examined for the data required.  The main details of 
importance were the site of blood sampling, preparation of the sample, and the 
method of sample analysis.  It was expected that all publications should include this 
data as a minimum, and attempts to contact authors not supplying this information 
were made, in order to minimise missing data.  As no publication was expected to 
include all details collected for this review, attempts were not made to contact 
authors for other missing data.  The absence of data relating to the processing of 
samples was used to determine whether published research can be accurately 
interpreted in the absence of such detail.  If an author had specifically referred to 
another publication, or a referenced method which included the data required, the 
original publication was sought and data from this extracted. 
3.2.2.10 Statistical Analysis 
Analyses correlating year of publication to categorical variables were analysed using 
Kendall’s Tau B test for correlation in non-parametric data.  These analyses were 
performed using exact year of publication, and not using year categories to avoid 
the problem of assigning equal proportions to each year category, when numbers in 
each category are variable.    Subgroup analyses of site of sampling and sample 
preparation were performed comparing publications used to develop/validate 
pharmacokinetic TCI models with all other publications using Fisher’s exact testing.  
P values of <0.05 were taken to be statistically significant.  All analyses were 
undertaken using Statistical Package for the Social Sciences (SPSS) Rel: 19.00. 
2010. Chicago: SPSS Inc. 
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3.2.3 Results 
 
Figure 15: Flowsheet showing number of reports at each point in review, including those 
excluded. 
 
The primary search generated a total of 1055 results.  After screening, we 
considered 267 publications to be potentially eligible and reviewed the full text.  
Following review of full text, 56 further reports were considered as ineligible (Figure 
15).  A total of 211 reports were eligible following full text review, and the data 
were inputted into an Excel spreadsheet, with data shown in Appendix 1. 
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Year of publication ranged from 1983 to 2013, with numbers in each year grouping 
shown in Table 10.  The trend in number of publications per year can be seen in 
Figure 16. 
     
 
Year Grouping 
Number 
Publications 
Percent 
Publications 
<1990 
1991 to 1995 
1996 to 2000 
2001 to 2005 
>2005 
Total 
22 10.4 
40 19.0 
33 15.6 
57 27.0 
59 28.0 
211 100.0 
Table 10: Publications per year grouping category. 
 
 
Figure 16: Graph showing number of publications analysed against year of publication. 
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3.2.3.1 Sample Preparation 
Year of publication was split in to discrete periods in order to visualise changes in 
practice over time.  Figure 17 and Figure 18 shows the change in chosen methods 
of sample preparation over time.  Figure 17 shows the absolute number of 
publications for each method of sample preparation, and Figure 18 shows the 
percentage of publications for each method of sample preparation at each time 
point.  Comparing plasma with whole blood preparation, a statistically significant 
increase over time in the proportion of publications first separating samples into 
plasma before analysis compared with those analysed as whole blood was 
determined using Kendall’s tau-b test for correlation, with a tau-b value 0.39, and 
significance (2 tailed) p<0.001.  For those samples prepared as plasma, data on 
time to centrifugation were collected.  Results were categorised into those prepared 
immediately (within 5 minutes), those prepared between 5 and 30 minutes, those 
prepared between 30 and 60 minutes, and those prepared beyond 60 minutes.  
Data were available for 39% of studies, and results are presented in Table 11.  
Sample preparation within 5 minutes, which reduces the likelihood of spurious 
results were only described in 17% of manuscripts, although the large proportion of 
studies failing to record this information make interpretation of these data difficult.  
Of the 39% of manuscripts including information about time to centrifuge, 56% 
studies did not perform immediate centrifugation. 
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Figure 17:  Number of publications for each chosen method of blood sample preparation 
over time.  Solid represents whole blood analysis, Dashed line plasma analysis, and dotted 
line serum analysis. 
 
Figure 18: Percentage of publications using each method of sample preparation for each 
year grouping over time.  Solid represents whole blood analysis, dashed line plasma 
analysis, and dotted line serum analysis. 
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 Number of Publications Percentage 
 
< 5 mins 15 17.0 
5 to <30 mins 9 10.2 
30 - 60 mins 2 2.3 
> 60 mins 8 9.1 
Not Stated 54 61.4 
Total 88 100.0 
Table 11:  Time until centrifugation (samples analysed as plasma specimens only). <5 mins 
represents the optimum time. 
 
Data on the choice of additive for anticoagulation and storage for the samples were 
missing in 44% studies.  Figure 19 shows sample additives for those studies 
including this information.  Three quarters of plasma samples used heparin as an 
anticoagulant, with the majority of the remainder (23%) using EDTA, and 2% using 
potassium oxalate.  Potassium oxalate was the preferred additive for whole blood 
samples (63%), with a minority of studies using heparin, citrate or EDTA (24%, 6% 
and 6% respectively).   
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Figure 19: Bar chart showing additives to blood specimens for storage of samples 
separated into plasma, whole blood and serum specimens.  Grey represents Potassium 
Oxalate, green represents heparinised samples, white citrate, purple EDTA, , and red no 
additive.  93 manuscripts (44%) with incomplete data excluded from figure. 
 
Temperature of storage of whole blood samples was available in 79% publications.  
Whole blood samples were stored in a fridge in 96% cases where this information 
was recorded. Use of refrigerated whole blood, and storage of these samples for 
longer than the 12 weeks recommended by Plummer was documented in only 5% 
of publications, although this information was not available in 78% manuscripts.  
Temperature of storage of plasma samples was completed in 76% publications.  
Plasma was stored in a fridge in 31% publications, frozen in a standard freezer in 
43%, and in a -60 to -80 oC freezer in 25% studies. 
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Method of propofol separation was better recorded, with this information available 
in 201 (95%) of manuscripts.  Of manuscripts recording the information, 95% used 
HPLC to extract propofol, and 4% used Gas Chromatography.   
 
3.2.3.2 Site of Blood Sampling 
Figure 20 shows the time related trend in chosen site of sampling, showing few 
early samples using arterial blood for sampling, but the majority of more recent 
publications sampling from arterial blood.  Analysis of changes from venous to 
arterial blood sampling over time was performed using Kendall’s tau-b test for 
correlation, with a tau-b value 0.18, and significance (2 tailed) p=0.03. 
 
Figure 20:  Change in site of sampling over time.  Red line represents arterial sampling (or 
arterial as well as other site), blue line represents venous sampling.  4 manuscripts (1.9%) 
with incomplete data excluded from the graph. 
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3.2.3.3 Subgroup analysis 
Studies in which blood propofol concentrations have been used to develop propofol 
TCI algorithms underwent subgroup analysis.  Twelve publications were identified 
as being used in the development of propofol TCI modelling. Table 12 shows the 
data comparing chosen method of sampling and sample site for both groups of 
publications.  These studies were published significantly earlier on average than 
other pharmacokinetic studies, with a Kendall’s Tau-b value of 0.11 (p=0.048).  
When comparing publications using whole blood verses plasma, a similar proportion 
of publications in both the PK model and standard group used whole blood rather 
than plasma separated blood for blood propofol concentration analysis (p=1.00 
using Fisher’s exact test).  The higher proportion of PK TCI modelling studies to use 
venous blood (58% vs 34%) than other studies probably relates to earlier sampling 
practice, but did not reach statistical significance (p=0.12 using Fisher’s exact test). 
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 Propofol TCI model 
PK publications 
Other propofol 
PK publications 
P value 
(Fisher’s exact test) 
Number publications 12 194  
Whole blood analysis 58.3% 54.6% 
1.00 
Plasma blood analysis 41.7% 42.8% 
Serum blood analysis 0% 2.6%  
Number publications 12 195  
Arterial analysis 41.7% 66.2% 0.12 
 Venous analysis 58.3% 33.8% 
Table 12:  Differences in method of sampling between publications used for 
pharmacokinetic TCI model development and other propofol pharmacokinetic publications.  
    
3.2.4 Discussion 
It is clear to those reading the literature involving measurement of blood propofol 
concentration for pharmacokinetic analysis that there are wide technical and 
temporal variations in the methods used to collect and analyse specimens.  There is 
evidence, highlighted at the beginning of this chapter that variations in 
methodology can significantly impact on the repeatability and reliability of results, 
which may have an impact on the interpretation of subsequent analyses.  Of 
particular significance, are the methods used for experiments developing and 
validating pharmacokinetic models for target controlled infusion of propofol.  The 
systematised analysis of the available literature involving propofol concentration 
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measurement performed in this chapter has highlighted a number of important 
points.   
Firstly, there would appear to have been a marked change in practice over the last 
25 years since the earliest pharmacokinetic studies were performed, with a swing 
towards the use of plasma blood samples rather than whole blood.  This change in 
practice has a number of implications.  Most important is the lack of consistency in 
method.  Both whole blood and preparation of specimens as plasma have benefits, 
and no clear guideline as to which method is preferable exists.  Whole blood 
analysis, most popular in early studies, has the benefit of ease of collection, without 
the requirement for immediate sample processing at the point of care.  Blood 
concentrations of propofol appear stable for up to 12 weeks when stored correctly 
at 4 0C.  There is also more likely to be consistency of results when using whole 
blood, with plasma sampling suffering from variations in time to centrifugation, 
which will lead to differences in measured plasma concentrations particularly during 
induction and emergence from anaesthesia.  Advantages of plasma preparation 
include the ability to store specimens indefinitely prior to analysis, when using low 
temperature freezers.  Whole blood samples should not be frozen, as this appears 
to lead to inaccuracy in measured propofol concentration (see section 3.3.3.3 for 
proposed mechanisms).  A further benefit of plasma preparation, when performed 
immediately following sampling, is that concentrations represent the true plasma 
concentration in blood, which may be significantly higher, or lower than whole 
blood concentrations depending on the phase of anaesthesia, where propofol has 
been allowed to bind to red blood cells over time (see chapter 3.1.2).  It is clear 
however, that immediate sample centrifugation is not performed in the majority of 
110 
 
cases.  This review was only able to confirm immediate sample processing in 17% 
of publications in which plasma was used.  Where data were recorded, the majority 
of publications did not perform immediate centrifugation.  It is thus likely that the 
lack of uniformity within, and between experiments will lead to significant variation 
in measured concentrations. 
Secondly, there has been a large swing over time from sampling venous, to using 
arterial blood when sampling.  Only one third of early publications (prior to 1990) 
performed their analyses on arterial blood, whereas almost three quarters (72%) of 
publications after 2005 used arterial blood for analysis.  Clearly there are 
advantages of using venous blood: for example, arterial puncture is not required.  
This is advantageous as there is a small reduction in the risk of complications in 
volunteer studies, and an increase in potential recruits in clinical studies, where 
enrolment need not be limited to those patients requiring invasive arterial access.  
However, it is arterial blood which is delivered to the brain, the effect site.  Venous 
blood concentrations will differ from arterial concentrations, particularly during the 
rapid induction and emergence phases of anaesthesia, or immediately following 
changes in targeted blood concentrations during propofol TCI.  This difference is of 
less significance during the maintenance phase of anaesthesia.  Of note, 58% of 
publications identified from this review as being used to develop pharmacokinetic 
TCI models were based on experiments using venous blood – probably a reflection 
of the era in which many of these experiments  were performed, when this was 
standard practice.  It may explain however, some of the reasons for the inaccuracy 
and bias found in these models, which are explored later in this thesis. 
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Thirdly, the data analysed in this review on the method of storage of samples 
showed fairly consistent practice.  Most whole blood samples were stored at 
approximately 4 0C prior to analysis as recommended by Plummer.(Plummer 1987)  
Analysis of such samples should be performed within 12 weeks, and only 5% of 
publications in which this information was available stored specimens for longer 
than this period.  These data were however poorly documented in manuscripts.  
Storage temperature of plasma specimens is less critical, with three quarters of 
specimens being stored in either standard or low temperature freezers.  It would 
make sense for all plasma specimens to be frozen prior to analysis, unless this is 
going to be done immediately, as this will minimise the degradation of propofol 
concentrations over time. 
Finally, the chosen method of propofol extraction was highly consistent throughout 
studies, with no change over time.  The overwhelming majority of publications 
documented the use of high performance liquid chromatography for drug extraction 
(95%).  Chosen method of extraction is therefore unlikely to have any bearing on 
differences in pharmacokinetic data generated between studies, although the 
details of specific HPLC apparatus performance were not specifically analysed in this 
work. 
The main conclusion from this review is that more consistency should be developed 
amongst the research community performing pharmacokinetic analysis using blood 
propofol concentrations.  If, as seems to be the trend, plasma concentrations are to 
be measured rather than whole blood, then specimens should be processed 
immediately, and this should be documented within the manuscript.  It may be 
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desirable to repeat some of the early pharmacokinetic research using arterial blood, 
and plasma specimens.  This may improve the performance of propofol based 
pharmacokinetic models developed in the future. 
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A series of experiments have been designed in the following section of this thesis to 
further clarify the potential significance of the differences in methodology 
highlighted in the literature review and systematised literature analysis performed 
above. 
 
3.3 The influence of method of sample preparation and storage on whole 
blood propofol concentrations 
Previous literature has suggested that whole blood may be stored for up to 12 
weeks at 4 oC in oxalated specimen tubes with acceptable retention of propofol 
concentrations.(Plummer 1987)  Some published literature however has 
recommended specimen analysis within 5 days to minimise the risk of significant 
degradation of drug concentrations.(Bienert, Zaba et al. 2005)  Both Plummer and 
Bienert advise against freezing whole blood specimens to prevent significant 
propofol loss. 
 
3.3.1 Aims 
A propofol storage experiment was designed to clarify the significance of the use of 
oxalate preservative, duration and temperature of storage on drug loss, and to 
examine whether blood sample storage would impact on the ability of the new 
propofol analyser to measure drug concentrations. 
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3.3.2 Methods 
300ml of heparinised volunteer blood previously screened for blood borne infections 
was drawn into a sterile container containing 3000 IU heparin to prevent 
coagulation.  The sample was used for experimentation immediately following 
donation. 
The sample was divided into five 50ml aliquots.  Propofol, prepared as Diprivan™ 
(obtained from Astra Zeneca, an emulsion of soya oil and propofol mixed in water 
at 10mg.ml-1) was used for spiking samples.   
Samples were prepared to achieve four clinically meaningful concentrations as 
follows: 
• 100ml heparinised whole blood spiked with 120 µl propofol to approximately 
achieve a propofol concentration of approximately 12 µg.ml-1.  The sample was 
placed on a roller mixer for 15 minutes to allow thorough mixing.  A 50ml 
aliquot was set aside. 
• 50ml heparinised whole blood was combined with 50ml of the above spiked 
blood to achieve a propofol concentration of approximately 6µg.ml-1.  The 
sample was placed on a roller mixer for 15 minutes to allow thorough mixing.  A 
50ml aliquot was set aside. 
• This process was repeated to obtain 50 ml samples of whole blood with propofol 
concentrations of approximately 3 µg.ml-1 and 1.5 µg.ml-1. 
• One 50 ml aliquot of whole blood was left unspiked for analysis. 
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Following this process, 50ml samples at approximately 0 µg.ml-1, 1.5 µg.ml-1, 
3 µg.ml-1, 6 µg.ml-1 and 12 µg.ml-1 were obtained.  Samples were decanted into 4ml 
oxalated tubes (“vacutainers” ™) for subsequent storage, with one sample at each 
concentration retained without oxalate for comparison. 
Samples were stored at 4 oC prior to analysis.  One set of samples at each 
concentration were frozen at -20 oC for storage immediately following preparation.  
All samples were allowed to return to room temperature and mixed thoroughly for 
one minute using a vortex mixer prior to analysis.  Samples stored at 4 0C were 
processed using the research propofol analyser at the following time points: 
• Day 0, day 14, day 28, and day 60. 
• Samples stored at -20 oC were thawed and analysed on day 14. 
• Samples comparing oxalated whole blood and without oxalate were analysed on 
day 0. 
Samples were processed in duplicate within four hours.  The mean propofol 
concentration, standard deviation, and coefficient of variation ([standard 
deviation/mean concentration] x 100) were calculated for analysis. 
The novel propofol analyser underwent daily three point calibration and quality 
control using propofol suspended in methanol as described in chapter 2.5.  
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3.3.3 Results 
3.3.3.1 Baseline values 
Analysis of duplicate samples of fresh propofol spiked blood, prepared in oxalated 
specimen tubes was performed to obtain baseline measured propofol 
concentrations.  Mean values and variations are shown in Table 13.  A maximum 
coefficient of variation of 1.9% for propofol concentrations between 1.5 and 
12 µg.ml-1 was calculated. 
 
Mean Concn 
(µg.ml-1) 
SD 
CV  
(%) 
Specimen 1 (0) 0.09 - - 
Specimen 2 (1.5) 1.67 0.01 0.42 
Specimen 3 (3) 3.06 0.06 1.85 
Specimen 4 (6) 6.39 0.04 0.55 
Specimen 5 (12) 12.21 0.20 1.62 
Table 13:  Measured concentrations of propofol (analysed in duplicate) in fresh oxalated 
whole blood using novel propofol analyser. SD – standard deviation, CV – coefficient of 
variation. 
 
3.3.3.2 Influence of oxalate preservative 
Baseline concentrations were compared with whole blood samples without the 
addition of oxalate, both analysed in duplicate, to identify whether this chemical 
had any influence on measured values using the research propofol analyser. 
Percentage deviation of samples was calculated.  Data are shown in Table 14.  
Percentage deviation between the unoxalated and the oxalated specimens ranged 
from -1.8 to 2.6%, which were similar to the within sample variations shown in 
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Table 13.  Thus, no identifiable differences in propofol concentrations were 
measured using the novel propofol analyser following the addition of the 
preservative oxalate. 
 
 Mean Concn 
Oxalated 
(µg.ml-1)) 
Mean Concn 
Unoxalated 
(µg.ml-1) 
% 
Deviation 
Specimen 1 (0) 0.09 0.14 - 
Specimen 2 (1.5) 1.67 1.64 -1.83 
Specimen 3 (3) 3.06 3.14 2.55 
Specimen 4 (6) 6.39 6.58 2.89 
Specimen 5 (12) 12.21 12.03 -1.50 
Table 14:  Mean measured concentrations of propofol in fresh un-oxalated whole blood 
compared to oxalated samples (data from Table 13) using novel propofol analyser. All 
samples analysed in duplicate. 
 
3.3.3.3 Temperature during storage 
Baseline values were compared following 14 days storage at 4 oC as recommended 
by Plummer and following storage at -20 oC.  Samples were analysed in duplicate 
within four hours and the data recorded in Table 15. 
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 Mean measured concentration (µg.ml-1)    
Specimen 
(conc.) 
Baseline  Stored  
4oC  
Stored 
 -20oC  
% Deviation 
stored 40C 
% Deviation 
stored -200C 
1 (0) 0.09 0.09 0.12 - - 
2 (1.5) 1.67 1.67 1.68 0.00 0.60 
3 (3) 3.06 3.15 3.13 2.94 2.29 
4 (6) 6.39 6.57 6.51 2.82 1.88 
5 (12) 12.21 12.27 12.00 0.49 -1.72 
Table 15:  Change in whole blood propofol concentration over 14 days of storage when 
refrigerated or frozen. Samples analysed in duplicate. Percentage deviation calculated as 
[(concentration difference from baseline/baseline concentration)x100]. 
 
The results of this experiment have demonstrated good agreement between 
unstored  blood and samples stored for 14 days at both 4oC and -20 oC.  These 
results contrast with previously published data suggesting deterioration in propofol 
concentrations when whole blood is frozen.  It was noted that there was significant 
cellular debris present in the frozen samples included in the sample analysis.  All 
values presented in Table 15 represent unfiltered samples.  This cellular debris was 
more likely to cause machine failure through clogging of fine-bore tubing.  A 
70 micron filter was employed to reduce the likelihood of the analyser clogging, but 
significant reductions in propofol concentration when filtration was performed were 
noted and so these values were not used.  It is likely that propofol is adherent to 
cellular debris, and this has reduced propofol values when sample filtration is 
performed.  It is postulated that sample filtration of thawed frozen samples in 
previous published work may have led to the loss of measured propofol.  This 
experiment demonstrates that using the research propofol analyser, specimens can 
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be frozen for storage and minimal loss of drug occurs provided cellular debris is not 
discarded through filtration. 
 
3.3.3.4 Duration of storage 
Baseline values at each concentration of propofol were compared with samples 
stored at 4 oC for predefined durations up to 60 days following sample preparation.  
Samples were analysed in duplicate within four hours of each other and the mean 
drug concentration recorded in Table 16. 
 
   Mean propofol concentrations (µg.ml-1)  
 Day 0 Day 14 Day 28 Day 60 
Approx Sample 
concn µg.ml-1 
Concn (SD) 
(µg.ml-1) 
Concn (SD) 
(µg.ml-1) 
% 
Deviation 
 
Concn (SD) 
(µg.ml-1) 
% 
Deviation  
Concn (SD) 
(µg.ml-1) 
 
% 
Deviation  
0 0.09 (0) 0.09 (0.01)  - - - - 
1.5 1.67 (0.03) 1.67 (0) 0.00 1.54 (0.05) -7.78 1.57 (0.01) -5.99 
3 3.06 (0.06) 3.15 (0.04) 2.94 3.08 (0.04) 0.65 2.38 (0.03) -22.22 
6 6.39 (0.04) 6.57 (0.11) 2.82 6.43 (0.09) 0.63 4.64 (0.05) -27.39 
12 12.21 (0.2) 12.27 (0.06) 0.49 11.11 (0.31) -9.01 9.78 (0.04) -19.90 
Table 16:  Change in measured whole blood propofol concentration with increasing 
duration of storage at 4 oC. Percentage deviation calculated as (concentration difference 
from baseline/baseline concentration)x100.  Samples analysed in duplicate, mean value 
shown with (SD). 
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Figure 21:  Change in measured whole blood propofol concentration with duration of 
storage at 4 oC.  Error bars represent 95% Confidence intervals. 
 
This experiment shows a small deterioration in measured whole blood propofol 
concentrations over the first 28 days of storage.  The concentrations reduced more 
appreciably over the following month, and were lower at day 60 by a clinically 
significant concentration (6 to 27% reduction in propofol concentration from 
baseline).  This degradation over time may represent loss of propofol from the 
specimen into the sample container headspace, as propofol is a volatile compound.  
There was approximately a one millilitre headspace in the storage containers used 
for these experiments, and replicates the standard headspace in storage containers 
used in most biochemical laboratories.  An attempt at reducing this headspace may 
have improved sample lifespan. 
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3.4 Are whole blood analyses or plasma analyses of propofol 
concentrations more reliable? 
The literature review has revealed varying data in published literature when 
comparing whole blood propofol analyses with plasma samples.  It is clear that drug 
concentrations in plasma samples are likely to be significantly dependent on the 
time to centrifugation, as the drug undergoes time dependent binding to red blood 
cells.  Some groups have suggested centrifuging samples immediately to prevent 
inconsistencies in drug concentration, although this is not standard practice across 
all clinically active groups.  The move over the last ten years from measuring whole 
blood, in which propofol concentrations are constant; to plasma, in which 
concentrations can vary according to time of centrifugation, has led to 
inconsistency.  The lack of consistency in method of sample collection and handling 
has been shown to affect measured drug concentrations, and is likely to affect 
pharmacokinetic interpretation based on the analyses. 
 
3.4.1 In Vitro experiment to compare whole blood with plasma samples and to 
determine influence of time to centrifugation of samples 
3.4.1.1 Aims 
An in vitro experiment was designed to determine whether there are significant 
fluctuations in plasma propofol concentration between whole blood and plasma.  
The influence of time from sample preparation to centrifugation was also assessed.   
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3.4.1.2 Methods 
50ml of heparinised volunteer blood previously screened for blood borne infections 
was drawn into a sterile container containing 500 IU heparin to prevent 
coagulation.  The sample was used for experimentation immediately following 
donation. 
Propofol prepared as Diprivan™ (obtained from Astra Zeneca, an emulsion of soya 
oil and propofol mixed in water at 10 mg.ml-1) was used for spiking samples.   
Samples were prepared to achieve three clinically meaningful concentrations as 
follows: 
• 20ml heparinised whole blood spiked with 20 µl Diprivan™ to achieve a propofol 
concentration of approximately 10 µg.ml-1.  The sample was placed on a roller 
mixer for 15 minutes to allow thorough mixing prior to analysis.  A 10ml aliquot 
was set aside for dilution below. 
• 10ml heparinised whole blood was combined with 10 ml of the above spiked 
blood to achieve a propofol concentration of approximately 5 µg.ml-1.  The 
sample was placed on a roller mixer for 15 minutes to allow thorough mixing 
prior to analysis.  A 10 ml aliquot was set aside for dilution below. 
• The above process was repeated to obtain a sample of whole blood with 
propofol concentration of approximately 2.5 µg.ml-1. 
Following this process, 10ml samples at approximately 2.5 µg.ml-1, 5 µg.ml-1, and 
10 µg.ml-1 were obtained and used for the experiment.  All blood specimens had 
123 
 
blood propofol measured using the research propofol analyser described previously. 
The research propofol analyser underwent three point calibration and quality 
control using propofol suspended in methanol as described in chapter 2.1.  
Plasma samples were centrifuged at 15 min (to allow thorough mixing on roller 
mixer), one hour, and six hours, and analysed immediately following centrifugation, 
which was performed for ten minutes at 10,000rpm.  Whole blood samples were 
analysed at 15 min, one hour and six hours following sample preparation.  All 
samples were analysed on the same day of sample preparation and analyser 
calibration.  Samples were not analysed in duplicate because of the time critical 
nature of the experiment. 
 
3.4.1.3 Results 
The results of this experiment are illustrated in Figure 22 below.  Whole blood 
propofol concentration did not vary appreciably over the six hours.  Plasma propofol 
concentrations were higher than whole blood concentrations for all samples and at 
all time points.  The mean difference in drug concentration for all samples was 
higher in the plasma samples than whole blood at 0.44 µg.ml-1 (SD 0.26), or 8.9% 
(range 3.8 to 15.1).  Plasma samples centrifuged immediately following 15 min 
mixing were not appreciably higher than samples measured following delayed 
centrifugation.  The mean difference in propofol concentration between plasma and 
whole blood was 8.0% when centrifuged immediately following mixing, and 9.3% 
for samples with delayed centrifugation. These findings differ to previously 
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published data from the literature, and suggest that time to centrifugation is less 
critical than previously thought. 
 
 
Figure 22:  Measured propofol concentrations of three blood samples spiked with propofol and 
analysed or centrifuged to obtain plasma at three time points.  Whole blood shown in red, plasma in 
yellow. 
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3.4.2 Reliability of whole blood versus plasma propofol sampling during the 
induction phase of TCI anaesthesia when compared to the maintenance 
phase. 
3.4.2.1 Aims 
The in vitro experiment in chapter 3.4.1 demonstrated higher propofol 
concentrations in plasma when compared with whole blood, confirming the 
evidence from the majority of the literature reviewed earlier in this chapter.  In 
order to confirm these results in a clinical setting, a further experiment was set up 
to compare whole blood samples with plasma samples from patients in the 
operating theatre undergoing propofol based intravenous anaesthesia.  As it is 
possible that propofol equilibration between red cells and plasma differs at 
induction compared with the maintenance phase of anaesthesia, the experiment 
was designed to determine the influence of plasma or whole blood sampling at the 
induction phase of anaesthesia, compared to later on during anaesthesia. 
 
3.4.2.2 Methods 
West Midlands Research and Ethics Committee approval was sought to draw 
samples of blood during anaesthesia from pre-existing arterial cannulae following 
written informed consent.  Samples were drawn during both the induction phase of 
anaesthesia (sampling prior to 30 min anaesthesia), and in the maintenance phase 
of anaesthesia (beyond 30 min anaesthesia and at least 15 minutes following a 
change in set propofol concentration).  5 ml samples were drawn, and immediately 
placed into heparinised “vacutainers”™.  The samples were divided into two 
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aliquots, one for whole blood analysis, and the second sample was centrifuged 
immediately at 10000 rpm for 10 minutes to obtain plasma.  All samples were 
analysed using the propofol analyser on the day of sampling. 
 
3.4.2.3 Sample size calculation and statistical Analysis 
An estimation of sample size required for the clinical experiment was based on 
previously published data from Coetzee.(Coetzee, Glen et al. 1995)  These data 
demonstrated a difference in propofol concentration between plasma and whole 
blood of 0.3 µg.ml-1, with a SD of the difference of 0.4.  Based on these figures, a 
power calculation was performed for a one-way 2 level ANOVA, with an alpha of 
0.05 and a power of 0.9 (MiniTab 16 ®, Statistical software, Pennsylvania, USA) 
with a calculated minimum sample size of 39 paired samples.  Differences between 
plasma and whole blood measurements were analysed using two tailed t-testing for 
paired samples.  The impact of phase of anaesthesia on the plasma/whole blood 
propofol concentration measured differences was analysed using univariate analysis 
of variance.  Analysis was performed using SPSS for Windows, Rel. 19.0.0. 2010. 
Chicago: SPSS Inc. 
 
3.4.2.4 Results 
30 patients undergoing propofol TCI using the Marsh algorithm with effect site 
targeting underwent blood sampling for whole blood and plasma propofol assay.  A 
total of 57 paired samples were drawn (mean number of samples per patient of 
1.9).  Patient characteristics of samples analysed included 60% male, mean age 48 
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years (range 17 to 72 years, SD 17.1), and mean body mass index 29.0 kg.m-2 
(range 23 to 38 kg.m-2, SD 4.5).   
The mean measured propofol concentrations was 5.6 µg.ml-1 (SD 2.4 µg.ml-1) for 
plasma samples and 5.2 µg.ml-1 (SD 2.1 µg.ml-1) for whole blood. The Bland-Altman 
difference plot (Figure 23), shows the spread of propofol concentrations measured, 
with a mean bias of 0.32 µg.ml-1, and limits of agreement (1.96SD) of -0.63 to 
1.2 µg.ml-1. Plasma propofol concentrations were on average 5.3% higher than 
whole blood (p<0.001). The Bland-Altman plot demonstrates a correlation between 
difference in blood propofol concentration and average propofol concentration.  
This is not unexpected, as bias is proportional to concentration measured. 
128 
 
 
Figure 23: Bland-Altman difference plot comparing plasma propofol concentrations with 
paired whole blood samples.  The mean line demonstrates a bias of 0.32 µg.ml-1. 
 
As shown in Table 17 below, when separated into samples during the induction 
phase (≤ 30 min) and maintenance phase (>30min) of anaesthesia, plasma 
concentrations of propofol were measured statistically significantly higher than 
whole blood during the induction phase than during maintenance phase of 
anaesthesia, with mean plasma concentrations measuring 7.7% and 2.5 % higher 
than whole blood concentrations respectively (p=0.02).  
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 N 
Mean % 
Difference, (SD) 
Significance 
(p) 
95% Confidence interval 
Lower bound Upper bound 
All samples 57 5.26 (8.50) <0.001*   
Induction 30 7.74 (5.95)  4.75 10.72 
Maintenance 27 2.50 (10.0)  -0.64 5.65 
Between induction and maintenance groups 0.02**  
Table 17: Mean percentage difference between plasma and whole blood, with data 
separated into induction phase (<30mins) and maintenance phase (>30mins) of 
anaesthesia. * paired samples T test, ** univariate analysis of variance between induction 
and maintenance groups. 
 
3.4.3 Discussion 
As expected from previous studies, whole blood samples had lower propofol 
concentrations than plasma samples in all cases in the in vitro experiment.  This 
was confirmed in the clinical study, and the difference found to be more apparent 
during the induction phase of anaesthesia.   
It was expected that samples centrifuged immediately following mixing in the in 
vitro experiment would have propofol concentrations significantly higher than 
samples centrifuged later than this because of equilibration of drug with red blood 
cells.  It was interesting that this experiment did not demonstrate this phenomenon 
and it may well have been overestimated in the literature.  It is possible however 
that the chosen period for mixing of 15 minutes was excessive, and may have 
allowed the binding of drug to red cells to have taken place, and thus hide any real 
difference in circulating plasma concentrations of drug.  If this is the case, it is likely 
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to only be significant in vivo during significant changes in circulating propofol 
concentration, such as during the induction phase of anaesthesia, during significant 
dose changes, and during the rapid washout phase of anaesthesia.  This is because 
at steady state, the equilibrium between red cells and plasma will have taken place 
in vivo over a period of 15 minutes.  The clinical experiment described confirms that 
plasma/whole blood propofol concentration differences are more exaggerated 
during the induction phase of anaesthesia. 
When developing or validating TCI algorithms, immediately centrifuged plasma 
samples are likely to best represent the drug concentration diffusing into the effect 
site.  Plasma measurements can be significantly different from whole blood during 
the induction phase of anaesthesia.  If blood propofol concentrations are measured 
for clinical utility during the maintenance phase of anaesthesia, whole blood 
sampling may be used, with the advantage of a reduced sample handling time, 
although concentrations are likely to slightly underestimate plasma concentrations, 
which may better represent the effect site.  However, if sampling during the 
induction phase, potential differences are larger, and may need to be compensated 
for.  
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4 CHAPTER 4 – STUDIES ON PROPOFOL ANAESTHESIA IN THE 
OPERATING ROOM  
Target controlled infusion of propofol to achieve estimated plasma concentrations of 
propofol using one of several available pharmacokinetic algorithms is in common 
practice in Europe following its introduction over the last twenty years.  The 
algorithms in use have been generated using small cohorts of patients.  Relatively 
little work has been done in significant numbers of patients to look at the correlation 
between measured blood propofol concentrations and  those estimated using 
available algorithms, particularly in diverse patient groups that do not conform to 
standardised inclusion criteria required in many validation studies.  In part, the lack of 
validation work relates to the difficulty of measuring blood propofol concentrations    
cheaply and time efficiently.   
The ability of TCI algorithms to accurately predict blood propofol concentrations is 
poor(Marsh, White et al. 1991; Coetzee, Glen et al. 1995), with measures of 
precision demonstrating errors of up to 60%.(Hoymork, Raeder et al. 2003)  
Significant bias and large errors in precision are also identified in patient groups 
falling outside of limits used in the development of these models.(Bailey, Mora et al. 
1996; Barvais, Rausin et al. 1996; La Colla, Albertin et al. 2009)  Studies have been 
conducted in which propofol TCI is titrated to a specific pharmacodynamic target, 
such as a specified Bispectral Index (BIS) value.  It is not clear whether this method 
is uniformly used in clinical practice, given the absence of guidelines recommending 
routine use of pharmacodynamic monitoring and lack of clear evidence of reduction 
in anaesthetic awareness. 
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4.1 Assessment of the method of practical use and performance of the 
effect site Marsh model for target controlled infusion of propofol 
during the maintenance phase of general anaesthesia in an 
unselected population of neurosurgical patients. 
 
4.1.1 Background 
The Marsh algorithm for propofol TCI was the first to be introduced to the 
commercial market, and is currently the preferred algorithm for many anaesthetists, 
given the widespread experience of its use.  This algorithm was developed to 
predict the propofol concentration within the central compartment (the plasma), as 
the most readily measurable surrogate for the concentration at the site of action 
within the brain.  The plasma concentration of intravenous anaesthetic drugs after a 
bolus peaks almost immediately, although the peak effect of the drug occurs a 
short time later when the brain concentration equilibrates with the central 
compartment.  This delay or hysteresis is because the site of action is at the 
biophase, the immediate milieu where the drug acts (receptors, enzymes, and 
membranes) rather than within the plasma.  The biophase or effect site has its own 
pharmacokinetic parameters within the traditional three-compartment model used 
for standard plasma targeted models previously described.  The rate constant (ke0) 
describes the removal of the drug from the effect site.  If a constant plasma 
concentration is maintained, then the time for the effect site concentration to reach 
50% of the plasma concentration is given by 0.693/ke0. (Wakeling, Zimmerman et 
al. 1999)  Thus the ke0 can be incorporated into the traditional three compartment 
model to calculate the dosing scheme to achieve a desired effect site concentration.  
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The effect site is a theoretical compartment in which the drug exerts its action and 
thus the concentration at this site is the determinant of its effect.  The ability of a 
TCI model to provide an effect compartment concentration rather than plasma 
concentration depends on the ability to perform pharmacokinetic and 
pharmacodynamic modelling with an effective and representative marker of level of 
consciousness.  This work has been done using spectral edge frequency, Bispectral 
index, or median EEG frequencies.  Using this work, effect site targeting as an 
alternative to plasma targeting has been introduced, using the constant ke0 to 
allow calculation of effect site concentration.(Dyck and Shafer 1992; Jacobs and 
Williams 1993)  The main benefit of targeting brain concentration over plasma 
concentration is a more rapid titration of depth of anaesthesia, overcoming the lag 
between the attainment of a set plasma concentration, and the time taken for 
plasma to equilibrate with the brain. This avoidance of lag is seen at the point of 
induction of anaesthesia and at the point of changes in set propofol concentration 
during the maintenance phase of anaesthesia.  Bispectral index (BIS) monitoring 
has been shown to correlate with EEG measures of depth of anaesthesia for various 
anaesthetic agents, when correlated with estimated anaesthetic concentrations. 
(Billard, Gambus et al. 1997)  Further work by Wakeling, (Wakeling, Zimmerman et 
al. 1999) and Schnider using EEG and sleep studies has provided some validation 
for the estimate for Ke0 using propofol infusion and bolus studies.(Schnider, Minto 
et al. 1999)  This work has subsequently been validated in healthy patients, 
demonstrating improved attainment of desired pharmacodynamic end points 
(anaesthesia as measured by EEG or Bispectral index), without significant side 
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effects (cardiovascular instability), although only the period of induction (first 12 
minutes of anaesthesia) was studied.(Struys, De Smet et al. 2000)   
Propofol TCI using the Marsh model in effect site mode has become one of the 
most popular algorithms in routine intravenous anaesthetic practice.  However, 
several other models are now available, including the Schnider model, which uses 
covariates including patient gender, age, and lean body mass in an attempt to 
further improve model performance.  It is likely that the popularity of the Marsh 
model stems from the fact that it was the first model to be made commercially 
available, and so has become familiar to many practitioners. 
 It must be borne in mind however, that it is not possible to measure the brain 
concentration of propofol currently, and these models are validated using estimates 
of the diffusion constant based on work with measures of brain activity such as 
EEG, which can not necessarily be directly correlated with depth of anaesthesia. 
The difference between expected plasma and effect site propofol concentration 
occurs during changes in set propofol concentration, and should disappear during 
the maintenance phase of the infusion (after a few minutes).   
It is clear that there is potential for drug interactions with co-administered drugs.  
Remifentanil for example, is very frequently co-administered with propofol as part 
of TCI anaesthesia.  It is clear that the presence of remifentanil causes significant 
pharmacodynamic changes which dramatically reduce the amount of propofol 
required to maintain anaesthesia.(Bouillon, Bruhn et al. 2004; Bienert, Zaba et al. 
2009)  There is also potential for pharmacokinetic influences for co-administered 
drugs.  Certainly, remifentanil pharmacokinetics are significantly altered in the 
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presence of propofol, with a large reduction in central volume of distribution (41%) 
and elimination clearance (15%). (Bouillon, Bruhn et al. 2002)  It was hypothesised 
by these researchers that the pharmacokinetic changes were caused by circulatory 
alterations (cardiac output or systemic vascular resistance), based on similar 
alterations to the pharmacokinetics of remifentanil during haemorrhagic 
shock.(Johnson, Egan et al. 2004)  Although this work was not able to demonstrate 
a significant reciprocal effect of propofol pharmacokinetics by the presence of 
remifentanil, there is evidence from other work.(Bienert, Zaba et al. 2009) 
 
As effect site sampling is not viable, it is not possible to validate the 
pharmacokinetics of propofol TCI in effect site mode, and so we rely on validation 
of the models in plasma targeting mode, or dispense with the measurement of 
propofol concentrations, and rely on assumptions about the equivalence of direct 
pharmacodynamic depth of anaesthesia monitors with effect site concentrations of 
propofol.  It is reasonable to make the assumption that the performance of such 
models using either plasma or effect site targeting is likely to be similar during the 
maintenance phase of anaesthesia, as the differences in timing of drug 
administration occur over a very short period during periods of induction or dose 
manipulation, and total dose administered will be almost identical several minutes 
following dose modification.  Additionally, given that the time taken for equilibration 
between the brain and the blood for these models is at maximum only several 
minutes, estimated plasma and estimated effect site concentrations using these 
models are identical after a short interval.  Therefore, if measurements are confined 
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to the maintenance phase by using blood sampling following a period of time for 
equilibration, model validation may be performed using plasma samples, although 
of course, the validation will only apply to the maintenance phase of anaesthesia.   
 
4.1.2 Aims 
To assess the method of use and dose titration of propofol TCI of anaesthetists at a 
large UK teaching hospital.  Pharmacokinetic analysis of the performance of the 
commonly used Marsh model for propofol TCI in effect site mode in adult patients 
undergoing elective neurosurgery at our institution was undertaken.  No attempt 
was made to exclude patients based on comorbid or demographic parameters, 
making the results representative of patients in clinical practice.  The patterns of 
propofol dose titration during anaesthesia were also analysed. 
 
4.1.3 Sample Size Estimation 
An estimate of patient numbers required to demonstrate a bias of twice that 
deemed acceptable by many (10 to 20%) (Schuttler, Kloos et al. 1988) was felt to 
represent a clinically significant difference in model performance.  Using a single 
sided sample size test of one proportion, with an alpha of 0.05, and a power of 
80% to detect a doubling of bias from an acceptable rate of 15% to a rate of 30% 
would require 43 patients.  A single sided test was chosen because only an increase 
in bias was deemed relevant for the purposes of sample size estimation. (MiniTab 
16 ®, Statistical software, Pennsylvania, USA) 
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4.1.4 Patients and methods  
After approval by the West Midlands Local Research Ethics Committee, and written 
informed consent, 50 adults ASA physical performance status I to III undergoing 
elective neurosurgery using propofol TCI at the Queen Elizabeth Hospital 
Birmingham, UK, were enrolled in the study.  All patients were scheduled for 
procedures in which the anaesthetist routinely used propofol TCI, and anaesthesia 
expected to last between 1 and 12 hours. 
General anaesthesia was induced and maintained using propofol TCI (Standard 
settings from Fresenius Kabi infuser: effect site Marsh model, Ke0 of 1.21 min-1, 
t1/2ke0 0.57 min, Time to peak effect 1.6 min) and remifentanil TCI (effect site 
Minto model) using the commercially available Orchestra Base Primea system, 
Fresenius Kabi, Runcorn, UK.  Induction and maintenance targets for propofol and 
remifentanil were determined by the anaesthetist by clinical judgement of the depth 
of anaesthesia, and not influenced by trial inclusion.  Following induction of 
anaesthesia, the patient’s trachea was intubated following the administration of 
0.5 mg.kg-1 atracurium or rocuronium, and the lungs were mechanically ventilated 
with oxygen-enriched air to achieve normocapnea.  Arterial access was obtained 
from the radial artery for invasive blood pressure monitoring and for blood sampling 
within 15 minutes of induction of anaesthesia. 
 
The following data were collected for each patient: 
• Demographic details, (including age, gender, height, weight) 
• Details of surgery  
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• Significant co-morbidities and ASA physical performance status 
• Anaesthetist overseeing care 
• Method of propofol infusion (infuser used, model algorithm used, estimated 
plasma concentration at times of blood analysis, times of modification to set 
propofol concentration), duration of propofol infusion.    
• Drugs used as part of anaesthesia 
• Presence of any depth of anaesthesia monitor 
 
4.1.4.1 Blood Sampling 
Arterial blood was sampled for measurement of propofol concentration from an 
arterial line placed for routine clinical use.  Samples were drawn at regular intervals 
during the course of the maintenance phase of general anaesthesia, at a minimum 
of 10 minutes following a change in set propofol concentration to allow equilibration 
between effect site and plasma.  Typically, samples were drawn at 15, 30, 60 
minutes and approximately hourly following this.  Sampling continued until surgical 
anaesthesia was no longer required.  A maximum of 50 ml blood was drawn from 
each patient. 
 
4.1.4.2 Measurement of Propofol Concentration 
Plasma was used for analysis rather than whole blood to conform with the majority 
of contemporary publications for propofol pharmacokinetics, as it may more closely 
approximate the effect site than whole blood.  Plasma was separated immediately 
following sampling in a centrifuge at 3600 rpm for 10 min and stored at -20 oC until 
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assayed.  Before analysis, samples were thawed to room temperature and 
vortexed, then centrifuged at 3600 rpm for 5 min.  Plasma propofol concentrations 
were measured using the research propofol analyser detailed in chapter 2, further 
developed and validated for commercialisation as a research analyser by Sphere 
Medical Ltd, UK. (Liu, Pettigrew et al. 2012) Briefly, this system is capable of 
measuring propofol concentration from a 0.7 ml sample of plasma using automated 
solid phase drug extraction and colorimetric analysis previously described.(Cowley, 
Laitenberger et al. 2012)  Total within device imprecision for blood samples 
compares favourably with the high performance liquid chromatography (HPLC) 
standard with linearity over the range 0-12 µg.ml-1, and a coefficient of variation of 
1.4% at 2.84 µg.ml-1 and 1.2% at 6.68 µg.ml-1, and overall bias of the system over 
the range 0 – 12 µg.ml-1 of 0.15 µg.ml-1 (95% confidence interval -0.11 to 
0.41 µg.ml-1) compared with HPLC reference.(Cussonneau, De Smet et al. 2007)  
Validation work performed by Sphere Medical Ltd., who have since successfully 
obtained CE marking for the analyser as a point of care test, have demonstrated no 
significant influence of reduction in haemoglobin concentration on the analyser 
performance at clinically utilised concentrations of propofol (personal 
communication).   
 
4.1.5 Data Analysis 
The predictive performance of the effect site targeting Marsh model was 
determined by applying percentage prediction error (PE) analysis.(Varvel, Donoho 
et al. 1992) 
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PE =   𝒎𝒆𝒂𝒔𝒖𝒓𝒆𝒅 𝒄𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏 – 𝒑𝒓𝒆𝒅𝒊𝒄𝒕𝒆𝒅 𝒄𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏
𝒑𝒓𝒆𝒅𝒊𝒄𝒕𝒆𝒅 𝒄𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏  x100 
The performance of the TCI system was quantified for each patient using the four 
parameters described by Varvel et al.(Varvel, Donoho et al. 1992)   The percentage 
median prediction error (MDPE) is a signed value and reflects the bias of the 
predicted concentration compared to the measured one, and is calculated for each 
patient as the median value of the sum of the PE at each sampling point.  
MDPEi = median     [PEij, j = 1,2,3.....Ni] 
Ni is the number of samples obtained for the ith patient, and j represents each sample. 
The absolute value of prediction error |PE| was calculated, and the median value 
for each patient formed the median absolute prediction error (MDAPE), reflecting 
the precision of the system.   
MDAPEi = median [|PEij|, j = 1,2,3.....Ni] 
Ni is the number of samples obtained for the ith patient, and j represents each sample. 
The model is most accurate the closer the value of MDPE and MDAPE is to 0.  
Typical accepted maximum values during TCI have been proposed as 10-20% for 
bias, and 30% for precision.(Schuttler, Kloos et al. 1988)  Divergence of the system 
was calculated from the slope of the linear regression equation of |PE| against time, 
and expressed as percentage divergence per hour.  A positive value indicates 
divergence between measured and estimated concentrations over time, and a 
negative value indicates convergence.  Divergence was also calculated using signed 
PE% over time, as advocated by Glen et al.(Glen and Servin 2009)  The calculation 
of divergence using signed PE data allow the influence of time related changes in 
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performance to be identified, which may otherwise be hidden, for example when 
divergence is positive early on, but negative later during anaesthesia.  The 
variability in PE was characterised by wobble, calculated as the median absolute 
deviation of PE from MDPE. 
In this study the PEs are known in some patients with more certainty than others 
because of the varying numbers of samples for each patient.  For this reason, 
patients with a low number of samples may influence the calculations unduly.  In 
common with others,(Wietasch, Scholz et al. 2006)  the Marsh Ce TCI model bias  
and precision using the pooled patient data was also calculated. This analysis has 
the advantage of weighting the individual values of each patient to calculate bias 
and precision for a typical patient, although it will be more influenced by patients 
with a larger number of samples.  Importantly, this method also allows further 
analysis of time related bias and precision. 
 
4.1.6 Results  
Of the 57 patients consented to take part, 50 patients (87.7%) underwent 
anaesthesia using the Marsh algorithm in effect site mode and were enrolled into 
this study between November 2011 and May 2012.  Of the patients not enrolled, 7 
were excluded because the anaesthetist chose a model other than Marsh in effect 
site mode; 5 patients (8.8%) were anaesthetised using the Marsh model in plasma 
targeting mode, and 2 patients (3.5%) using the Schnider model in effect site 
mode.     Anaesthesia of recruited patients was performed by fourteen of the 
eighteen consultant neuroanaesthetists working in the Trust, and four anaesthetists 
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undergoing higher training in neuroanaesthesia.  None of the attending 
anaesthetists elected to use any form of advanced depth of anaesthesia 
pharmacodynamic monitoring, despite their availability within the trust.  A total of 
254 samples were analysed for plasma propofol concentration, with a mean of 5.1 
samples from each patient (range 3 to 9).  Patient characteristics are summarised 
in Table 18.  A summary of the operative procedures is listed in Table 19.  Figure 
24 and Table 20 show that few changes in targeted propofol concentration were 
made following induction of anaesthesia, during the maintenance phase of 
anaesthesia, with 46% anaesthetists not changing targeted propofol concentration 
at all following induction, and 78% making no more than one change.  Remifentanil 
targeted concentrations were changed more frequently, with a mean of 2.7 
changes (range 0 to 10) between induction and end of maintenance anaesthesia.  
No instances of anaesthetic awareness were identified on follow up visit. 
 n=50 
Standard 
Deviation 
Range 
Age (years) 52.6 14.5 21-83 
ASA I;II;III  (n,%) 6(12.0); 30(60.0); 14(28.0)   
Weight (kg) 79.7 16.1 45-110 
Height (cm) 167.4 9.6 150-188 
BMI (kg.m-2) 28.2 4.7 19-38 
Gender (M:F) 18:32   
Table 18: Characteristics of study participants. Values are mean, SD (range). 
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Procedure n (%) 
Craniotomy (tumour excision) 28 (56.0) 
Cerebellopontine angle tumour excision 6 (12.0) 
Craniocervical junction surgery 4 (8.0) 
Thoracic Tumour excision 3 (6.0) 
Craniotomy (aneurysm clipping) 2 (4.0) 
Transphenoidal Hypophysectomy 2 (4.0) 
Microvascular decompression 2 (4.0) 
Endoscopic Ventriculostomy 2 (4.0) 
Decompressive cervical spine surgery 1 (2.0) 
Table 19: Summary of procedure performed (n= number of patients). 
 
 
Figure 24: Number of changes in targeted propofol concentration per patient following 
initiation of propofol TCI and end of maintenance phase of anaesthesia. 
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 Values are mean, SD (range) 
Sampling period (min) 196.7, SD 112.3 (56 to 650) 
No. changes to targeted effect site propofol 
concentration following induction during 
sampling period 
0.9, SD 1.1 (0 to 4) 
No. changes to targeted propofol effect site 
concentration per hour during sampling period 
0.3, SD 0.5 (0-1.8) 
Table 20: Characteristics of anaesthetic for the 50 enrolled patients. 
 
Performance of the Marsh algorithm in effect site mode during the maintenance 
phase of anaesthesia was first analysed for each patient (Table 21).  This has been 
represented graphically in Figure 25, which shows PE over time for each patient, 
with each line representing a single patient.  For clarity, Figure 26 shows these data 
for the patients with the best and worst performance, as defined as the MDPE 
closest to and furthest from 0% respectively.  MDPE, representing intra-patient bias 
(direction and size of deviation from predicted concentration), ranged from -30.3 to 
101.3% with a median value of 27.6 (IQR 8.4;44.2).  MDAPE, a measure of 
imprecision, ranged from 4.0-101.3%, with a median of 29.4 (IQR 18.4;44.2).  The 
divergence was calculated at -13.0 %.hr-1, or -11.9 %.hr-1 if using signed PE for the 
calculation; suggesting a tendency towards convergence between measured and 
predicted values over time.  Wobble, representing intra-patient variation in 
performance error, ranged from 2.3 to 86.3%, with a median value of 12.0%.  
Table 13 shows the median values and interquartile ranges for these parameters. 
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Parameter median  25th;75th percentile  
of the values 
MDPE (%) 27.6  8.4;44.2 
MDAPE (%) 29.4  18.4;44.2 
Wobble (%) 12.0  6.3;19.3 
Divergence (%.h-1) absolute -13.0  -29.0;-3.9 
Divergence (%.h-1) signed -11.9  -26.0;-3.9 
Table 21: Analysis of unpooled data showing performance of Marsh model in effect site 
mode. Bias assessed using median performance error (MDPE), precision assessed using 
median absolute performance error (MDAPE). 
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Figure 25: Changes in performance error (PE) over time.  Each line represents a single 
patient (n=50). 
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Figure 26: Changes in performance error (PE) over time for the best (black line) and worst 
(blue line) performing patients.  Best and worst performance defined by closest and 
furthest MDPE from 0% respectively. 
 
Analysis of performance was repeated with pooled data (see Table 22).  Figure 27 
shows the PE over time for all samples, with a mean value of 32.0%, representing a 
similarly marked positive bias in the pooled data.  Precision of pooled data are 
represented by the standard deviation of -8.7 to 72.6%.  To determine the 
influence on duration of anaesthesia on the level of bias, the pooled data were split 
into early anaesthesia (up to 30 min) and later anaesthesia (>30 min), with a mean 
PE (bias) of 51.6% and 26.9% respectively.  Figure 28 shows the variation of 
measured propofol concentration at each predicted propofol concentration.  These 
data have been split into early anaesthesia (15-30 min) or later anaesthesia (>30 
min), and show worse performance early on in anaesthesia.  This is further 
  
        MDPE 88.5% 
 
 
 
MDPE -1.83% 
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graphically represented in Figure 29, in which time intervals have been categorised 
into 15 minute blocks from induction of anaesthesia, showing poorer performance 
early on. 
Parameter % (n = number of samples) 
Mean error (bias) 32.0 (n=254) 
Mean error (bias) early anaesthesia 51.6 (n=52) 
Mean error (bias) late anaesthesia 26.9 (n=202) 
Precision (±1SD of mean) -8.7 to 72.6 
Table 22:  Analysis of pooled data showing performance of Marsh model in effect site 
mode.  Data demonstrating bias are split into early anaesthesia, and later anaesthesia 
(beyond 30 min) to demonstrate differences in model performance between these time 
points. n = number of samples in each group. 
 
 
Figure 27: Performance error (PE) over time for pooled data.  Bias is represented by mean 
of 32.0%, and precision by ±1SD of the mean -8.7 to 72.6%. 
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Figure 28:  Measured propofol concentration at each set propofol concentration.  Data are 
split into early maintenance anaesthesia (up to30 min) in blue and later maintenance (>30 
min) in black. 
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Figure 29: Mean PE% for samples categorised into time intervals.  Each time interval 
represents a 15 minute period (interval 0 = 0-15  mins, interval 1 = 15.1-30 mins, etc.). 
Error bars represent 95% confidence intervals. Time intervals truncated after 165 min 
anaesthesia because of low sample numbers in subsequent interval groups. 
 
In order to determine the influence of covariates on the performance of the Marsh 
model in this population, subgroup analysis was performed on pooled data (see 
Figure 30).  BMI was split into values <30 kg.m-2, and those ≥30 kg.m-2, 
representing obesity.  In common with others, we demonstrated that increased BMI 
was significantly associated with increased model bias, with mean PE 24.0 
percentage points higher (95%CI: 14.0, 34.0) for the obese group with a BMI 
≥30 kg.m-2 (p<0.001, t-test for independent samples).   
Analysis of variance testing was performed to identify differences in PE for a given 
ASA physical status score (a globally utilised score of fitness for anaesthesia: 
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1=healthy, 2= mild systemic disease, 3=severe systemic disease).  This was found 
to be significant (p=0.028).  Tukey’s post-hoc test identified a significant difference 
between ASA status scores 2 and 3 (p=0.021), with mean PE 15.7 percentage 
points lower (95% CI: -1.91, -29.4) in the ASA 3 group.  None of the other post-hoc 
comparisons of ASA status score were found to be significant. 
Mean PE was 12.8 percentage points lower (95% CI: -2.4, -23.1) in female patients 
(p=0.016), and 25.3 percentage points lower (95% CI: -8.3, -42.2%) for those 
patients over 70 years (p=0.004), using independent samples t-testing. 
 
Figure 30:  Influence of covariates on mean prediction error % (PE) for pooled data.  Error 
bars show 95% confidence intervals. 
 
As the individual covariates measured had the potential for interaction, univariate 
analysis of variance was performed for all covariates (see Figure 31).  The further 
covariate; ‘time interval from initiation of anaesthesia’, was added to the model to 
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adjust for the influence of time of sampling within the analysis, given that PE 
changed over time (Figure 29).  For this analysis, samples were grouped into 15 
minute time periods from initiation of anaesthesia.   
Parameter 
Coefficient  
(95% CI) p-Value 
Intercept 26.5 (11.0, 42.0) <0.001** 
Time Interval -1.9 (-2.6, -1.3) <0.001** 
ASA Score   0.559 
1 - - 
2 -0.6 (-14.1, 12.9) 0.932 
3 -6.6 (-22.5, 9.3) 0.413 
BMI   <0.001** 
≤25 - - 
>25 to <30 (overweight) 34.6 (24.1, 45.2) <0.001** 
≥30 (obese) 35.6 (24.1, 47.1) <0.001** 
Age   0.034* 
<70 - - 
≥ 70 -18.8 (-36.2, -1.4) 0.034* 
Gender   0.590 
Male - - 
Female -2.5 (-11.8, 6.7) 0.590 
 
Figure 31:  Multivariable analysis of PE (%). Coefficients represent the percentage point 
difference from the reference category for categorical variables, or the percentage point 
increase for a one unit increase in continuous variables.  P values <0.05 are marked with *, 
and <0.01 marked with **. 
 
After accounting for the other potentially confounding variables in the multivariable 
model, the relationship between BMI and PE remained significant (p<0.001). 
Relative to those patients with BMI ≤25 kg.m-2, overweight and obese patients had 
higher PE, with average differences of 34.6 percentage points (95% CI: 24.1, 45.2; 
p<0.001) and 35.6 percentage points (95% CI: 24.1, 47.1; p<0.001) respectively. 
The difference in PE between the overweight and obese patients was minimal. 
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Age was also found to be significant in the model (p=0.034), with patients aged 
≥70 years having on average a lower PE by 18.8 percentage points (95% CI: -1.4, 
-36.2).  The time interval was also significant (p<0.001), as was suggested by 
Figure 25 and Figure 29.  For every 15 minutes of anaesthesia, the PE was found to 
fall by 1.9 percentage points (95% CI: -2.6, -1.3). 
After accounting for the other variables in the model, neither the ASA physical 
status score (p=0.559), nor gender (p=0.590) was found to be significantly 
associated with PE.  
 
4.1.7 Discussion  
This study has demonstrated a number of interesting points about the current 
practice of propofol TCI administration in our institution, which may represent wider 
practice within the UK.  Table 18 shows that the study patients enrolled represent a 
broad population of patients with varying age, BMI and ASA physical performance 
status representative of routine clinical practice.  From analysis of initial screening 
data; the Marsh algorithm for Propofol TCI in effect site mode was the preferred 
model in our institution with 88.7% choosing this mode, despite the availability of 
alternative models, and the availability of plasma targeting on the infusers.  It is 
unclear whether this preference reflects more general practice within the UK or 
Europe.  The Marsh model is likely to be popular because it was the first model to 
be available to clinicians, and so is likely to benefit from familiarity.  Although effect 
site targeting has not been available for as long, its reduced time to induction of 
anaesthesia, and reduced time to clinical effect from dose modification are likely to 
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be popular amongst anaesthetists, encouraging selection of effect site targeting in 
preference to plasma targeting models.  There was no evidence of a change in 
model choice in special circumstances, including the presence of extremes of age or 
comorbidity, when the Schnider model, which incorporates age into the model, may 
have been more appropriate.   
All the patients had routine invasive physiological monitoring, but none of the 
anaesthetists used any form of supplemental pharmacodynamic depth of 
anaesthesia monitoring, despite its availability within the trust.  Again, it is not clear 
whether this reflects local practice alone, or that of anaesthetists within the UK 
more generally.  The lack of clear guidelines or evidence in favour of depth of 
anaesthesia monitoring to prevent awareness may have led to this practice. 
All anaesthetists used remifentanil TCI using the Minto model in effect site mode in 
addition to propofol, although this was not a specific requirement for study 
inclusion.  Use of propofol in combination with remifentanil for TCI, particularly in 
neuroanaesthetic practice has become very popular.  This is likely to be a result of 
the stable and rapidly adjustable haemodynamics possible whilst using this drug, 
the reduction in the requirement for neuromuscular blockade, and its propofol 
sparing actions.  
Changes in targeted propofol concentration during the course of anaesthesia were 
few (see Table 20 and Figure 24), with almost half of anaesthetics not undergoing a 
change in targeted propofol dose at all during the studied period from induction of 
anaesthesia to the end of the maintenance phase.  This practice suggests a reliance 
on the model, based on experience, to deliver an adequate amount of propofol to 
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maintain unconsciousness and the ability to adjust remifentanil targets to changing 
levels of surgical stimulation. Anaesthetists were three times more likely to 
manipulate remifentanil target concentration than propofol (mean 2.7 verses 0.9 
changes per anaesthetic respectively), suggesting a preference to adjust 
remifentanil targets to changing levels of surgical stimulation.  The more consistent 
and short half life of remifentanil, even when delivered at high concentrations is 
likely to explain the preference for dose adjustment of remifentanil over propofol. 
 
Results from both unpooled and pooled patient data demonstrate a positive bias in 
the Marsh model when used in effect site mode during the maintenance phase of 
anaesthesia, with a median value of MDPE of 27.6%.  This indicates an 
underestimation of predicted propofol concentrations when compared to measured 
concentrations, breaching the guide of 10-20% proposed by Schuttler.(Schuttler, 
Kloos et al. 1988)  Similarly, a mean MDAPE of 29.4% represents suboptimal 
precision in this cohort.  The significant under-prediction of propofol concentrations 
found in this study are greater than those found in most previous studies in which 
the Marsh model has been investigated.(Lim, Gin et al. 1997; Fechner, Albrecht et 
al. 1998; Swinhoe, Peacock et al. 1998; Pandin, Cantraine et al. 2000; Ihmsen, 
Jeleazcov et al. 2004; Li, Xu et al. 2005; Glen and Servin 2009)   It is possible that 
the large positive bias and imprecision seen in this work results from the varied 
cohort of patients recruited, perhaps better representing a clinical population than 
some previous pharmacokinetic validation studies.  Other causes of poor model 
performance may have included variability in the surgery performed, with 
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differences in level of patient stimulation, blood loss, and patient temperature 
control.  Analysis of patient covariates demonstrated that obesity was most 
significantly associated with poor model performance, as has been well documented 
previously with the Marsh model.  After correction for interaction of covariates; 
increased age was the only other patient covariate associated with a significant 
influence on model performance, with lower PEs in patients over 70 years.  It is not 
clear why this should be the case, but may represent closer pharmacokinetic 
approximation of this group to the original dataset used for Marsh model 
development.   
Pharmacokinetic interaction, caused by the co-administration of other drugs with 
propofol, in particular remifentanil, could partly explain the  model 
inaccuracies.(Wietasch, Scholz et al. 2006)  It is unlikely that the changes in the 
timings of propofol administration in the effect site model should lead to any 
significant deterioration in model performance given the small changes in overall 
dose delivered.  The relatively small difference in total dose of propofol delivered 
over time makes a significant change to pharmacokinetics unlikely.  An alternative 
hypothesis is that the pronounced positive bias in this work may be influenced by 
the direct measurement of plasma in this study, rather than whole blood which was 
common in early work. This would explain the higher level of bias early on in 
anaesthesia, when equilibration of propofol between plasma and red cells has not 
occurred, as demonstrated in chapter 3.4, currently published as an 
abstract.(Cowley and Clutton-Brock 2012) 
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Another consideration, when comparing the performance results from this work to 
other pharmacokinetic studies, is that this work confined pharmacokinetic analysis 
to the maintenance phase of anaesthesia, and few propofol concentration changes 
were made. In many studies, a large proportion of samples would have been taken 
during induction and emergence from anaesthesia, or directly following a dose 
modification, when propofol concentrations are rapidly changing.  When using the 
methods of Varvel and colleagues to calculate performance,(Varvel, Donoho et al. 
1992) additional weight is placed on the performance at these time points because 
of the large number of samples drawn.  A more important measure might be the 
total time spent within an acceptable range during the course of anaesthesia.  
Certainly, two studies have demonstrated an increase in the negative bias when the 
propofol concentration is decreasing, and an increasing positive bias at greater 
propofol concentrations.(Pandin, Cantraine et al. 2000; Ihmsen, Jeleazcov et al. 
2004) 
A limitation of our pharmacokinetic analysis is the constraint of blood sampling to 
the maintenance phase of propofol anaesthesia, having allowed at least ten minutes 
between changes to the targeted propofol concentration for equilibration between 
effect site and blood to occur.  As sampling at the effect site is currently not 
feasible, our evaluation was only possible using plasma at assumed equilibration as 
a surrogate. 
The investigation of pharmacokinetics in a clinical setting during anaesthesia for 
surgery with all the necessary polypharmacy and resultant haemodynamic changes 
has potential impact on the measurements obtained.  The influence of propofol on 
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pharmacodynamics is not readily interpretable in the setting of variable surgical 
stimulus and concurrent potent analgesic administration,(Hoymork, Raeder et al. 
2003) and must therefore be left to the less generalisable situation of fit patients 
undergoing anaesthesia without stimulus or multiple drug administrations.  The 
benefit of research on patients in the routine clinical setting is that results are more 
likely to represent plasma concentrations of anaesthetic achieved in clinical practice.    
This work has demonstrated that in one large centre, the majority of anaesthetists 
have a preference for the Marsh model in effect site mode, and infrequently modify 
the targeted concentration during the maintenance phase of anaesthesia, relying 
more on remifentanil dose manipulation.  The pharmacokinetic analysis of the 
Marsh model performance in these patients suggests the need for caution when 
relying on these values, although no incidents of awareness were detected.  For 
anaesthetists relying on a hypnotic concentration of propofol, whilst manipulating 
remifentanil to changing surgical stimulus, improved reliability of propofol TCI 
model performance is desirable.  Further work with the propofol analyser used for 
this study to assess the value of blood propofol measurement to identify and 
correct performance errors at the point of care is addressed in the next chapter.  
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4.2 Assessment of a proposed proportional correction method during the 
maintenance phase of anaesthesia 
4.2.1 Introduction 
Continuous monitoring of blood propofol concentrations is currently not possible, 
and extra vigilance is required for patients undergoing propofol TCI, when risk of 
infusion pump failure, disconnection or drug leakage are all possible – potentially 
leading to anaesthetic under-dosing and risk of awareness.  Pharmacodynamic tools 
including Bispectral Index monitors are widely available to attempt to minimise such 
risks, but have yet to prove any reduction in anaesthetic awareness.  In addition to 
the risk of disconnection, pharmacokinetic variability leads to widely differing actual 
plasma propofol concentrations when compared to those estimated using 
modelling.  It is possible that the accuracy and bias of these models could be 
improved using point calibration during anaesthesia to correct bias.   Up until now, 
point of care blood propofol analysis has not been possible, and so the potential 
utility of correction of inter-individual bias has not been assessed.  The blood 
propofol analyser validated in chapter 2.5 is capable of measuring blood 
concentrations within a clinically meaningful timeframe at the point of care, and 
therefore may be used to improve inter-individual variability within the operating 
room.  A system which monitors blood propofol continuously or regularly would 
clearly have advantages over a single point measurement, as errors in 
pharmacokinetic accuracy as well as consistent bias could be improved, although no 
such device is currently available.   
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4.2.2 Proposed Single Point Proportional Correction 
An alternative strategy to continuous or regular intermittent sampling is to select a 
suitable time point during the course of anaesthesia to correct system bias.  As 
discussed in chapter 1.6.3, TCI models have been developed from a small 
population of physiologically normal individuals, and generalisation to the broader 
population leads to problems of system bias and imprecision.  As shown in the 
previous validation experiments for the popular Marsh propofol TCI model, bias is a 
significant component of model error.  It is a proposed that a single point 
calibration performed during the maintenance phase of anaesthesia could 
significantly reduce model bias, and therefore reduce the problem of inter-individual 
variability.  For a single point calibration to be of clinical utility, there are a number 
of requirements: 
• For a single point calibration to be safe and of clinical utility, it is desirable 
for TCI model bias to be consistent throughout the course of anaesthesia.  
As this is not necessarily the case, it is important to explore the viability of 
point calibration prior to its implementation. 
• The measured propofol concentration must be available in a clinically 
acceptable timeframe. 
• It should be possible to make the measurement early on during anaesthesia, 
in order to maximise the clinical benefit of dose modification.   
From the experiments in chapter 4.1, it has been determined that for the Marsh 
propofol TCI model, system bias is significantly higher during the first half hour of 
anaesthesia.  This is likely to be because of the much less predictable nature of 
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plasma propofol concentrations during the phase of induction of anaesthesia.  For 
this reason, a minimum time of 30 minutes into anaesthesia for blood propofol 
measurement was required.  A proportional correction much beyond 30 minutes 
following induction of anaesthesia was judged to be of limited clinical utility, as at 
this point, patient preparation for surgical incision is likely to have occurred. 
4.2.3 Justification for validity of point of care proportional correction 
Experiments in chapter 4.1 on the Marsh model, when used in effect site mode 
have detected model bias in the study population of 28% (IQR 8 to 44%) and 
imprecision of 29% (IQR 18-44%).  Clinical validation experiments on the novel 
point of care propofol analyser initially validated in chapter 2.5 demonstrated a 
coefficient of variation of 4.1% at 3.6 µg.ml-1 and 3.1% at 5.4 µg.ml-1, representing 
propofol doses commonly used to achieve general anaesthesia.  The device has 
since undergone further development and commercialisation as a research propofol 
analyser, with improved coefficients of variation of 1.4% at 2.84 µg.ml-1 and 1.2% 
at 6.68 µg.ml-1.(Liu, Pettigrew et al. 2012) Thus, analyser measurement error using 
the commercialised propofol analyser represents between 4 and 5% of the 
previously identified model error at concentrations of propofol commonly required 
during general anaesthesia, allowing significant scope for improvement. 
 
4.2.4 Aims 
It was hypothesised that the performance of the Marsh model propofol TCI when 
used in effect site mode could be made more accurate using a single point 
calibration method in order to reduce patient specific bias. 
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4.2.5 Methods 
After approval by the West Midlands Local Research Ethics Committee, and written 
informed consent, 50 adults ASA physical performance status I to III undergoing 
elective neurosurgery using propofol TCI at the Queen Elizabeth Hospital 
Birmingham, UK, were enrolled in the study.  All patients were scheduled for 
procedures in which the attending anaesthetist routinely used propofol TCI, and 
anaesthesia expected to last between 1 and 12 hours. 
General anaesthesia was induced and maintained using propofol TCI (effect site 
Marsh model, Ke0 of 1.21 min-1, t1/2ke0 0.57 min, Time to peak effect 1.6 min) and 
remifentanil TCI (effect site Minto model) using the commercially available 
Orchestra Base Primea system, Fresenius Kabi, Runcorn, UK.  Induction and 
maintenance targets for propofol and remifentanil were determined by the 
attending anaesthetist by clinical judgement of the depth of anaesthesia, and not 
influenced by trial inclusion.  Following induction of anaesthesia, the patient’s 
trachea was intubated following the administration of 0.5 mg.kg-1 atracurium or 
rocuronium, and the lungs were mechanically ventilated with oxygen-enriched air to 
achieve normocapnoea.  No further neuromuscular blocking agents were 
administered.   
4.2.5.1 Blood Sampling 
Arterial blood was sampled for measurement of propofol concentration from an 
arterial line placed for routine clinical use.  Samples were drawn at regular intervals 
during the course of the maintenance phase of general anaesthesia, at a minimum 
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of 10 minutes following a change in set propofol concentration to allow equilibration 
between effect site and plasma.  A whole blood sample was taken at a minimum of 
30 min following induction of anaesthesia, at a minimum of 10 minutes following 
any change in set propofol concentration.  Further blood samples for plasma 
propofol concentration were drawn at approximately 60 minutes intervals following 
induction of anaesthesia.  Sampling continued until surgical anaesthesia was no 
longer required.  A maximum of 50 ml blood was drawn from each patient. 
4.2.5.2 Measurement of Propofol Concentration 
Fresh whole blood was analysed for the 30 min sample for proportional correction 
using the research propofol analyser, further developed and commercialised for 
research use by Sphere Medical Ltd, UK. (Liu, Pettigrew et al. 2012) previously 
described in chapter 4.1.4.2.  Plasma was used for analysis of subsequent samples 
rather than whole blood to conform with the majority of contemporary publications 
for propofol pharmacokinetics.  Plasma was separated immediately following 
sampling in a centrifuge at 3600 rpm for 10 min and stored at -20 oC until assayed.  
Before analysis, samples were thawed to room temperature and vortexed, then 
centrifuged at 3600 rpm for 5 min.   
4.2.5.3 Proportional Correction Formula: 
The propofol concentration measured was analysed retrospectively and new 
predicted plasma propofol concentrations calculated.   
New estimated blood propofol conc. = Uncalibrated estimated propofol conc. x recalibration factor 
Recalibration factor =    measured blood propofol concentration at 30 minutesestimated blood propofol concentration at 30 minutes   
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 The software package TIVAtrainer© (F. Engbers, Leiden University Hospital) was 
used to construct graphs of estimated propofol concentration from data recorded 
on the manipulation of the propofol TCI machine during anaesthesia. 
4.2.6 Data Analysis 
A sample size calculation was performed using data from the previous experiment, 
demonstrating a Marsh model bias of 32%, and assuming a proposed halving of 
this error, with a power of 0.8 and an alpha of 0.05.  A single sided sample size test 
of one proportion calculated a minimum of 39 required patients, (MiniTab 16 ®, 
Statistical software, Pennsylvania, USA). 
The predictive performance of the uncorrected and corrected Marsh models was 
determined by applying percentage prediction error (PE) analysis, detailed in 
chapter 4.1.5. (Varvel, Donoho et al. 1992) 
PE =   𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 – 𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛  x100 
For both uncorrected and corrected PE, values were only calculated for specimens 
taken after the 30 minute blood propofol measurement for model correction.  
The percentage median prediction error (MDPE) is a signed value and reflects the 
bias of the predicted concentration compared to the measured one, and is 
calculated for each patient as the median value of the sum of the PE at each 
sampling point. The MDPE was calculated using plasma propofol concentrations 
drawn beyond 30 minutes of anaesthesia for both uncorrected and corrected 
models.  MDAPE, the measure of model precision was not calculated, as this could 
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not be influenced using a single point correction beyond a correction in bias, as 
determined by MDPE. 
 
4.2.7 Results 
50 patients underwent anaesthesia using the Marsh algorithm in effect site mode 
and were enrolled into this study.  A total of 162 samples were analysed for plasma 
propofol concentration following the calibration point at 30 min.  The ratio of male 
to female patients was 1:2.  Patients had a mean age of 53 years (IQR 43 to 64 
years) and a mean body mass index (BMI) of 28 kg.m-2 (IQR 25 to 32). 
 
The Marsh model bias, as represented by MDPE is shown before and after 
proportional correction formula is applied in Table 23.  The models both prior to 
and following the application of a proportional correction show a statistically 
significant difference from the zero bias point (one-sample t-test p<0.0001 for 
uncorrected and corrected formula). 
 
 Prior to Correction Following Correction 
MDPE (%) 17.0 -16.3 
Interquartile Range (%) 1.25 to 33.17 -31.0 to -8.7 
95% Confidence Intervals (%) 11.6 to 26.29 -23.7 to -13.9 
Table 23: Bias before and after proportional correction point calibration is applied at 30 
min. 
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4.2.8 Discussion 
The hypothesis was tested that a simple proportional correction to the Marsh model 
in effect site mode early on in anaesthesia may improve bias by reducing inter-
individual variability.  However, the results of this work demonstrate a significant 
overcorrection of bias when recalibrating the Marsh model at 30 minutes following 
induction of anaesthesia.  It is possible that the chosen point for model recalibration 
was too early.  The significant positive bias of the Marsh model at this point served 
to overcorrect the model (from 17.0% to -16.3%).  This led to an overall 
underestimation of blood propofol concentration using the corrected Model.  This 
would have led to an overall reduction in predicted propofol concentration by one 
third.  Although the overall bias remained essentially unchanged (but negative 
instead of positive), there could be a significant risk of anaesthetic awareness from 
under-dosing.  It is possible that the point calibration was performed too early, 
suffering from the problem of excessive early bias.  However, a later point 
calibration would have been of limited clinical utility for anaesthetics of standard 
duration, and so alternative solutions need to be sought beyond later sampling. 
 
Although a single point recalibration at 30 min has been demonstrated to be of no 
clinical utility when using the Marsh model in effect site mode, there are several 
possible areas in which the potential utility of single or multiple point blood propofol 
concentration measurements remain: 
166 
 
• There is potential clinical utility from model recalibration when reserved for 
prolonged periods of anaesthesia or sedation, in which calibration points can 
be undertaken well beyond the period of induction in which the Marsh model 
suffers from significant positive bias.  During prolonged infusions, in which 
propofol concentrations near steady state, it is more likely that bias will 
remain stable and therefore suitable for recalibration. 
• Recalibration may be of clinical utility during periods of prolonged propofol 
infusion in situations with less predictable pharmacokinetics, such as: 
a. During cardiopulmonary bypass when there are significant changes in 
volume of distribution and core body temperature. 
b. During prolonged anaesthesia or sedation of morbidly obese patients, 
in which TCI models are poorly validated. 
• In the critical care environment, intermittent blood propofol measurement 
could be undertaken in order to minimise propofol dosing in patients with 
significant organ failure, in which level of consciousness testing is difficult 
(e.g. whilst receiving non-depolarising neuromuscular blockers).  
 
4.2.8.1 Alternative Strategies to Improve Proportional Correction Performance 
The Marsh model was chosen for this experiment for pragmatic reasons.  It remains 
popular, and was shown in our institution to be the preferred model of a wide 
group of anaesthetists for 90% of anaesthetics (shown in chapter 4.1.6).  Our work 
has demonstrated that the performance of the Marsh model during early 
anaesthesia in a relatively unselected group of patients is suboptimal, and this has 
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led to poor performance of the proposed proportional correction method.  It is 
possible that alternative propofol TCI models, such as the Schnider model, which 
includes lean body mass and age covariates in the modelling may suffer less from 
this problem.  Further work to determine whether this is the case is required prior 
to repeating these experiments using such an alternative TCI model.   
4.2.8.2 Bayesian approach to modelling 
An alternative area of future research when attempting to predict propofol 
concentrations is the incorporation of Bayesian forecasting into TCI models.  This 
has already begun, with early attempts at linking pharmacokinetic propofol TCI 
models with depth of anaesthesia in order to optimise ‘closed loop’ anaesthesia, in 
which propofol dosing is modified to achieve a constantly evolving end-point. (De 
Smet, Struys et al. 2007)  Bayesian optimisation, as proposed by Sheiner et al is 
classically used in pharmacokinetic-pharmacodynamic modelling to individualise a 
dosing regimen by combining individual patient-specific information with prior 
knowledge containing previously determined properties of the parameter to be 
estimated. (Sheiner, Beal et al. 1979)  Sheiner, using the example of plasma 
digoxin measurement, determined that a single point measurement could improve 
individual patient forecast accuracy by 40%, and that such improvements were 
much greater than those achievable through prior knowledge of covariates such as 
gender, age and so on.   
When using Bayesian methodology, probability distributions are created using a 
combination of ‘prior information’, which may include known drug pharmacokinetics 
for a given population, as well as sample data (for instance blood sampling 
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information or pharmacodynamic data such as depth of anaesthesia monitoring) 
expressed as a ‘likelihood function’.  The prior information and sample data are 
combined to calculate a ‘posterior distribution’, which is a weighted compromise 
between the two sets of data. (Lunn, Best et al. 2002)  In general, the posterior 
distribution will be high only when both information sources support the determined 
value.  This form of analysis lends itself well to modelling in which additional 
information, for instance additional propofol measurements, are generated in real 
time.  
 
  
169 
 
4.3 Appendix to Chapter 4 - A case study of propofol TCI during 
haemorrhage with volume resuscitation 
Work on both rats and humans to assess pharmacokinetic influences of significant 
haemorrhage and subsequent volume resuscitation have demonstrated that the 
hypnotic potency of propofol is increased, perhaps related to an increase in 
unbound propofol.(De Paepe, Belpaire et al. 2000; Takizawa, Takizawa et al. 2006)  
A study in swine confirms an increase in propofol potency following resuscitated 
haemorrhage, without demonstrating changes in propofol 
pharmacokinetics.(Johnson, Egan et al. 2004)  Later animal work has identified 
both pharmacokinetic and pharmacodynamic alterations leading to increased 
propofol potency during haemorrhagic shock.(Kurita, Takata et al. 2009)  There is 
no good evidence to define the ability of commercially available target controlled 
infusion (TCI) algorithms to predict plasma propofol concentrations during fluid 
resuscitation or active haemorrhage.  One clinical study of haemodilution following 
bolus administration of propofol has demonstrated a statistically significant drop in 
blood propofol concentrations.(Tang, Wu et al. 2011) One case report of massive 
transfusion during liver transplantation demonstrated fall in propofol concentration 
during constant rate infusion, although this was complicated by the influence of lack 
of liver metabolism of propofol.(Turner, Kam et al. 1999) 
 
4.3.1 Methods 
A patient undergoing elective neurosurgery was recruited into a clinical study 
involving serial arterial plasma propofol measurement throughout Marsh TCI 
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anaesthesia.  The patient was noted to have intra-operative surgical blood loss of 
15 ml.kg-1, and subsequent volume resuscitation with 45 ml.kg-1 of fluid.  Serial 
measured propofol concentrations were compared with concentrations estimated 
using the Marsh algorithm.  Results for bias (MDPE) for this patient were compared 
with the median value for all 50 patients included in the study in chapter 4.2.1. 
 
4.3.2 Results 
A total of 9 samples of blood were drawn at intervals, between 15 minutes and 250 
minutes following induction of anaesthesia.  Patient demographic characteristics 
included age 61 years, male gender, weight 74 kg, height 180cm, BMI 23 kg.m-2, 
haemoglobin concentration 11.2 g.dL-1, ASA physical performance status III 
(limiting Chronic Obstructive Pulmonary Disease).  The Marsh model bias (MDPE) 
for this patient was calculated as -15.3%.  This figure differs markedly from the 
median values for all 50 patients for bias of 27.6%.  Figure 32 demonstrates a 
depression in measured plasma propofol concentrations during the maintenance 
phase of anaesthesia when compared to estimated plasma concentrations using the 
Marsh algorithm. Depression of measured propofol concentrations correlated with 
periods of fluid resuscitation correlating with the period of volume resuscitation.  
The lowest measured plasma propofol concentration of 2.1 μg.ml-1, represents a 
concentration one third lower than anticipated, and represents a figure that many 
anaesthetists would predict a significant risk of anaesthetic awareness.  No 
evidence of anaesthetic awareness was identified during the anaesthetic follow up 
visit.  Figure 33 shows an example for comparison of plasma propofol measured in 
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a different patient in the same study, in which volume resuscitation did not take 
place.  
 
Figure 32:  Measured plasma propofol concentrations compared with estimated 
concentrations (Cp propofol) during an operation in which significant fluid resuscitation 
took place (bags of fluid represent 5 ml.kg-1 fluid resuscitation (crystalloid or colloid)). 
 
Figure 33:  Measured plasma propofol concentrations compared with estimated 
concentrations (Cp propofol) during an operation without fluid resuscitation for comparison. 
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4.3.3 Discussion 
Work done by others, and the clinical study described in chapter 4.1, has 
demonstrated a significant positive bias for the Marsh model, representing an 
under-prediction of estimated propofol concentrations (of 27.6% in our work).  
During volume resuscitation for bleeding, we have noted an over-prediction of 
estimated plasma propofol concentrations with a negative bias of 15%, 
representing a 43.0% difference in estimated propofol concentration overall.  It is 
not possible to draw clear conclusions from a single case evaluation, particularly 
given the variable pharmacokinetics with propofol anaesthesia.  However, this case 
shows a clear temporal relationship between volume resuscitation and falling blood 
propofol concentrations which should at least highlight the need for further work to 
establish whether this can be consistently demonstrated.  Vigilance should be 
employed when monitoring for clinical or pharmacodynamic measures of depth of 
anaesthesia when administering propofol TCI during periods of blood loss and fluid 
resuscitation, as this can lead to significant dips in plasma propofol concentration, 
which TCI models do not predict.  Given the general trend towards positive bias in 
the Marsh model, the dip in measured propofol concentrations below predicted in 
this patient represents a potentially clinically significant difference.  The risk of 
anaesthetic awareness during such dips in anaesthetic concentration is likely to be 
low.  Previous work by others discussed in the introduction has highlighted an 
increased concentration of anaesthetically active unbound propofol in these patients 
secondary to loss of plasma proteins during haemorrhage and volume replacement.  
Nevertheless, it must be borne in mind that during anaesthesia with significant 
haemorrhage, whichever propofol model is being used to deliver the drug, it is 
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unlikely that the estimated drug concentrations are representative of those patients 
for whom the model was developed and validated.  Traditional measures of 
anaesthetic depth such as cardiovascular parameters will be difficult to interpret in 
this group, and alternative methods of pharmacodynamic monitoring may be 
indicated in this group. 
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5 CHAPTER 5 - STUDIES ON PROPOFOL SEDATION IN THE INTENSIVE 
CARE UNIT 
5.1 Propofol Infusions in Intensive Care 
5.1.1 Introduction 
Following the introduction of propofol into anaesthetic practice for induction and 
maintenance of anaesthesia and sedation, the drug became popular as an agent for 
sedation in the intensive care unit.  Propofol is currently one of the most popular 
agents used for sedation in adult intensive care worldwide.  Its use in paediatric 
critical care is limited because of an increased incidence of the propofol infusion 
syndrome in children. 
Propofol is infused for days or weeks in critically ill patients, who often have 
profound organ dysfunction, and yet there are few published data on the 
pharmacokinetics of propofol infusion for prolonged periods in critical care.  
Currently, it is usual practice to use propofol by continuous infusion in intensive 
care, rather than using target controlled infusion.  This is likely because of 
unpredictable pharmacokinetics in organ dysfunction, as well as additional 
expenditure required to update syringe drivers.  Furthermore, critically ill patients 
are more susceptible to the cardiovascular side effects of propofol, and careful dose 
titration is therefore required. 
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5.1.2 Pharmacokinetics of Prolonged Propofol Infusion 
Data on propofol drug concentrations in critically ill patients on prolonged infusions 
of propofol from two studies demonstrated increased volumes of distribution and 
decreased elimination characteristics when compared to short-term infusions in 
surgical patients. (Albanese, Martin et al. 1990; Frenkel, Schuttler et al. 1995)  
Bailie analysed the clearance of propofol following its prolonged infusion (>24 
hours) in intensive care patients. (Bailie, Cockshott et al. 1992).  This work showed 
no difference in clearance between pre-existing data on fit patients and in the 
critically ill patients studied, although significant liver dysfunction was an exclusion 
criterion in this study.  Peeters assessed the propofol pharmacokinetics of 21 
critically ill cardiac surgical patients using both Bispectral index, and the Ramsay 
sedation scale as endpoints. (Peeters, Bras et al. 2008)  The severity of illness as 
determined by the Sequential Organ Failure Assessment (SOFA) score was found to 
significantly impact on the pharmacodynamics, and to a lesser extent the 
pharmacokinetics of propofol.  Patients were more deeply sedated for increasing 
levels of SOFA score.  They also demonstrated an increase in volume of distribution, 
possibly explained by the durations of infusion being longer than the work of 
others, and reductions in propofol clearance of over one third compared to work on 
physiologically normal patients, suggesting the need to adjust dosing in critically ill 
patients.  The disproportionate effect on pharmacodynamics over pharmacokinetics 
for increasing disease severity may result from the increased unbound fraction of 
propofol in these patients. (Takizawa, Takizawa et al. 2008)  Propofol is extensively 
bound to plasma proteins, the unbound fraction being less than 3%.(Hiraoka, 
Yamamoto et al. 2004)  As for other drugs with a high hepatic clearance, propofol 
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extraction is sufficiently efficient that plasma protein binding is not limiting and 
elimination is non-restrictive.  Protein binding does not limit drug removal. 
(Wilkinson and Shand 1975)  Free drug concentrations are likely to be elevated in 
low protein states, as demonstrated for propofol in the case of cardiopulmonary 
bypass. (Hiraoka, Yamamoto et al. 2004) 
 
5.1.3 Target Controlled Infusion (TCI) Propofol in Critical Care 
Cavaliere et al attempted to administer target controlled infusions in intensive care 
using the Marsh algorithm, specifically looking at the influence of 
hypoalbuminaemia on the accuracy of the algorithm. (Cavaliere 2005)  
Hypoalbuminaemia is a marker of ill health and thus organ dysfunction, and can 
also directly affect the pharmacokinetics of drugs including propofol which bind to 
albumin avidly.  Prior in vitro experimentation on plasma from critically ill patients 
has demonstrated an increase in the unbound fraction of propofol in the presence 
of severe hypoalbuminaemia; thus increasing drug pharmacodynamic action for a 
given measured plasma concentration. (Zamacona, Suarez et al. 1997).  Cavaliere’s 
work on TCI demonstrated no significant deterioration in the accuracy of predicted 
propofol concentrations in the hypoalbuminaemic group, although any differences 
may have been disguised by the poor degree of accuracy achieved by the TCI 
device.  Nonetheless, the group stated that the accuracy of the TCI in critically ill 
patients was acceptable by recommended (but generous) standards proposed by 
Schuttler. (Schuttler, Kloos et al. 1988)  McMurray has also performed validation 
experiments on the use of the Marsh algorithm in 122 adult intensive care patients. 
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(McMurray, Johnston et al. 2004)  They identified a target plasma propofol range of 
between 0.2-2 µg.ml-1 in order to achieve desired levels of sedation.  This group did 
not however measure the level of sedation at the point of sampling.  They also 
reported acceptable efficacy of the Marsh algorithm in this patient cohort with 
deviation of predicted from measured propofol concentrations, with an overall bias 
of 4.3%, and inaccuracy of 19.6%.  However, this group subdivided patients into 
general and post-cardiac patients, and this analysis revealed significant variation in 
bias (-7% vs 18% respectively) demonstrating the heterogeneity of the intensive 
care population, and thus that caution should be exercised when using predictive 
models developed for healthy patients.  An attempt has been made to develop a 
pharmacokinetic model suitable for use in critical care.  Barr et al developed a three 
compartment model using lean and fat body mass as covariates, based on titration 
of propofol infusions to maintain a given level of sedation as defined by the 
commonly used Ramsay sedation scale (maintenance of a score between 2 and 
5).(Barr, Egan et al. 2001)  They went on to test this model on 10 patients, 
assessing its predictive ability to maintain a desired level of sedation.  Results 
showed an ability to deliver light vs deep sedation with 73% accuracy.  They also 
presented how measured values of propofol concentration correlated with 
probability modes for sedation score (sedation score of 2, 3, 4 and 5 from propofol 
concentrations of 0.25, 0.6, 1.0, and 2.0 μg.ml-1 respectively).  
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5.2 Propofol Sedation during Prolonged Infusion in Intensive Care 
5.2.1 Aims 
Given that propofol is used in most adult intensive care units throughout the world, 
there are limited published data on propofol concentrations achieved in patients 
sedated in the intensive care unit, and how these concentrations correlate to clinical 
measures of sedation.  It is important to establish current practice for several 
reasons: 
• to correlate actual propofol concentrations with clinical measures of sedation. 
• to identify any need for more accurate measurement of propofol sedation, and the 
incidence of unexpectedly high drug concentrations in critically ill patients. 
• to identify suitable blood propofol concentrations to target should the facility to 
estimate (TCI) or measure propofol concentrations at the bedside be available.   
It is anticipated that certain groups of patients, in particular those with significant 
vasopressor requirement, may be difficult to consistently sedate given that current 
practice is to titrate propofol infusion rates to effect, and reducing infusion rates in the 
event of haemodynamic instability.  It is likely that the pharmacokinetics of propofol in 
this patient group differs markedly from the subjects in which its pharmacokinetics 
have been established. This study aims to identify:  
• propofol concentrations achieved in clinical practice in patients sedated in 
intensive care.   
• The correlation between measured blood propofol concentration and level of 
sedation in the critical care setting.   
179 
 
• The influence of illness severity as defined by level of organ failure on the ability to 
predict blood propofol concentrations using the most commonly utilised 
pharmacokinetic model (Marsh). 
 
5.2.2 Methods 
Patients with tracheal intubation and propofol sedation in critical care will invariably 
have regular blood gas analysis using an indwelling arterial line.  Two millilitre 
samples of heparinised blood are drawn and run on a near patient blood gas 
analyser.  The residual blood from the specimen (approximately 1.5 ml) is then 
discarded.  Local ethics committee consents were obtained to collect discard blood 
samples from routinely drawn arterial blood samples from patients sedated with 
propofol on intensive care in University Hospital Birmingham Queen Elizabeth 
Hospital, Birmingham.  Patients were recruited from all four intensive care units, 
which include general intensive care, neuro-intensive care, cardiac intensive care, 
and liver intensive care.  No patient identifiable information was retained.   
 
5.2.2.1 Inclusion Criteria: 
• Patient in Intensive care 
• Not previously recruited into the study on this critical care episode 
• Trachea intubated and sedated using propofol by infusion at the time of sampling 
• Arterial access and presence of heparinised discard blood following arterial blood 
gas analysis 
 
180 
 
5.2.2.2 Patient Screening 
On those days when Dr Cowley was available to collect and analyse samples 
(August –December 2010), a screening round of all four intensive care units in 
Queen Elizabeth Hospital Birmingham was performed to identify patients meeting 
the inclusion criteria.  Staff reminder sheets were given to the nurse looking after 
the patient to retain residual arterial blood sample following blood gas analysis (see 
Appendix 4). 
 
The following patient information was collected: 
• Age, Gender, Height, Weight 
• Propofol infusion data (drug concentration, duration and rate of infusion, changes 
in rate of infusion, pauses in infusion) 
• Use of concurrent sedatives at time of sampling 
• Use of concurrent opiate infusion at time of sampling 
• Richmond Agitation Scale score at time of sampling 
• Organ failure data at time of sampling (Sequential Organ Failure Assessment – 
SOFA score) 
• Inotrope/Vasopressor requirement 
 
5.2.2.3 Choice of organ failure assessment tool 
The SOFA score (see Appendix 4) is a tool incorporating easily collectable patient 
physiological and biochemical data into a score between 0 and 24 which numerically 
quantifies level of organ dysfunction.  It has been validated extensively and used in 
many Intensive Care based trials for intermittent quantification or temporal 
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quantification of illness severity, and has been successfully correlated with 
outcomes.(Vincent, Moreno et al. 1996; Vincent, de Mendonca et al. 1998; Ferreira, 
Bota et al. 2001)  Various cut offs have been suggested to distinguish severe organ 
dysfunction with poor outcome with less severe disease.  One such measure is to 
separate patients into less severe organ failure with a score of less than six.  These 
divisions have been validated previously. (Chase, Pretty et al. 2010)  
 
5.2.2.4 Choice of Richmond Agitation Scale tool to assess level of sedation 
The Richmond agitation scale (see Appendix 6) has been increasingly used as a 
standard of care in critical care over the last decade.(Sessler, Gosnell et al. 2002)  
It is used to assess both levels of sedation, as well as agitation.  It is the standard 
method of recording sedation in the Queen Elizabeth Hospital, Birmingham, and so 
was ideal for the purposes of this study. 
 
5.2.2.5 Blood Sampling and Propofol Measurement 
Discard heparinised whole blood specimens were retained following routine arterial 
blood gas analysis, and time of sampling recorded.  Samples were stored at 4 0C 
following collection and analysed within 12 hours of sampling.  Plasma propofol 
concentrations were measured using the research propofol analyser detailed in 
chapter 2, further developed and validated for commercialisation as a research 
analyser by Sphere Medical Ltd, UK, (Liu, Pettigrew et al. 2012) and previously 
detailed in chapter 4.1.4.2 
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5.2.2.6 Estimated Propofol Concentration Calculation 
Propofol concentrations were estimated using the Marsh algorithm.  Demographic 
data and propofol infusion data were collected, including drug concentration used, 
duration and rate of infusion, and duration of any pauses.  The recorded 
information was entered into a software program to calculate estimated propofol 
concentrations, using the Marsh model pharmacokinetic dataset (Marsh, White et 
al. 1991) - ‘Marsh Propofol calculations validation’ available from DEmED®, 
Hollebeek, Belgium; http://www.demed.be/downloads.htm.  
 
5.2.2.7 Sample size and Analysis 
It was estimated that approximately 50 samples would be required to gain a 
representative proportion of the different levels of sedation achieved on the critical 
care unit, in order to assess propofol concentrations achieved in each group.  It was 
assumed that statistical analysis on such data would be heavily influenced by the 
highly disparate nature of critical care patients, and would therefore be of limited 
benefit.  The work would however be useful for hypothesis generation and as a 
stimulus for further work. 
Calculated propofol concentrations were compared with measured blood 
concentrations, and the correlation co-efficient calculated.  Correlation co-efficients 
were calculated for groups divided into severe organ failure based on an organ 
failure SOFA score of greater than or equal to 6, and less severe organ failure 
based on a SOFA score of less than 6.   
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5.2.3 Results 
53 samples from 43 patients were collected between August and December 2010.  
Patients were allowed to be included on more than one occasion when discharged 
and readmitted to the critical care as a separate ‘patient episode’.  Patient 
characteristics’ data are presented in Table 24 and Table 25: 
 Number Percentage Mean Range 
Male 26/53 49   
Female 27/53 51   
Age   53.6 22-80 
Weight (kg)   76.6 49-110 
Height (M)   1.71 1.50-1.89 
Richmond Agitation Scale   -3.3 -1 to -5 
SOFA score   5.1 0 to 11 
Use of concurrent sedatives 10/53 19   
Use of concurrent opiates 37/53 70   
On vasopressor/inotropic support 31/53 58   
Table 24:   Characteristics of patients recruited to intensive care sedation study. 
 
Category of Intensive Care Number Percentage 
Neuro surgical/medical 15 28 
Cardiac surgical 20 38 
General 12 23 
Not recorded 6 11 
Table 25:  Specialty of Intensive care unit from which patients were recruited. 
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5.2.3.1 Propofol Infusion Data 
• Propofol was infused for a mean of 33 hours (interquartile range 14-44 hours) 
• Mean rate of propofol infusion was 2.18 mg-1.kg-1.hr-1  
• Mean measured whole blood propofol concentration was 1.37µg.ml-1 (range 
0.29 to 2.60 µg.ml-1) 
   
5.2.3.2 Correlation of measured propofol concentrations in critically ill patients with 
those estimated using the Marsh algorithm 
There was a strong correlation between whole blood propofol concentrations 
measured using the research propofol analyser, and those predicted based on the 
Marsh pharmacokinetic model.  Figure 34 below shows this relationship with a 
regression line, with an R2 value of 0.5005.  Figure 35 shows a difference plot of 
the same data.  This graph plots the average of the measured and estimated 
propofol concentrations against the difference between measured and estimated 
concentrations, and is useful to show how changes in drug concentrations affect 
the correlations.  These data demonstrate a small positive bias, with measured 
values 0.2µg.ml-1 higher than estimated concentrations.  The precision with which 
the propofol drug concentration was estimated is represented by one standard 
deviation from the mean (+/- 0.4 µg.ml-1).  The limits of agreement, representing 
1.96 standard deviations from the mean are drawn on the difference plot.  Upon 
visual inspection of Figure 35, it appears that although the data overall show a 
positive bias, representing higher measured than estimated propofol 
concentrations, this is not reflected in the patients with higher propofol 
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concentrations above 1.5 µg.ml-1.  It is not clear why this relationship should be 
reversed at higher propofol concentrations, although numbers are small in this 
group (n=8).  It could be postulated that those with lower estimated propofol 
concentrations are more likely to be critically ill, requiring lower rates of infusion in 
order to achieve adequate sedation, but with a positive bias representing impaired 
propofol elimination from plasma.  The influence of organ dysfunction on measured 
propofol concentration is further analysed in chapter 5.2.3.3 below. 
 
 
Figure 34:  Scatter plot showing measured blood propofol concentration using novel 
propofol analyser against concentrations calculated using the Marsh algorithm in all 
patients.  Regression line shown with R2 value.  Dashed lines represent 95% confidence 
intervals. 
186 
 
 
Figure 35:  Difference plot (Bland-Altman) showing how predicted compare with calculated 
blood propofol concentrations at average propofol concentrations.  Black line shows mean 
difference (bias), and dashed lines show the limits of agreement. 
 
5.2.3.3 Influence of severity of organ failure on predicted propofol concentrations 
The patients recruited were divided into those with significant organ failure, based 
on assessment of SOFA score.  Patients were separated into the severe organ 
failure group if their SOFA score was above or equal to six, and all other patients 
were placed in the less severe organ failure group.  Regression lines were plotted 
for each group, and correlation coefficients calculated.  Figure 36 below shows a 
shallower regression line (dark blue) for patients with more severe organ failure, 
indicating a tendency for higher measured propofol concentrations than those 
estimated using the Marsh algorithm.  The correlation coefficients demonstrate that 
propofol concentrations can be predicted with much higher accuracy in patients 
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without severe organ failure with a R2 value of 0.73; representing a strong 
association.  Although an association can be made in the more severe organ failure 
group, this is weak, with an R2 value of 0.36.  A weaker association and higher 
measured propofol concentrations in the more severe organ failure group is likely to 
be caused by abnormal distribution, metabolism and elimination of propofol in these 
more critically ill patients. 
 
Figure 36:  Plot of measured blood propofol concentration using novel propofol analyser 
against that calculated using the Marsh algorithm.  Samples split into those with and 
without significant organ failure (SOFA – sequential organ failure assessment). 
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5.2.3.4 Measured propofol concentrations in critical care correlate with sedation 
score 
The recruited patients were monitored for level of sedation as part of standard care 
during their stay in intensive care.  Data for level of sedation were missing for one 
of the 53 patients.  Available data were used to assess the level of sedation at the 
point of blood sampling for analysis of propofol concentration.  As expected, a 
correlation was identified between level of sedation and blood propofol 
concentration.  Table 26 and Figure 37 show the mean measured propofol 
concentration at each level of sedation (see Appendix 6 for full scoring system).  A 
sedation score of -1, represents a very light level of sedation, and is commonly 
targeted in critically ill patients.  This level of sedation was represented by a mean 
propofol concentration of 0.74 µg.ml-1 (95% CI 0.50 to 0.97 µg.ml-1).  Deep levels 
of sedation were represented by propofol concentrations of around twice this 
concentration. These propofol concentrations are similar to those achieved in a 
previous study using target controlled infusion of propofol for sedation in critical 
care, where the range of concentrations was calculated as 0.26-1.87 µg.ml-1 (10th 
to 90th percentile).(McMurray, Johnston et al. 2004)  This work however did not 
include data on level of sedation achieved, and so was unable to suggest 
appropriate propofol concentrations to achieve a desired level of sedation.  Work by 
Barr used a different sedation score, the Ramsay sedation scale, but demonstrated 
similar levels of sedation for a given propofol concentration overall, although lower 
propofol concentrations at a low level of sedation (0.25 µg.ml-1 at a sedation score 
of 2, correlating broadly with a Richmond agitation scale score of -1 in which our 
data measured 0.74 µg.ml-1).(Barr, Egan et al. 2001)  Those patients receiving 
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neuromuscular blocking agents to achieve muscle relaxation represent some of the 
most unwell patients in critical care.  Common reasons for the infusion of 
neuromuscular blocking drugs include severe lung injury, and raised intracranial 
pressure.  These patients are at significant risk of haemodynamic instability, and 
are therefore at increased risk from the haemodynamic pharmacodynamic actions 
of propofol.  As levels of sedation cannot be assessed in these patients, it is 
standard practice to increase the sedation infusion dose to ensure unconsciousness.  
The mean measured propofol concentrations in these patients was 1.2 µg.ml-1 
(95% CI 1.15 to 1.22 µg.ml-1).  This correlates with a sedation score of between -2 
and -3 in the cohort of patients not receiving neuromuscular blockade, representing 
a fairly deep level of sedation.  It was noted that all patients receiving 
neuromuscular blockade were also receiving a second sedative agent (midazolam), 
compared with only 10% of patients not receiving neuromuscular blockade.  It is 
speculated that the use of additional sedative agents was likely to have been 
chosen to further decrease the risk of awareness, although at the expense of 
heightened side effects. 
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RAS Mean propofol concn 
(µg.ml-1) (SD) 
95% CI  
(µg.ml-1) 
Number of 
Patients 
-5 1.66 (0.35) 1.44 to1.88 10 
-4 1.41 (0.45) 1.15 to 1.66 12 
-3 1.56 (0.52) 1.29 to 1.83 14 
-2 1.14 (0.35) 0.91 to 1.37 9 
-1 0.74 (0.24) 0.50 to 0.97 4 
P 1.19 (0.03) 1.15 to 1.22 3 
Total 1.39  52 
Table 26:  Average measured propofol concentrations at each assessed level of sedation, 
and whilst receiving neuromuscular blockade. RAS: Richmond Agitation Scale, P: use of 
neuromuscular blocker. SD: standard deviation. 
 
Figure 37:  Histogram showing mean measured blood propofol concentrations for 
each given recorded score on the Richmond Agitation Scale, p= patient receiving 
neuromuscular blocking drug.  Error bars show 95% confidence intervals. 
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5.2.4 Discussion 
This work, reflecting a broad cohort of critically ill patients, helps to define the 
propofol concentrations required during very prolonged periods of sedation (mean 
duration of infusion 33 hours).  These data are important for those wishing to 
develop pharmacokinetic models for propofol infusion in critical care, and for those 
investigating the potential side effects of prolonged propofol infusion, which 
includes both commonly occurring pharmacodynamic effects such as cardiovascular 
instability, but also serious infrequently occurring events such as the propofol 
infusion syndrome, discussed in chapter 1.5.6.  
In the second part of this work, an assessment was made of whether the Marsh 
model, a commonly used pharmacokinetic model for estimation of propofol 
concentrations by infusion during anaesthesia, could be used to predict measured 
propofol concentrations.  These data demonstrated a strong correlation between 
the estimated and measured propofol concentrations; although a positive bias was 
seen, reflecting higher than anticipated measured propofol concentrations, 
particularly in patients requiring lower propofol concentrations.  Following this, it 
was demonstrated that propofol concentrations were better correlated with 
predicted concentrations in patients with less severe organ failure, as defined by a 
SOFA score below 6.  Mean propofol concentrations were also determined for each 
measured level of sedation using the Richmond agitation scale, which correlated 
with work by others. (McMurray, Johnston et al. 2004)  Higher concentrations of 
propofol were detected in patients receiving neuromuscular blockers, in whom level 
of consciousness could not be clinically assessed.  All of the patients receiving 
neuromuscular blockade were also receiving additional hypnotic agents.  It is 
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postulated that clinicians may have used excessive sedation in this group because 
of concern about preventing awareness.  It is possible that the use of depth of 
anaesthesia monitoring may have helped clinicians to better estimate level of 
sedation in this group, although these devices are not validated in this population.  
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6 CHAPTER 6:  GENERAL DISCUSSION, LIMITATIONS AND FUTURE 
WORK 
Following its introduction in the 1980s, the use of propofol has become so 
widespread that the majority of general anaesthetics throughout the world 
incorporate the drug as either an induction agent, or by infusion for maintenance of 
anaesthesia.  It has also become one of the drugs of choice for sedation both for 
short procedures and on the critical care unit.  The reason for this global adoption is 
the ease of use, predictable onset and offset of action, and favourable side effect 
profile.  As early as the drug was introduced into clinical practice, research had 
begun on the complex pharmacokinetics of this drug in order to understand how to 
achieve a steady drug concentration for stable anaesthesia when delivered by 
infusion.  The properties of propofol which make it an ideal anaesthetic agent, such 
as its very large volume of distribution and rapid clearance make it difficult to 
accurately predict blood concentrations using simple methods of calculation.  Initial 
work focused on the administration of a bolus induction dose followed by 
decreasing constant rate infusions, and subsequent work has led to the 
development of complex multi-compartment models in order to allow induction, 
maintenance of anaesthesia, and dose manipulation.  This work has involved a 
huge amount of pharmacokinetic analysis and the development of complex 
software to allow models which incorporate multiple covariates.  
 
The work presented in this thesis has been divided into several areas with the 
common theme of blood propofol measurement, with particular reference to point 
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of care testing.  The initial focus has been on methods of propofol sampling and 
analysis, and potential influence of such differences on published work.  A novel 
propofol analyser has been validated and used in subsequent experiments to 
investigate propofol pharmacokinetics within the critical care and the operating 
theatre, as well as an investigation of its potential utility for use at the point of care 
during propofol anaesthesia.  The practice of anaesthetists when using propofol TCI 
in the clinical setting has been examined.   
 
The work within this thesis has been divided into discrete sections, the conclusions 
and limitations of which are examined separately below: 
6.1 Validation experiments on a novel propofol analyser 
In Chapter 2, a novel machine, capable of performing blood propofol concentration 
measurements within a clinically meaningful timeframe was evaluated.  The data 
for this chapter was collected by others, and my involvement was in the analysis 
and interpretation of the data collected, in order to assess the validity of the 
analyser.  This work necessarily involved the close collaboration with the medical 
devices development company, Sphere Medical Ltd, Cambridge, UK, who were 
responsible for the technical development and manufacture of the machine.  The 
collaboration between Sphere Medical Ltd. and our group to develop and validate 
the machine was funded by a grant from the Health Technology Agency (HTA).  My 
involvement was at the tail end of this work, following the development of the 
machine and data collection.  The analyses which I performed, presented in this 
thesis demonstrate that the propofol analyser performs with good linearity and 
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repeatability within the clinical range for which it was designed, without significant 
interference following co-administration of commonly used drugs.  A clinical study 
comparing the new analyser with the HPLC reference standard, performed on 
patients undergoing cardiac surgery with propofol anaesthesia corroborated the in 
vitro work.   Work to assess the influence of haemoglobin concentration on the 
propofol analyser performance, performed in chapter 2.5.5 showed that at high 
concentrations of propofol, as haemoglobin concentration increases, there is a 
tendency for negative bias, although this was not demonstrated at the lower 
concentrations commonly maintained during anaesthesia.  Samples with lower 
haemoglobin concentrations, in particular samples prepared as plasma, are not 
susceptible to such bias, as these samples more closely match the solutions used to 
calibrate the analyser.  It would have been relevant to have performed an 
experiment to compare the HPLC standard with the new analyser for plasma 
specimens and whole blood, in order to quantify any possible differences.  It can be 
assumed that the accuracy of plasma specimens is better than that of whole blood 
following these experiments, however, a confirmatory study to demonstrate this is 
warranted.   
Limitations of the validation work include relatively small numbers in experimental 
groups, and indeed subsequent work by Sphere Medical Ltd has been performed to 
add to this work in order to achieve an in vitro diagnostic licence for the machine. 
Future Work by others on point of care propofol concentration analysis is likely to 
be focused on improving usability, including possible reductions in sample volume 
to allow capillary sample analysis, and validation of such methods.  Rapid 
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intermittent blood propofol concentration measurement may be possible using a 
continuous feed of blood and performing rapid serial analyses, however, such a 
system would be limited to outputs only once every five minutes at a maximum 
using the technology used within the analyser validated in this thesis.  This would 
significantly limit any potential clinical utility of such a device, where measurement 
of rapid changes in blood propofol concentration may be desired.  Furthermore, 
much of the benefit of existing inhalational anaesthetic monitors stems from the 
continuous nature of feedback, allowing rapid detection of interruption of drug 
delivery (for instance through machine failure, or inadvertent failure of user to refill 
drug).  This would not be possible with the system as it is currently designed. 
Potential measurement of exhaled gases to measure propofol concentrations, 
similar to those routinely used to measure inhalational anaesthetic agents are not 
likely to be of clinical utility, certainly with currently available technology, as 
concentrations of propofol in exhaled breath are low and not uniformly correlated 
with blood concentrations (see chapter 1.8).  Alternatively, further development in 
pharmacodynamic monitoring, including depth of anaesthesia monitors developed 
from those discussed in chapter 1.9.2 could lead to improvements in their response 
time and specificity, leading to a reduction in the potential utility for measured 
propofol concentrations.  More evidence of benefit, in particular benefit in the 
prevention of anaesthetic awareness in patients undergoing propofol TCI, is 
required in order to drive the routine use of depth of anaesthesia monitors or a 
more advanced form of continuous propofol measurement in this group.  Recent 
work in the UK has suggested that awareness during general anaesthesia is 
perhaps a lot less common than previous work has suggested, with rates as low as 
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1:15000. (Pandit, Cook et al. 2013)  This may reflect the UK practice of routine end 
tidal anaesthesia monitoring, or the fact that UK anaesthesia is predominantly 
delivered by doctors, although such links are speculative.   
 
6.2 Review of Publications in which blood was sampled for propofol 
pharmacokinetic analysis 
It is clear that although the research on propofol pharmacokinetics leads the field, 
there is wide temporal and research variation in the methods used to collect, store, 
and process blood samples for analysis.  Review of published literature has 
demonstrated that measured propofol concentrations vary significantly depending 
on the chosen route of sampling (arterial or venous), and on the method of sample 
preparation (whole blood or plasma), and indeed there is variation if plasma is not 
prepared in a standardised way, with processing immediately following sample 
collection.  Chapter 3 of this thesis includes a series of experiments designed to 
clarify the influence of sample preparation on blood propofol concentrations, to add 
to the current literature on the topic.  These data generally corroborated work by 
others, although the influence of plasma versus whole blood was less marked.  It is 
possible that these experiments were limited by allowing too long a period for 
equilibration in vivo or in vitro, allowing red blood cells to equilibrate with plasma, 
disguising differences.   
As those developing pharmacokinetic models to deliver propofol strive to improve 
performance, such variability in pharmacokinetic research methodology becomes 
important, particularly when groups pool data from multiple studies in order to 
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generate new models, without knowing precisely the differences in sampling.  
Organisations such as the ‘openTCI’ initiative aim to allow free access to 
researchers data in order to facilitate such pooling of results, although it is 
concerning that sample processing differences may impair the ability of such 
initiatives to generate improved pharmacokinetic models.(Open_TCI_Initiative 
2013) 
The work presented in chapter 3 includes a systematised analysis of literature 
involving the measurement of propofol in blood for pharmacokinetic analysis.  This 
demonstrates huge swings in practice, with recent publications favouring plasma 
samples from arterial sites, and older publications tending to rely on venous whole 
blood.  Modern practice is by no means homogeneous however, with publications 
within the last few years based on whole blood analysis.  This literature review 
attempted to systematically analyse propofol concentration measurement for clinical 
pharmacokinetic studies.  This represents a large number of publications, 
necessitating limited data extraction.  Data were frequently missing from 
manuscripts.  Attempts were made to contact authors for the data deemed most 
important, but as the majority of the publications did not include the full data-set, it 
was not possible to collect all of the anticipated data.  Lack of contact details for 
many of the older publications hampered data collection.  An alternative analysis of 
publications involving pharmacokinetic data for the development of TCI models may 
have represented a more manageable number, and would have facilitated a more in 
depth analysis.  However, the chosen design of this review was able to identify 
temporal changes in practice as well as highlight the difficulties of pooling datasets 
when original publications seldom contain sufficient information to adequately 
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assess the robustness of the sampling methodology.  The main utility of this work 
will be to highlight to the research community, particularly those involved in 
collaborative work such as the ‘Open TCI’ initiative in which it is anticipated that 
models could be developed using pooled data, that such data will contain a variety 
of differences in site of sampling, sample preparation, storage, and extraction, all of 
which may serve to increase biases and errors in work involving pooled data. 
 
6.3 Studies on propofol anaesthesia in the operating room 
The work presented in this thesis performed within the operating room was 
designed to assess current practice with respect to the use of TCI within one large 
institution, to assess the performance of the most commonly chosen TCI model, the 
Marsh model in effect site mode, and finally to test a proposed simple proportional 
correction hypothesis, in which a single point of care measurement of blood 
propofol could be used to recalibrate inter-patient bias out of the Marsh model. 
Data were collected on choice of model for TCI in the Queen Elizabeth Hospital 
neuro-anaesthesia department, where TCI is frequently performed.  The Marsh 
model used in effect site mode was the preferred model by anaesthetists in this 
institution, and for this reason, the further work was performed using this model.  It 
is of course possible that this choice only reflects local preferences, and other 
institutions within the UK, and wider Europe may have other preferences.  A UK 
wide or European wide survey of preference would be a useful addition to this 
work, to clearly determine what is happening on the ground.  It was interesting to 
note the lack of use of depth of anaesthesia monitors in any patient studied, as well 
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as a heavy reliance on predicted propofol concentrations, with minimal dose 
titration during anaesthesia.  Again, this may reflect local practice only, although 
recent guidelines published by the National Institute of Healthcare and Clinical 
Excellence (NICE) advising that depth of anaesthesia (DoA) monitoring should be 
‘considered’ in those undergoing propofol TCI may lead to a change in practice.  
The reasons for advising the consideration of DoA monitors were however based on 
cost effectiveness rather than patient safety.(NICE 2012)  One limitation of this 
work was that the anaesthetist using the TCI model was aware of the participation 
of the patient in the study, and this may have influenced the propofol dosing 
regimen chosen during the course of anaesthesia.  As the anaesthetist was aware 
that the work was a test of model performance, and not an assessment of their 
anaesthetic technique, this is unlikely to have led to significant changes in practice. 
 
Data on Marsh model performance in a group of neurosurgical patients undergoing 
propofol TCI were analysed.  These data corroborated much previous work, 
highlighted in chapter 4, demonstrating that the Marsh model is susceptible to bias 
and imprecision, particularly in patient groups which may not be representative of 
those used to develop the model.  This work was designed to assess a commonly 
used model, as it is generally used in practice: using the propofol infuser in effect 
site titration mode.  The validation of a model using effect site mode presents a 
number of problems already highlighted in chapter 4.  Logistically, it was necessary 
to allow a period of time to elapse following dose modification to allow the effect 
site to equilibrate with the blood used for concentration measurement.  This 
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strategy prevented precise regularity of the sampling times throughout anaesthesia, 
which needed to be modified slightly based on time from any propofol dose 
modification.  In view of this, it was not possible to sample during the induction or 
emergence phases of anaesthesia – this may be viewed as a limitation of the work, 
as the model was not tested for performance during induction when depth of 
anaesthesia is clearly important.  However, it is perhaps during the induction and 
emergence phase that these models should be relied on least, when many other 
drugs influencing depth of anaesthesia may be co-administered, and performance is 
poorest.  It is certainly valid to assess the performance of these infusers during 
maintenance anaesthesia, as this is the period when many anaesthetists would 
expect them to perform well, and expect effect site estimations to be an accurate 
reflection of actual circulating concentrations of propofol.  The knowledge that the 
Marsh model does not perform well during maintenance anaesthesia is important 
for practicing anaesthetists to be aware of, particularly given the data in this thesis 
showing a significant level of reliance on estimated propofol concentrations. 
 
The poor performance of many TCI models is not just related to inaccuracies in 
pharmacokinetic modelling, but relates to inter-individual variability of drug 
pharmacokinetics.  These differences can be improved upon to some extent by the 
inclusion of additional covariates to the model, although no model can be 
specifically tailored to an individual patient.  It was proposed that a single point of 
calibration incorporated into the existing Marsh model, using a propofol analyser 
may reduce inter-individual bias.  A single point for calibration was chosen, as the 
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point of care propofol technology developed could not be easily developed to run 
continuously because of the methods used to extract the propofol.  It was also felt 
that both the economic and time constraints during anaesthesia would limit the 
number of discrete measurements that anaesthetists would be willing to make.  A 
single point recalibration would only be of clinical utility if performed early on in the 
course of general anaesthesia.  The time from induction of anaesthesia at which a 
single point calibration could reasonably be undertaken must necessarily be a 
compromise between clinical utility; the earlier the better, and conversely allowing 
adequate time to pass from the initial phase of induction which is susceptible to 
wide variability.   A proportional correction was applied to the Marsh model using 
blood propofol concentrations measured 30 min following induction of anaesthesia.  
30 min was chosen as a compromise between these two conflicting factors;  data 
from chapter 4.1.6 indicate increased bias earlier than 30 mins after induction of 
anaesthesia, and measurements beyond  this time would be very likely to push into 
surgical operating time, a time before which any recalibration should be performed 
to limit risks of awareness during surgical stimulation.  Results demonstrated an 
overcorrection of the Marsh model making the chosen proportional correction of no 
clinical utility.  This overcorrection was caused by the tendency of the Marsh model 
to under-predict propofol concentrations at thirty minutes relative to later in the 
course of anaesthesia.  It is possible that the Schnider model, in which early bias 
may be less pronounced, could be improved with a single point calibration, 
although close analysis of time related imprecision would be required prior to 
testing this hypothesis.   
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Other potential utilities of intermittent propofol measurement may be during more 
prolonged infusions in which fluctuations in drug concentrations are less 
pronounced, for instance on critical care.  It is also possible that the use of multiple 
point calibrations during the course of prolonged anaesthesia could serve to better 
improve TCI model performance, although at the expense of added time and cost 
for repeated blood sample analysis.  The development of an analyser capable of 
measuring blood propofol concentrations continuously or at regular intervals would 
offer advantages over single time-point sampling:  Early warning of infuser failure 
or disconnection, as well as offering a method for continuously correcting estimated 
propofol concentration using TCI.  Unfortunately, technology has not yet been 
developed to permit continuous propofol measurement.  Work has instead been 
directed at methods of directly measuring anaesthetic depth using EEG based 
monitors.  As yet, these devices have not become the standard of care, both 
because of expense and lack of consistent evidence demonstrating reductions in 
anaesthetic awareness with their use, as discussed in chapter 1.9.2.  
 
6.4    Studies within critical care 
Propofol is one of the commonest drugs used to provide sedation in critically ill 
adults.  A study was performed to evaluate the propofol concentrations required to 
sedate critically ill patients, and to assess the level of correlation between drug 
concentration and level of sedation, as defined by the commonly used Ramsay 
agitation scale, see appendix 6.  Although there was a correlation between depth of 
sedation and propofol concentration measured, it is clear that the depth of sedation 
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is subject to multiple confounders in this group – relating to factors such as 
concurrent drugs infused, level of brain injury, organ dysfunction, drug protein 
binding, etc.  The results do serve to reassure clinicians that blood propofol 
concentrations are actually remarkably low in these patients, despite frequent organ 
dysfunction. 
Propofol TCI may be applied to any patient population, although the groups of 
patients used to develop pharmacokinetic data, and subsequent validation 
experiments may differ from those in which the propofol TCI model is being used in 
the clinical setting.  An extreme example of where pharmacokinetic and 
pharmacodynamic variables differ from the fit, healthy population is in the critical 
care unit, as highlighted in chapter 5.1.  Here, multiple sources of interaction, 
including altered organ function, disturbed body compartment composition, 
abnormal protein binding capacity, and polypharmacy using many potent drugs 
unlikely to have been used during model validation all contribute to disturbance in 
predictability of drug handling.   
A study was performed to measure propofol concentrations in critically ill patients 
undergoing propofol infusion for sedation with concentrations predicted using the 
Marsh model in order to identify the extent to which critical illness affects the utility 
of the pharmacokinetic propofol TCI model.  The work demonstrated a strong 
correlation between blood propofol concentrations predicted by the Marsh model 
and measured blood propofol concentrations.  However, those patients with higher 
levels of organ dysfunction, as defined by the presence of a Sequential Organ 
Failure Evaluation score of greater than 6, had less predictable blood propofol 
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concentrations, with higher concentrations than those predicted using the Marsh 
model.  This finding fits with the assumption that drug handling by the critically ill 
patient is impaired.  This is however not the only factor contributing to drug effect.  
It is possible that those patients with most deranged physiology are likely to suffer 
from both the effects of increased bound propofol, but also higher free drug, 
because of depression in circulating protein concentrations in critical illness.  This 
will serve to compound the disparity between predicted blood propofol 
concentration and clinical effect.   
6.4.1 Limitations 
Recruitment to interventional clinical trials of critically ill patients remains a 
challenge, as patient consent is not directly obtainable, and personal or professional 
legal representative consent is therefore required.  In order to simplify this process, 
it was decided to use discard blood samples, with waived consent by the national 
ethics committee, for the purposes of this study.  Although this maximised 
recruitment, it had the disadvantage of limiting the scope of the study; for instance, 
preventing the application of BIS monitoring to patients, or the collection of 
anything but basic clinical data.  Furthermore, we were not able to deliver propofol 
using TCI infusers, rather relying on calculation of estimated propofol 
concentrations.  Given that all patients were receiving long periods of propofol at 
fixed concentrations, it was felt that there would be little improved accuracy in 
estimated propofol concentrations, as patients should have reached steady state 
concentrations at the point of sampling.  Numbers recruited to this study remained 
lower than hoped, primarily because of the move away from propofol as a sedating 
agent in critical care, other than for short periods, which were specifically excluded 
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from this work.  However, we feel that an adequate number of patients were 
recruited in order to perform a number of valuable analyses on propofol 
concentration, and correlations with level of organ dysfunction and sedation score. 
One limitation of this set of experiments is the use of an assay which measures 
total propofol concentration rather than free drug.  Propofol is extensively bound to 
plasma proteins, the unbound fraction being less than 3%.(Hiraoka, Yamamoto et 
al. 2004)  Propofol is non-restrictively cleared from the body, and protein binding 
does not limit drug removal in this situation.(Wilkinson and Shand 1975)  Given the 
results that higher SOFA scores are associated with lower propofol concentrations in 
our work, it is possible that this in fact reflects an increase in unbound propofol 
concentrations occurring as a result of altered body protein composition in critical 
illness, such as hypoalbuminaemia.  This has been previously proposed by 
Takizawa.(Takizawa, Takizawa et al. 2008)  A clear increase in unbound propofol 
concentrations has been seen, without an increase in total propofol concentrations 
during cardiopulmonary bypass, a process known to reduce plasma protein 
concentrations and hence plasma binding of drugs.(Hiraoka, Yamamoto et al. 2004)  
It would have been useful to have repeated these experiments using an assay 
capable of measuring free propofol to confirm this theory such as equilibrium 
dialysis, as used to measure free propofol by others,(Hiraoka, Yamamoto et al. 
2004) although the complexity of the assay, and lack of access to this equipment in 
our group prevented this. 
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6.4.2 Choice of Outcome Measures 
The Sequential Organ Failure Assessment (SOFA) score was used to determine the 
level of organ dysfunction of recruited patients at the time of blood sampling.  This 
scoring system has the advantage that it is frequently used for research purposes, 
for which it has been validated, and it can be applied on a daily basis, rather than 
the other commonly used disease severity index the APACHE II score, which is 
routinely collected on all critically ill patients in the majority of UK critical care units. 
(Knaus, Draper et al. 1985)  The disadvantage of the APACHE II score, is that it is 
calculated once during the first 24 hours of the critical care admission, based on 
admission disease severity, and so may not be indicative of organ dysfunction at 
the time of recruitment (which may have improved, or deteriorated).  No disease 
severity index however is without problems, and the SOFA score, for instance, 
suffers from a lack of inclusion of other disease severity markers such as age, 
comorbidities, and admission diagnosis.  This serves to make the score easier to 
collect, analyse, and validate, because of ease of application, but may lead to 
inaccuracies in the true disease severity. 
The Richmond agitation scale was used to allow comparison of level of sedation 
with measured propofol concentration.  The main benefit of this tool is its 
widespread use throughout critical care, allowing results to be widely applicable.  
An alternative strategy would have been to have used a depth of anaesthesia 
monitor or EEG, in an attempt to directly assess level of brain activity.  It was felt 
that as the use of such monitors are not validated in the critical care population, 
primarily being developed to assess level of unconsciousness during anaesthesia, 
that results would be difficult to interpret.  There is some evidence for the use of 
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BIS monitoring in critical care, although caution is suggested, with risks of under or 
over-sedation. (Vivien, Di Maria et al. 2003; LeBlanc, Dasta et al. 2006) 
 
6.5 Future work 
Further research on blood propofol analysis at the point of care is required in 
several areas to push this technology towards being of potential clinical utility 
during propofol TCI anaesthesia. 
• Technological developments in the method of sample analysis to allow a near 
continuous, or continuous blood propofol concentration would allow tighter 
control of drug concentrations, and mirror the safety advantage of 
continuous inhalational anaesthetic agent monitoring by early detection of 
interruption of anaesthetic supply.  If using the technology used within the 
analyser validated within this thesis, this would require one analyser per 
patient, and would likely to be prohibitively expensive. 
• Further research is warranted on the potential utility of point of care blood 
propofol measurement to improve the performance of propofol TCI.  The 
simple proportional correction method applied in this thesis did not perform 
adequately well to improve model performance, and further work could be 
done on alternative models to identify if single point recalibration is effective.  
Alternatively, a more complex Bayesian approach could be taken, as 
overviewed in chapter 4.2.8.2. 
• Work should be undertaken to enable a point of care analyser to perform 
blood propofol measurements on small volumes, for instance using finger 
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prick capillary micro-samples.  This would allow an expansion in the patient 
cohorts for which drug concentration analysis would be useful, as the device 
currently requires a minimum of half a millilitre of blood, and therefore 
arterial access for sampling is desirable.  Validation would need to be 
repeated for the use of capillary samples, and would likely be limited to the 
maintenance phase of anaesthesia, where arterial and venous blood drug 
concentrations are similar. 
Improvements in uniformity of blood sampling, preparation, storage and analysis 
should be pushed for in future research publications.  It is possible that much of the 
early pharmacokinetic work and model development performed on venous whole 
blood should be replicated using arterial plasma.  Certainly, development of more 
complex models aimed at further reducing bias and imprecision in propofol TCI 
should pay particular attention to the sampling methodology to avoid introducing 
unnecessary error. 
It is possible that improvements in propofol TCI modelling may come not from 
measuring drug levels directly, but by increasing the number of covariates available 
to modify the model and increase validity for wider patient groups.   Error from 
inter-patient variability will however never be entirely eliminated, and further 
attention to enhancing existing depth of anaesthesia monitors to improve their 
response time and specificity may provide an alternative answer.  Such devices 
could use Bayesian methods of feeding real time patient data back into 
mathematical models to better tailor the infusion to the patient and so improve the 
performance of propofol TCI anaesthesia. 
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8 APPENDICES 
 
Appendix 1: Search used using MEDLINE (Ovid SP 1950 to May 2013) and EMBASE (Ovid 
SP 1980 to May 2013) for review of publications involving measurement of blood propofol 
concentration for pharmacokinetic analyses 
Search # Search Term Number of Records 
1 propofol.ti,ab. 32613 
2 *propofol/pk [pharmacokinetics] 1400 
3 pharmacokinetic$.ti,ab. 250624 
4 diprivan.ti,ab. 855 
5 diisopropylphenol.ti,ab. 434 
6 "35868".ti,ab. 41 
7 1 or 4 or 5 or 6 32898 
8 3 and 7 1683 
9 2 or 8 2435 
10 Remove duplicates from 9 1607 
11 Limit 10 to humans 1299 
12 Limit 11 to English Language 1055 
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Appendix 2: Blank data extraction form for literature review of blood propofol concentration 
for pharmacokinetic analyses 
 category tick Free text 
Year of publication 
 
Prior to 1990 
1991 to 1995 
1996 to 2000 
2001 to 2005 
>2005 
 Year: 
Chemicals added for 
anticoagulation/preservatives: 
 
Oxalate 
EDTA 
Heparin 
Citrate 
Other 
Not stated in full text 
  
Preparation of sample 
 
Whole blood 
Plasma 
Serum 
Not stated in full text 
  
Time to centrifugation of plasma 
specimens (time recorded in mins, 
and categorised into: 
 
<5 min 
>5 min but <30min 
30 to 60 min 
>60 min 
not stated in full text 
 Time 
(mins): 
Site of blood sampling 
 
Arterial 
Venous 
Other 
Not stated in full text  
 Other: 
Sample vial composition recorded if 
stated and categorised as: 
 
Glass/polypropylene 
Other 
Not stated in full text 
 Material: 
Storage temperature (temperature 
in 0C recorded and categorised as: 
 
Room temperature (12 to 250C) 
Refrigerated temperature of 3-5 0C 
standard freezer temp (-18 to -25 0C),  
Cold freezer -60 to -80 0C 
Other temperature 
not stated in full text 
 Temp (oC) 
Storage duration.  Recorded in 
weeks and categorised for whole 
blood: 
 
< 12 weeks 
>12 weeks 
Not stated in full text 
 Duration 
(weeks): 
Method of sample analysis  
 
 
HPLC 
GC 
Other 
Not stated in full text 
 
 Other: 
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Appendix 3:  Table of publications relating to propofol pharmacokinetics involving blood propofol measurement.  Those used to construct 
propofol TCI models are listed in the final column 
Publication Year 
Published 
Vial Storage 
Chemicals Used 
Blood 
Preparation 
Analysed 
Time to 
Centrifuge 
Site 
sampled 
Vial composition Temperature 
Sample 
stored (oC) 
Duration of 
Sample 
Storage 
Method of 
Sample 
Analysis 
Model 
developed 
with data 
(Altermatt, Bugedo et al. 2012) 2012 Not Stated Plasma 2 hours Arterial Not Stated -20 Not Stated HPLC  
 (Tang, Wu et al. 2011) 2011 Not Stated Plasma Not Stated Venous Not Stated 4 Not Stated HPLC  
(Cortinez, Anderson et al. 2010)  2010 Not Stated Plasma Not Stated Arterial Not Stated -20 Not Stated HPLC Cortinez 
(obese) 
(Bienert, Kusza et al. 2010) 2010 Heparin Plasma Immediately Arterial Not Stated 4 < 8 weeks HPLC  
(La Colla, Albertin et al. 2009) 2009 Not Stated Whole Not Stated Arterial Not Stated Not Stated Not Stated HPLC  
(Nishinarita, Yamamoto et al. 1990) 2009 Oxalate Whole Not Stated Venous ‘syringes’ 4 <12 weeks HPLC  
(Masui, Kira et al. 2009) 2009 Heparin Plasma < 1 hour Arterial polyethylene -20 Not Stated HPLC  
(Bienert, Zaba et al. 2009) 2009 Heparin Plasma Immediately Venous Not Stated 4 <8 weeks HPLC  
(Han, Greenblatt et al. 2009) 2009 EDTA Plasma <30 min Arterial Not Stated -70 Not Stated HPLC  
(Grossherr, Hengstenberg et al. 2009) 2009 Heparin Plasma Not Stated Arterial Monovette -20 Not Stated HPLC  
(Barbosa, Santos et al. 2009) 2009 EDTA Plasma Not Stated Arterial glass -20 Not Stated HPLC  
(Rigouzzo, Girault et al. 2008) 2008 Not Stated Plasma Immediately Venous Not Stated -40 Not Stated HPLC  
(Kim, Choi et al. 2007) 2007 EDTA Plasma Not Stated Arterial Not Stated -70 Not Stated HPLC  
(Albertin, Poli et al. 2006) 2006 Not Stated Whole - Arterial Not Stated Not Stated Not Stated HPLC  
(Takizawa 2006) 2006 EDTA Whole - Arterial polyethylene 4 Not Stated HPLC  
(Wietasch, Scholz et al. 2006) 2006 Not Stated Plasma Not Stated Arterial Not Stated -80 Not Stated HPLC  
(Shangguan, Lian et al. 2006) 2006 Heparin Plasma <30 min Arterial polypropylene 4 <14 weeks HPLC  
(Cavaliere 2005) 2005 Heparin Plasma Immediately Arterial Not Stated -60 Not Stated HPLC  
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Publication Year 
Published 
Vial Storage 
Chemicals Used 
Blood 
Preparation 
Analysed 
Time to 
Centrifuge 
Site 
sampled 
Vial composition Temperature 
Sample 
stored (oC) 
Duration of 
Sample 
Storage 
Method of 
Sample 
Analysis 
Model 
developed 
with data 
(Frolich 2005) 2005 Not Stated Plasma Not Stated Venous Not Stated -75 N   ot stated HPLC-MS  
(Takizawa, Sato et al. 2005) 2005 Not Stated Whole - Arterial Not Stated Not Stated <2 days HPLC  
(Hiraoka, Yamamoto et al. 2005) 2005 Heparin Whole - Arterial polyethylene -20 <2 days HPLC  
(McMurray, Johnston et al. 2004) 2004 Not Stated Not Stated Not Stated Arterial Not Stated Not Stated Not Stated HPLC  
(Calvo, Telletxea et al. 2004) 2004 Not Stated Not Stated Not Stated Not Stated Not Stated Not Stated Not Stated HPLC  
(Absalom, Amutike et al. 2003) 2003 EDTA Plasma Not Stated Arterial Not Stated 4 Not Stated GC  
(Servin, Bougeois et al. 2003) 2003 Not Stated Not Stated Not Stated Venous Not Stated Not Stated Not Stated HPLC  
(Li, Rui et al. 2003) 2003 Heparin Plasma <30 mins Arterial Polypropylene -20 14 weeks HPLC Chinese 
(Abad-Santos, Galvez-Mugica et al. 2003) 2003 Heparin Plasma Not Stated Venous Glass -30 Not Stated HPLC  
(Yoshitani, Kawaguchi et al. 2003) 2003 Not Stated Plasma Immediately Arterial Not Stated -30 Not Stated HPLC  
(Hoymork, Raeder et al. 2003) 2003 Heparin Plasma 3 hours Arterial Not Stated -18 Not Stated HPLC  
(Bouillon, Bruhn et al. 2002) 2002 Not Stated Plasma Not Stated Arterial Not Stated -20 Not Stated HPLC – MS  
(Ward, Norton et al. 2002) 2002 Not Stated Plasma Immediately Venous Not Stated ‘frozen’ Not Stated Not Stated  
(Theilen, Adam et al. 2002) 2002 Not Stated Plasma Not Stated Venous Not Stated Not Stated Not Stated HPLC  
(Morikawa, Oishi et al. 2002) 2002 Not Stated Plasma Not Stated Not Stated Not Stated -4 Not Stated HPLC  
(Vuyk, Oostwouder et al. 2001) 2001 Oxalate Whole - Arterial ‘testtubes’ 4 < 12 weeks HPLC Vuyk (elderly) 
(Barr, Egan et al. 2001) 2001 Heparin Plasma Not Stated Arterial Not Stated 4 Not Stated hplc  
(Schnider, Minto et al. 1999) 1999 Not Stated Plasma Not Stated Arterial Not Stated Not Stated Not Stated Not Stated  
(Knibbe, Voortman et al. 1999) 1999 Oxalate Whole - Arterial Glass 4 Not Stated HPLC  
(Turner, Kam et al. 1999) 1999 Not Stated Plasma Not Stated Arterial Not Stated -20 Not Stated HPLC  
(Schnider, Minto et al. 1998) 1998 Heparin Plasma 2 hours Arterial polypropylene -20 Not Stated HPLC Schnider 
(Ickx, Cockshott et al. 1998) 1998 Not Stated Whole - Arterial Not Stated 4 <12 weeks HPLC  
(Tsubokawa, Yamamoto et al. 1998) 1998 Heparin Whole - Arterial Not Stated 4 <3 days HPLC  
(Oei-Lim, White et al. 1998) 1998 Plain Serum Not Stated Venous Not Stated -20 <30 days HPLC  
(Kazama, Ikeda et al. 1998) 1998 Not Stated Plasma Not Stated Arterial Not Stated 5 Not Stated HPLC  
(Doenicke, Roizen et al. 1997) 1997 Not Stated Whole - Venous Not Stated 4 Not Stated HPLC  
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Publication Year 
Published 
Vial Storage 
Chemicals Used 
Blood 
Preparation 
Analysed 
Time to 
Centrifuge 
Site 
sampled 
Vial composition Temperature 
Sample 
stored (oC) 
Duration of 
Sample 
Storage 
Method of 
Sample 
Analysis 
Model 
developed 
with data 
(Bailey, Mora et al. 1996) 1996 Heparin Plasma Not Stated Arterial polypropylene -70 Not Stated HPLC  
(Barvais, Rausin et al. 1996) 1996 Oxalate Whole - Arterial Not Stated 4 Not Stated HPLC  
(Murat, Billard et al. 1996) 1996 Oxalate Whole - Venous Not Stated 4 < 3 weeks HPLC  
(Coetzee, Glen et al. 1995) 1995 Clotted multiple Not Stated both polypropylene -4 Not Stated HPLC  
(Lee, Khoo et al. 1995) 1995 Oxalate Whole - Venous Not Stated 4 <3 weeks HPLC  
(Vuyk, Engbers et al. 1995) 1995 Oxalate Whole - Arterial ‘test tubes’ Not Stated Not Stated HPLC  
(Kataria, Ved et al. 1994) 1994 Heparin Plasma Not Stated Venous glass -70 Not Stated HPLC Kataria (child) 
(Servin, Farinotti et al. 1993) 1993 Not Stated Whole - Arterial Not Stated 4 Not Stated HPLC  
(Bailie, Cockshott et al. 1992) 1992 Oxalate Whole - Arterial Not Stated 4 Not Stated HPLC  
(Marsh, White et al. 1991) 1991 Not Stated Whole - Venous Not Stated Not Stated Not Stated GC Marsh 
(Tackley, Lewis et al. 1989) 1989 Oxalate Whole - Venous Not Stated 4 Not Stated HPLC   
(Schuttler, Kloos et al. 1988) 1988 Not Stated Whole - Not Stated Not Stated Not Stated Not Stated HPLC   
(Shafer, Doze et al. 1988) 1988 Not Stated Whole - Venous Not Stated 5 <18 weeks HPLC   
(Kay, Sear et al. 1986) 1986 Oxalate Whole - Venous Not Stated 4 Not Stated HPLC   
(White, Kenny et al. 2008) 2008  Plasma Not Stated Venous Not Stated   HPLC  WhiteKenny 
(White and Kenny 1990) 1990 Not Stated Whole - Venous Not Stated Not Stated Not Stated GC paedfuser 
(Schuttler, Stoeckel et al. 1985) 1985 Oxalate Whole - Arterial Not stated Not stated Not Stated HPLC paedfuser 
(Smith, McEwan et al. 1994) 1994 Heparin Whole - Arterial Not Stated 4 Not Stated HPLC paedfuser  
(Saint-Maurice, Cockshott et al. 1989) 1989 oxalate Whole - Venous Not Stated 4 Not Stated HPLC paedfuser  
(Kirkpatrick, Cockshott et al. 1988) 1988 oxalate Whole - Venous Not Stated 4 Not Stated HPLC paedfuser  
(Adachi, Watanabe et al. 2001) 2001 Not stated plasma Not Stated venous Not Stated ‘frozen’ Not Stated HPLC  
(Adachi, Watanabe et al. 2001) 2001 Not stated Plasma Not Stated Arterial Not stated ‘frozen’ < 4 weeks HPLC  
(Albanese, Martin et al. 1990) 1990 Oxalate Whole - Arterial Not stated 4 Not stated HPLC  
(Al-Jahdari, Kunimoto et al. 2006) 2006 Heparin Whole - Arterial Not stated 4 Not stated HPLC  
(Allegaert, Peeters et al. 2007) 2007 Not Stated Whole - Arterial Not Stated Not Stated Not Stated HPLC  
(Andrews, Leslie et al. 1997) 1997 Heparin Whole - Arterial Not stated 4 <10 weeks HPLC  
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Publication Year 
Published 
Vial Storage 
Chemicals Used 
Blood 
Preparation 
Analysed 
Time to 
Centrifuge 
Site 
sampled 
Vial composition Temperature 
Sample 
stored (oC) 
Duration of 
Sample 
Storage 
Method of 
Sample 
Analysis 
Model 
developed 
with data 
(Bauer, Wilhelm et al. 2004) 2004 Nil Serum Not Stated Arterial Sarstedt Monovette -80 Not Stated GC  
(Bienert, Wiczling et al. 2011) 2011 Heparin Plasma Immediately Venous Not stated 4 < 8 weeks HPLC  
(Bjornsson, Norberg et al. 2010) 2010 Not Stated Plasma Not Stated Arterial Not stated Not Stated Not Stated HPLC  
(Bleeker, Vree et al. 2008) 2008 Not Stated Plasma Not Stated Arterial Not Stated -20 Not Stated HPLC  
(Boer, Ros et al. 1990) 1990 Not Stated Whole - Venous Not Stated 4 Not Stated HPLC  
(Bouillon, Bruhn et al. 2004) 2004 Not Stated Plasma Not Stated Arterial Not Stated -20 Not Stated Not Stated  
(Briggs and White 1985) 1985 Oxalate Whole - Venous Not Stated 4 Not Stated HPLC  
(Cockshott, Briggs et al. 1987) 1987 Oxalate Whole - Venous Not Stated 4 Not Stated HPLC  
(Campbell, Morgan et al. 1988) 1988 Heparin Whole - Arterial 
(ven late) 
Glass 4 Not Stated HPLC  
(Chen, Zhu et al. 2006) 2006 Not Stated Plasma Not Stated Arterial 
(and portal 
vein) 
Not Stated -20 Not Stated HPLC  
(Bjelland, Klepstad et al. 2013) 2013 None Serum Not Stated Arterial ‘cryotube’ -80 Not Stated Not stated  
(Chidambaran, Sadhasivam et al. 2013) 2013 Not Stated Whole - Venous Not Stated 4 < 8 Weeks HPLC  
(Coppens, Eleveld et al. 2011) 2011 EDTA Plasma Not Stated Venous Not Stated -80 Not Stated HPLC  
(Crankshaw, Brown et al. 2010) 2010 Not Stated Whole - Arterial Not Stated Not Stated Not Stated HPLC  
(Dailland, Cockshott et al. 1989) 1989 Oxalate Whole - Venous Not Stated 4 Not Stated HPLC  
(Dawidowicz, Fijalkowska et al. 2003) 2003 Not Stated Plasma Not Stated Arterial Not Stated Not Stated Not stated HPLC  
(Dawidowicz, Fornal et al. 2000) 2000 Not Stated Plasma - Arterial 
(also 
RA&PA) 
Not Stated Not Stated Not Stated HPLC  
(Dawidowicz and Kalitynski 2003) 2003 Not Stated Plasma Not Stated Arterial Not Stated Not Stated Not Stated HPLC  
(Dawidowicz, Kalitynski et al. 2003) 2003 Heparin Plasma Not Stated Arterial Not Stated Not Stated Not Stated HPLC  
(Dawidowicz, Kalitynski et al. 2004) 2004 Heparin Plasma Not Stated Arterial Not Stated Not Stated Not Stated HPLC  
(Dawidowicz, Kalitynski et al. 2006) 2004 Heparin Plasma Not Stated Arterial Not Stated Not Stated Not Stated HPLC   
(Dixon, Roberts et al. 1990) 1990 Not Stated Whole - Venous Not Stated 4 Not Stated HPLC  
(Doufas, Bakhshandeh et al. 2003) 2003 Not Stated Plasma Not Stated Venous Not Stated 4 Not Stated HPLC  
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Publication Year 
Published 
Vial Storage 
Chemicals Used 
Blood 
Preparation 
Analysed 
Time to 
Centrifuge 
Site 
sampled 
Vial composition Temperature 
Sample 
stored (oC) 
Duration of 
Sample 
Storage 
Method of 
Sample 
Analysis 
Model 
developed 
with data 
(Doufas, Morioka et al. 2009) 2009 Not Stated Plasma Not Stated Arterial Not Stated Not Stated Not Stated HPLC  
(Engelhardt, McCheyne et al. 2008) 2008 EDTA Plasma <30 mins Venous 
(likely) 
Not Stated -80 Not Stated HPLC  
(Fassoulaki, Farinotti et al. 1993) 1993 Oxalate Whole - Venous Not Stated 4 Not Stated HPLC  
(Gepts, Camu et al. 1987) 1987 Oxalate Whole - Arterial Not Stated 4 Not Stated HPLC  
(Frolich 2005) 2005 Not Stated Plasma ‘immediately’ Venous Not Stated -75 Not Stated LC-MS  
(Gepts, Jonckheer et al. 1988) 1988 Oxalate Whole - Arterial Not Stated 4 Not Stated HPLC  
(Gill, Wright et al. 1990) 1990 Oxalate Whole - Venous Not Stated 4 Not Stated HPLC  
(Gin, Yau et al. 1991) 1991 Oxalate Whole - Venous Not Stated 4 Not Stated HPLC  
(Gin, Yau et al. 1991) 1991 Not Stated Whole - Venous Not Stated Not Stated Not Stated HPLC  
(Hammaren, Yli-Hankala et al. 1996) 1996 Heparin Plasma <20mins Arterial Not Stated -70 Not Stated  Not stated  
(He, Ueyama et al. 2000) 2000 Heparin Plasma Immediately Arterial Not Stated 4 <48 hrs HPLC  
(Higuchi, Adachi et al. 2001) 2001 None Serum - Venous Not Stated -4 Not Stated HPLC  
(Hiraoka, Yamamoto et al. 2004) 2004 EDTA Whole Not Stated Arterial Polyethylene -20 <48hrs HPLC  
(Horiuchi, Nakayama et al. 2008) 2008 Not Stated Plasma Not Stated Venous Not Stated Not Stated Not Stated HPLC  
(La Colla, La Colla et al. 2007) 2007 Not Stated Plasma Not Stated Arterial Not Stated Not Stated Not Stated HPLC  
(McMurray, Collier et al. 1990) 1990 Not Stated Whole - Arterial Not Stated 4 <24hrs GL-Chrom  
(Paul, Dueck et al. 2003) 2003 Not Stated Plasma < 1 hr Venous Polypropylene -20 Not Stated HPLC  
(Roberts, Dixon et al. 1988) 1988 Not Stated Whole - Venous Not Stated 4 Not Stated HPLC  
(Russell, Wright et al. 1989) 1989 Heparin Whole - Arterial Not Stated 4 Not Stated HPLC  
(Servin, Desmonts et al. 1988) 1988 Oxalate Whole - Arterial Not Stated 4 Not Stated HPLC  
(Hoymork and Raeder 2005) 2005 Heparin Plasma A few hours Venous Not stated -18 Not stated HPLC  
(Jones, Chan et al. 1990) 1990 Heparin Whole - Venous Starstedt LH/5 4 Not Stated HPLC  
(Kirvela, Olkkola et al. 1992) 1992 Heparin Plasma Not Stated Venous Not Stated -70 Not Stated HPLC  
(Lange, Stephan et al. 1990) 1990 Not Stated Plasma Not stated Arterial 
(plus 
pa/hepV 
Not Stated Not Stated Not Stated HPLC  
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Publication Year 
Published 
Vial Storage 
Chemicals Used 
Blood 
Preparation 
Analysed 
Time to 
Centrifuge 
Site 
sampled 
Vial composition Temperature 
Sample 
stored (oC) 
Duration of 
Sample 
Storage 
Method of 
Sample 
Analysis 
Model 
developed 
with data 
(Major, Aun et al. 1983) 1983 Not Stated Whole - Arterial (+ 
venous/cvp) 
Not Stated Not Stated Not Stated HPLC  
(Massey, Sherry et al. 1990) 1990 Oxalate Whole - Arterial Not stated 4 Not stated HPLC  
(Morris, Acheson et al. 2005) 2005 Not stated Plasma Not Stated Arterial Not Stated ‘ice’ Not stated HPLC  
(Okell, Mapleson et al. 1991) 1991 Oxalate Whole - Arterial and 
Venous 
Not stated 4 Not stated HPLC  
(Raoof, van Obbergh et al. 1995) 1995 Heparin Whole - Venous Not Stated 4 Within 24hrs HPLC  
(Sear and Glen 1995) 1995 Not Stated Whole - Venous Not Stated Not Stated Not Stated HPLC  
(Sepluveda, Cortinez et al. 2011) 2011 Not Stated Plasma < 2 hr Arterial Not Stated -20 Not Stated HPLC  
(Servin, Cockshott et al. 1990) 1990 Not stated Whole - Arterial Not Stated 4 Not Stated HPLC  
(Short, Aun et al. 1994) 1994 Not Stated Whole - Venous Not Stated 4  Not Stated HPLC  
(Short, Lim et al. 1996) 1996 Not Stated Whole - Arterial Not Stated 4 Not Stated  HPLC  
(Takizawa, Sato et al. 2005) 2005 Not Stated Whole - Arterial and 
PA/PV/HA 
Not Stated Not Stated Within 48hrs HPLC  
(Teh, Short et al. 1994) 1994 Not Stated Whole - Venous Not Stated 4 Not stated HPLC  
(Knibbe, Melenhorst-De Jong et al. 2002) 2002 Oxalate Whole - Arterial Not Stated 4 Not Stated HPLC  
(Knibbe, Voortman et al. 1999) 1999 Oxalate Whole - Arterial Glass 4 Not stated HPLC  
(Knibbe, Zuideveld et al. 2005) 2005 Not Stated Whole - Arterial Not Stated 4 Not Stated HPLC  
(Morgan, Campbell et al. 1990) 1990 Heparin Whole - Arterial and 
venous 
later 
Glass 4 Not Stated HPLC  
(Karalapillai, Leslie et al. 2006) 2006 Not Stated Whole - Arterial Not Stated 4  < 10 weeks HPLC  
(Leslie, Sessler et al. 1995) 1995 Heparin Whole - Arterial Not Stated 4 < 10 weeks HPLC  
(Lichtenbelt, Olofsen et al. 2010) 2010 Not Stated Whole - Arterial Not Stated 4 <12 weeks HPLC  
(Veselis, Glass et al. 1997) 1997 Heparin Plasma < 4 hours Arterial Not Stated -70 Not Stated HPLC  
(Vuyk, Engbers et al. 1995) 1995 Oxalate Whole - Arterial Not Stated Not Stated Not Stated HPLC  
(Vuyk, Lichtenbelt et al. 2009) 2009 Oxalate Whole - Arterial Not Stated 4 < 12 weeks HPLC  
(Ibrahim, Park et al. 2002) 2002 Not stated Plasma Not Stated Venous Not Stated -20 Not Stated GC-MS  
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Publication Year 
Published 
Vial Storage 
Chemicals Used 
Blood 
Preparation 
Analysed 
Time to 
Centrifuge 
Site 
sampled 
Vial composition Temperature 
Sample 
stored (oC) 
Duration of 
Sample 
Storage 
Method of 
Sample 
Analysis 
Model 
developed 
with data 
(Kakinohana, Nakamura et al. 2006) 2006 Not stated Plasma Not Stated Arterial Not Stated Not Stated Not Stated HPLC  
(Kuizenga, Proost et al. 2001) 2001 EDTA Whole - Arterial Not Stated 4 Not Stated HPLC  
(Ludbrook, Visco et al. 2002) 2002 Not stated Plasma Not Stated Arterial and 
jug bulb 
Not Stated -20 Not Stated GC  
(Mertens, Olofsen et al. 2004) 2004 Oxalate Whole - Venous Not Stated 4 <12 weeks GC  
(Mertens, Olofsen et al. 2003) 2003 Oxalate Whole - Arterial Not Stated 4 < 12 weeks HPLC  
(Pandin, Cantraine et al. 2000) 2000 ‘silicon’ Serum - Arterial Not Stated 4 Not Stated HPLC  
(Peeters, Prins et al. 2006) 2006 Not Stated Whole - Arterial Not Stated 4 < 1 week HPLC  
(Rigby-Jones, Nolan et al. 2002) 2002 oxalate Whole - Arterial Not Stated 4 Not Stated HPLC  
(Rigouzzo, Servin et al. 2010) 2010 Not Stated Plasma ‘immediately’ Venous Not Stated -40 Not Stated HPLC  
(Wang, Lian et al. 2006) 2006 Heparin Plasma <30 mins Arterial Polypropylene 4 < 14 Weeks HPLC  
(Reed, Yamashita et al. 1996) 1996 Oxalate/then 
heparin 
Whole - Arterial Not Stated -70 < 8 weeks HPLC  
(Hoymork, Raeder et al. 2000) 2000 Heparin Plasma < 10 mins arterial Not Stated -18 Not Stated HPLC  
(Song, Zhang et al. 2009) 2009 Heparin Plasma Immediately Arterial Not Stated 5 <24 hours HPLC  
(Tsubokawa, Yamamoto et al. 2003) 2003 Heparin Whole - Arterial Not Stated 4 Not Stated HPLC  
(Wu, Zhu et al. 2005) 2005 Heparin Plasma Not Stated Arterial Not Stated 4 < 3 Weeks HPLC  
(Knibbe, Zuideveld et al. 2002) 2002 Not Stated Whole - Arterial Not Stated Not Stated Not Stated HPLC  
(Loryan, Lindqvist et al. 2012) 2012 EDTA Plasma Not Stated Arterial Not Stated 4 < 4 hrs HPLC  
(Nitsun, Szokol et al. 2006) 2006 Not Stated Plasma Not Stated Venous Not Stated ‘frozen’ Not Stated HPLC  
(Peeters, Bras et al. 2008) 2008 oxalate Whole - arterial Not Stated 4 Not Stated HPLC  
(Okada, Kawamoto et al. 2000) 2000 Not Stated Whole - Arterial Not Stated 4 Not Stated GC  
(Frolich 2005) 2005 Heparin Plasma <30 mins Arterial Not Stated -20 <14 Weeks HPLC  
(Yamauchi-Satomoto, Adachi et al. 2012) 2012 Not Stated Plasma Not Stated Arterial and 
venous 
Not Stated -40 Not Stated HPLC  
(Vianna, Vilela et al. 2002) 2002 Oxalate Whole - Venous Not Stated 4 Not Stated HPLC  
(Yamashita, Kaneda et al. 2010) 2010 EDTA Plasma < 30 min Arterial Not Stated -70 Not Stated HPLC  
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Publication Year 
Published 
Vial Storage 
Chemicals Used 
Blood 
Preparation 
Analysed 
Time to 
Centrifuge 
Site 
sampled 
Vial composition Temperature 
Sample 
stored (oC) 
Duration of 
Sample 
Storage 
Method of 
Sample 
Analysis 
Model 
developed 
with data 
(Kansaku, Kumai et al. 2011) 2011 Not Stated Plasma Not Stated Venous Not Stated Not Stated Not Stated Not Stated  
(Takizawa, Takizawa et al. 2006) 2006 Not Stated Whole - Arterial Not Stated Not Stated Not Stated HPLC  
(Van Brandt, Hantson et al. 1998) 1998 Heparin Whole - Arterial Not Stated 4 Not Stated HPLC  
(Wang, Wu et al. 2010) 2010 Heparin Plasma ‘immediately’ Arterial Not Stated -70 Not Stated HPLC  
(Wessen, Persson et al. 1994) 1994 Oxalate Whole - Venous Not Stated 4 Not Stated HPLC  
(Yamakage, Iwasaki et al. 2005) 2005  Plasma  Arterial    HPLC  
(Mi, Sakai et al. 2003) 2003 Not Stated Plasma Not Stated Arterial Not Stated -70 Not Stated HPLC  
(Keyl, Trenk et al. 2009)   2009 Not Stated Plasma Not Stated Not Stated Not Stated Not Stated Not Stated HPLC  
(Takizawa, Ito et al. 2006) 2006 Not Stated Whole - Arterial Not Stated Not Stated Not Stated HPLC  
(Puri, Medhi et al. 2012) 2012 Heparin Plasma Immediately Venous Not Stated -20 Not Stated HPLC  
(Lim, Gin et al. 1997) 1997 Heparin Whole - Arterial Not Stated 4 Not Stated HPLC  
(Sanchez-Alcaraz, Quintana et al. 1998) 1998 Not Stated Plasma Not Stated Venous 
&Uart Uvein 
Not Stated -20 Not Stated HPLC  
(Takizawa, Nishikawa et al. 2005) 2005 Not Stated Whole - Arterial Not Stated Not Stated Not Stated HPLC  
(Peeters, Aarts et al. 2008) 2008 Oxalate Whole - Arterial Glass 4 Not Stated HPLC  
(Simons, Cockshott et al. 1988) 1988 Oxalate Whole - Venous Glass 4 Not Stated HPLC & GC-
MS 
 
(Kay, Uppington et al. 1985) 1985 Oxalate Whole - Venous Not Stated 4 Not Stated HPLC  
(Knell and McKean 1985) 1985 Not Stated Whole - Venous Not Stated Not Stated Not Stated HPLC  
(Tsubokawa, Ohta et al. 2003) 2003 Not stated Not stated - Arterial Not Stated Not Stated Not Stated HPLC  
(Takizawa, Takizawa et al. 2006) 2006 Not Stated Whole  Arterial  Not Stated <48 hours HPLC  
(Schwilden, Fechner et al. 2003) 2003 Heparin Plasma < 2 hours Arterial Not Stated -20 Not Stated HPLC  
Peeters (Peeters, Allegaert et al. 2010) 2010 Not Stated Not Stated Not Stated Arterial Not Stated Not Stated Not Stated Not Stated  
(Fechner, Hering et al. 2003) 2003 Heparin Plasma < 4 hours Arterial Not Stated -70 Not Stated HPLC  
(Diepstraten, Chidambaran et al. 2012) 2012 Not Stated Whole - Venous Not Stated 4 Not Stated HPLC  
(La Colla, Albertin et al. 2009)    2009 Not Stated Whole - Arterial BD vacutainer 4 Not Stated HPLC  
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Published 
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developed 
with data 
(Chen, Buell et al. 2009) 2009 EDTA Plasma Not Stated Venous Not Stated Not Stated Not Stated HPLC  
(Jungheinrich, Scharpf et al. 2002) 2002 EDTA Plasma Not Stated Venous Not Stated Not Stated Not Stated HPLC  
(Schinella, Mazzi et al. 1995) 1995 EDTA Whole - Venous Not Stated 4 Not Stated HPLC  
(Sorbara, Armellin et al. 1998) 1998 Citrate Whole - Arterial Not Stated 4 Not Stated HPLC  
(Debruyne, Tartiere et al. 1995) 1995 Heparin Whole - Arterial Not Stated ‘frozen’ <7 days HPLC  
(De Gasperi, Noe et al. 1997) 1997 Citrate Whole - Arterial Not Stated 4 Not Stated HPLC  
(Vree, De Grood et al. 1997) 1997 Heparin Plasma Not Stated Arterial ‘eppendorf’ 4 Not Stated HPLC  
(Cockshott, Douglas et al. 1990) 1990 Oxalate Whole - Venous Not Stated 4 Not Stated HPLC  
(Raoof, Van Obbergh et al. 1996) 1996 Oxalate Whole - Arterial 
(&PV) 
Not stated 4 Not stated HPLC  
(Vandermeersch, Van Hemelrijck et al. 
1989) 
1989 Oxalate Whole - Venous Not Stated 4 Not Stated HPLC  
(Gray, Park et al. 1992) 1992 Oxalate Whole (and 
Plasma) 
Immediately Arterial  & 
venous 
Not Stated 4 Not Stated HPLC  
(De Gasperi, Cristalli et al. 1994) 1994 Citrate Whole - Venous Not Stated 4 Not Stated HPLC  
(Frenkel, Schuttler et al. 1995) 1995 Not Stated Whole - Arterial Not Stated 4 Not Stated HPLC  
(Su, Chen et al. 2003) 2003 Heparin Whole - Arterial and 
venous 
Not Stated 4 Not Stated HPLC  
(Valtonen, Isalo et al. 1989) 1989 Not Stated Whole - Venous Not Stated 4 Not Stated HPLC  
(Smits, De Cock et al. 2012) 2012 Oxalate Whole - Arterial plastic 4 < one month HPLC  
(Hans, Coussaert et al. 1997) 1997 Oxalate Whole - Arterial Not Stated 4 Not Stated HPLC  
(Fijalkowska, Dawidowicz et al. 2001) 2001 Not Stated Whole and 
Plasma 
-, not stated Venous Not Stated Not Stated Not Stated HPLC  
(Jones, Chan et al. 1992) 1992 Heparin Whole - Venous Sarstedt LH/5 4 Not Stated HPLC  
(Dyck and Shafer 1992) 1992 Not Stated Whole - Arterial Not Stated Not Stated Not Stated Not Stated  
(Kanto and Rosenberg 1990) 1990 Not Stated Whole - Venous 
(and umb 
cord) 
Not Stated Not Stated Not Stated HPLC  
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(Lim, Tam et al. 1996) 1996 Not Stated Whole - Arterial Not Stated Not Stated Not Stated HPLC  
(de Gasperi, Mazza et al. 1996) 1996 Citrate Whole - Venous Not Stated 4 Not Stated HPLC  
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Appendix 4:  Request for residual blood sample for critical care propofol study 
 
 
 
Measurement of Propofol level Using Discard ABG blood 
 
Please place remainder of ABG blood with sticker, and time of collection following routine ABG analysis in 
designated storage box for collection 
ONLY ONE SAMPLE NEEDED 
 
 
Thanks 
Dr TH Clutton-Brock  
Senior Lecturer 
Consultant Intensive Care 
 
Dr Nick Cowley 
Research fellow Intensive Care 
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Appendix 5:  The Sequential Organ Failure Assessment score (SOFA) used in critical care 
study 
 
(Vincent, Moreno et al. 1996) 
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Appendix 6:  The Richmond Agitation Scale used in the critical care study 
 
(Sessler, Gosnell et al. 2002)
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Appendix 7:  Example of approved Patient information sheet used for clinical trial (this example was 
used for proportional correction study) 
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Appendix 8:  Example of approved consent form (proportional correction study)
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Appendix 9:  Abstract presented in SIVA-UK conference, published in Anaesthesia Journal.  
Comparison of whole blood with plasma sampling during intravenous anaesthesia with propofol
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Appendix 10:  Publication in Anaesthesia Journal: Evaluation of a new analyser for rapid 
measurement of blood propofol concentration during cardiac surgery 
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Appendix 11:  European Journal of Anaesthesia manuscript (proof) – in press.  Assessment of the 
performance of the Marsh model in effect site mode for target controlled infusion of propofol during 
the maintenance phase of general anaesthesia in an unselected population of neurosurgical 
patients. 
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